

Funding Opportunities Monthly Edition March 2023 Due Dates

<u>Introduction</u>

This funding opportunity packet contains information on funding opportunities with deadlines in March 2023. The opportunities are organized in the following order:

- 1. National Institutes of Health (NIH)
- 2. National Science Foundation (NSF)
- 3. Other Federal
- 4. Non Federal

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
113746	Notice of Special Interest (NOSI): Prospective Study Designs for Liq Detection of Cancers	Utilization of Cohorts and uid Biopsy Assay Validation for Early	National Cancer Institute/NIH/DHHS	NOT- CA-23- 05-F 004	Feb-2023	Not Specified
	Contact Name	Matthew Young, Ph.D.				
	Contact Telephone	240-276-5846				
	Contact Email	matthew.young@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	2023, 13-Jun-2023, 01-Jul-2023, 10 Oct-2023, 05-Jan-2024, 07-Jan-2024, 11-Jun-2024, 12-Jun-2024, 01-Jul-	2023 , 14-Feb-2023 , 01-Mar-2023 , 05- <i>J</i> J-Jul-2023 , 05-Sep-2023 , 07-Sep-2023 , 4 , 05-Feb-2024 , 13-Feb-2024 , 01-Mar-2024 2024 , 05-Sep-2024 , 07-Sep-2024 , 01-O 5-Feb-2025 , 13-Feb-2025 , 01-Mar-2025	01-Oct-2023 , 0 2024 , 05-Apr-20 ct-2024 , 05-Oc	5-Oct-2023 , 10-O 024 , 07-May-2024 t-2024 , 10-Oct-20	ct-2023 , 11- 4 , 05-Jun-2024 024 , 11-Oct-
	Synopsis	biomarker technology developers wi and biorepository researchers. Propo qualification, and validation utilizing	Interest (NOSI) is to encourage research th assays for early cancer detection, and osals that facilitate early cancer biomark statistically powered retrospective coho d study design are responsive to this NO	d population-baser assay develoorts and/or thro	sed researchers, ir pment, verificatio	ncluding cohort n,
112442	NCI Clinical and Translational Exp Clinical Trial Optional)	loratory/Developmental Studies (R21	National Cancer Institute/NIH/DHHS	PAR-22- 216	-eb-2023	275,000 USD
	Contact Name	William C. Timmer, Ph.D				
	Contact Telephone	240-276-6130				
	Contact Email	william.timmer@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)		-2023 , 01-Jul-2023 , 10-Oct-2023 , 01-No -Nov-2024 , 13-Feb-2025 , 01-Mar-2025			024 , 12-Jun-



SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	------------------	--------------	----------------	---------------	-------------------

This Funding Opportunity Announcement (FOA) supports preclinical and early phase clinical research, as well as correlative studies, directly related to advancements in cancer treatment, diagnosis, prevention, comparative oncology, symptom management, or reduction of cancer disparities. This includes (but is not limited to) development and testing of the following: new molecular agents or biologics for cancer treatment; management strategies for cancer-related symptoms or treatment-related toxicity; cancer screening or diagnostic tools, such as imaging techniques; cancer preventive agents or approaches; predictive and prognostic biomarkers for patient selection or stratification; clinically relevant in vivo or in vitro tumor models (including genetically engineered mouse models, patient-derived xenograft models, organoids, and cell lines); and strategies to address therapeutic outcome disparities among underserved populations. In addition to novel agents, new treatment strategies may involve repurposed agents or novel combinations of interventions (including radiation), based on established mechanisms of action. Comparative correlative studies in cancer patients with age, gender, racial/ethnic, or health disparities are encouraged to explore mechanisms underlying their differential responses (efficacy and toxicity) and resistance to therapeutic interventions. Comparative oncology studies in dogs investigating strategies for treatment and diagnosis of human disease are supported as well. This FOA does not support research that focuses on basic cancer biology (such as studies of cancer-related pathways, molecular mechanisms, or mechanisms of metastasis), late-stage clinical trials, risk assessment studies, epidemiological studies, or studies of behavioral interventions. These applications will be deemed not responsive to this FOA and will not be reviewed (see below for a more detailed description of studies that are not responsive for this FOA). The R21 mechanism is intended to encourage exploratory and developmental research projects by providing support for the early and conceptual stages of these projects. These studies may involve considerable risk but may lead to breakthroughs in particular areas, or to the development of novel techniques, agents, methodologies, models, or applications that could have a major impact on cancer research (preclinical or clinical).

113233 Bioengineering Research Grants (BRG) (R01 Clinical Trial Optional)

National Cancer Institute/NIH/DHHS

PAR-22-07-Jan-2023 243

Not Specified

Contact Name Rao Divi, Ph.D.

Contact Telephone 240-276-6913

Contact Email divir@mail.nih.gov

Sponsor Website

Program URL Link to program URL

07-Jan-2023, 05-Feb-2023, 05-Mar-2023, 07-May-2023, 05-Jun-2023, 05-Jul-2023, 07-Sep-2023, 05-Oct-2023, 05-Nov-Deadline Dates (ALL) 2023, 07-Jan-2024, 05-Feb-2024, 05-Mar-2024, 07-May-2024, 05-Jun-2024, 05-Jul-2024, 07-Sep-2024, 05-Oct-2024, 05-Deadline Dates (ALL) 2023, 07-Jan-2024, 05-Feb-2024, 05-Mar-2024, 07-May-2024, 05-Jun-2024, 05-Jul-2024, 07-Sep-2024, 05-Oct-2024, 05-Deadline Dates (ALL) 2023, 07-Jan-2024, 05-Feb-2024, 05-Mar-2024, 07-May-2024, 05-Jun-2024, 05-Jun-2024, 07-Sep-2024, 05-Deadline Dates (ALL) 2023, 07-Jan-2024, 05-Deadline Dates (ALL) 2024, 07-Sep-2024, 07-Sep-2024 Nov-2024, 07-Jan-2025, 05-Feb-2025, 05-Mar-2025, 07-May-2025, 05-Jun-2025, 05-Jul-2025, 07-Sep-2025

			3 11			
SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Synopsis	sciences that: 1) apply a multidiscipli optimize, validate, translate or other research or clinical problem in basic, directed, developmental, discovery-clinical integrative approach to increase our science. This FOA will support clinical not intended to support conventional	nity announcement is to encourage collary bioengineering approach to the so wise accelerate the adoption of promisi translational, or clinical science and pradriven, or hypothesis-driven research an understanding of and solve problems in al trials that test functionality or validation as the sesearch are not sought by and will not boroduction.	lution of a biome ing tools, method actice. An applica ad is appropriate a biological, clinic e performance in ae primary motiv	edical problem; and ds, and technique ation may propose for small teams a cal, or translation the chosen settivation. Application	nd 2) integrate es for a specific e design- applying an al ang. This FOA is as that propos
	ntegration of Imaging and Fluid-E Therapy (R01 Clinical Trial Option	Based Tumor Monitoring in Cancer nal)	National Cancer Institute/NIH/DHHS	PAR-21- 290	an-2023	499,999 USD
	Contact Name	Shane Woodward				
	Contact Telephone	240-276-6624				
	Contact Email	woodwars@mail.nih.gov				
	Sponsor Website					
	Program URL	<u>Link to program URL</u>				
	Deadline Dates (ALL)		2023 , 07-May-2023 , 05-Jun-2023 , 05-J 5-Mar-2024 , 07-May-2024 , 05-Jun-202)23 , 05-Nov-
	Synopsis	monitoring (liquid biopsy) assays dur	es applications for research projects thating cancer therapy in patients to detern and/or emergence of resistance. This F	nine the optimal	use of those mod	dalities in the
	Notice of Special Interest (NOSI): Jtilization and Health Outcomes	Disparities Affecting Healthcare Among Childhood Cancer Survivors	National Cancer Institute/NIH/DHHS	NOT- CA-22- 28-D 029	ec-2022	Not Specified
	Contact Name	Veronica Chollette, RN, MS				
	Contact Telephone	240-276-6969				



Contact Email cholletv@mail.nih.gov

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Sponsor W	ebsite					
	Prograi	n URL <u>Link to p</u>	rogram URL				
	Deadline Dates	2023 , 25 s (ALL) 26-Sep-2	5-May-2023 , 26-May-2023 , 2023 , 05-Oct-2023 , 09-Oct-2 5-Feb-2024 , 07-Mar-2024 , 0	2023 , 26-Jan-2023 , 05-Feb-2023 , 16-F 05-Jun-2023 , 07-Jun-2023 , 16-Jun-20 2023 , 16-Oct-2023 , 05-Nov-2023 , 28- 07-May-2024 , 25-May-2024 , 05-Jun-20	23 , 26-Aug-2023 Dec-2023 , 07-Jar	, 07-Sep-2023 , 2 n-2024 , 25-Jan-20	5-Sep-2023 , 024 , 05-Feb-
	Sy	Population to dispare that focus intervent	on Sciences (DCCPS) in receirities in survivorship care, he is on factors that extend beytion that involves healthcare	ight the interest of the National Cancer ving applications to understand and ad althcare utilization, and health outcom yond the individual (e.g., survivor, careg te teams, healthcare system, community tcomes and result in inequitable surviv	dress the full spe les among childho giver, clinician) to r, payer, and/or p	ctrum of factors to ood cancer survive include an exami policy-level factors	hat contribute ors. Studies nation or s that
1116761	Basic Research in Cancer Ho Allowed)	ealth Disparities	(R01 Clinical Trial Not	National Cancer Institute/NIH/DHHS	PAR-21- 322 05-F	eb-2023	Not Specified
	Contact	Name Anu Shar	rman, Ph.D.				
	Contact Tele	ohone 240-276-	-6250				
	Contact	Email sharman	anu@nih.gov				
	Sponsor W	ebsite					
	Prograi	n URL <u>Link to p</u>	rogram URL				
	Deadline Dates		.023 , 05-Mar-2023 , 05-Jun- 5-Jul-2024	2023 , 05-Jul-2023 , 05-Oct-2023 , 05-N	lov-2023 , 05-Feb	o-2024 , 05-Mar-2	024 , 05-Jun-
	Syı	into the l studies d nopsis factors a strategie also desi	biological/genetic causes of lesigned to investigate biolo ssociated with cancer dispans, (2) the development and gned to aid and facilitate the	is applications from investigators interecancer health disparities. These researd gical/genetic bases of cancer disparities rities, including those related to basic retesting of new methodologies and mode growth of a nationwide cohort of sciewho can expand available resources ar	ch project grants s, such as (1) med esearch in cancer lels, and (3) secol entists with a high	(R01) will support chanistic studies of biology or cancer ndary data analyse level of basic res	t innovative If biological Prevention es. This FOA is earch expertise



SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		nodels, and methods that are necess esearch Project (R01) award mechar	ary to conduct basic research in cancer nism.	health dispariti	es. This FOA will ເ	use the NIH
IIIh/x/	Mechanisms that Impact Cancer Ris Clinical Trial Optional)	k after Bariatric Surgery (R01	National Cancer Institute/NIH/DHHS	PAR-21- 331 05-F	eb-2023	2,500,000 USD
	Contact Name Ed	dward R. Sauter, M.D., Ph.D.				
	Contact Telephone 24	40-276-7657				
	Contact Email ec	dward.sauter@nih.gov				
	Sponsor Website					
	Program URL <u>Li</u>	nk to program URL				
		5-Feb-2023 , 05-Mar-2023 , 05-Jun-2 024 , 05-Jul-2024	2023 , 05-Jul-2023 , 05-Oct-2023 , 05-No	ov-2023 , 05-Feb	o-2024 , 05-Mar-2	024 , 05-Jun-
	Synopsis ta	f investigator-initiated studies addre	nouncement (FOA), the National Cance essing mechanisms by which bariatric su c surgery to investigate its effects on ca	irgery impacts c	ancer risk, and se	eks to draw i
113232 <u> </u>	Bioengineering Research Grants (BR	RG) (R01 Clinical Trial Not Allowed)	National Cancer Institute/NIH/DHHS	PAR-22- 242 07-Ja	an-2023	Not Specified
	Contact Name Ra	ao Divi, Ph.D.				
	Contact Telephone 24	40-276-6913				
	Contact Email <u>di</u>	ivir@mail.nih.gov				
	Sponsor Website					
	Program URL <u>Li</u>	nk to program URL				
	Deadline Dates (ALL) 20	023 , 07-Jan-2024 , 05-Feb-2024 , 05	.023 , 07-May-2023 , 05-Jun-2023 , 05-J -Mar-2024 , 07-May-2024 , 05-Jun-202 5 , 05-Mar-2025 , 07-May-2025 , 05-Jun	4 , 05-Jul-2024 ,	07-Sep-2024 , 05	-Oct-2024 , C
			ity announcement is to encourage collaborary bioengineering approach to the so		·	•

integrate, optimize, validate, translate or accelerate adoption of promising tools, methods and techniques: a) that fulfill an

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		capable of enhancing our understand propose design-directed, developme	earch or clinical problem in basic, transl ding of health and disease, and/or c) imp ntal, discovery-driven, or hypothesis-dr approach to increase our understanding	orove practice of iven research, ar	f medicine. Applic nd this FOA is app	ations may ropriate for
1111//12 -	Modular R01s in Cancer Control a	and Population Sciences (R01 Clinical	National Cancer Institute/NIH/DHHS	PAR-21- 190	1ar-2023	1,250,000 USD
	Contact Name	Scott Rogers, MPH				
	Contact Telephone	240-276-6932				
	Contact Email	rogerssc@mail.nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	07-Mar-2023 , 05-Nov-2023 , 07-Mar	-2024			
	Synopsis	sciences. The overarching goal is to potential to substantially advance ca	nent (FOA) encourages applications for reprovide support to promote research efforcer research in statistical and analytic for all interventions, health care delivery,	orts on novel sc methods, epider	ientific ideas that miology, cancer su	have the
	Notice of Special Interest (NOSI): Enabled Care Delivery Models to	New Information Technology- Improve Depression Care in Cancer	National Cancer Institute/NIH/DHHS	NOT- CA-21- 07-Ja 085	an-2023	Not Specified
	Contact Name	Gurvaneet S. Randhawa, M.D., M.P.H	ł.			
	Contact Telephone	240-276-6940				
	Contact Email	Gurvaneet.Randhawa@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	07-Jan-2023 , 05-Feb-2023 , 16-Feb-2 2023 , 16-Oct-2023 , 05-Nov-2023 , 0	2023 , 07-Mar-2023 , 07-May-2023 , 05 7-Jan-2024 , 05-Feb-2024 , 16-Feb-2024	Jun-2023 , 16-Ju I , 07-Mar-2024	n-2023 , 07-Sep-2	023 , 05-Oct-



SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Synopsis	and Population Sciences in receiving) highlights interest of the National Canc ginvestigator-initiated applications for co technology (IT)-enabled care delivery m	onducting resear	ch on the design	and
	Notice of Special Interest (NOSI): Teamwork and Coordination Duri	Research on Interprofessional ing Cancer Diagnosis and Treatment	National Cancer Institute/NIH/DHHS	NOT- CA-22- 28-D 014	ec-2022	Not Specified
	Contact Name	Sallie J. Weaver, PhD, MHS				
	Contact Telephone	240-276-6254				
	Contact Email	sallie.weaver@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	2023 , 25-May-2023 , 26-May-2023 26-Sep-2023 , 05-Oct-2023 , 09-Oct-	2023 , 26-Jan-2023 , 05-Feb-2023 , 16-Fe , 05-Jun-2023 , 07-Jun-2023 , 16-Jun-202 2023 , 16-Oct-2023 , 05-Nov-2023 , 28-D 07-May-2024 , 25-May-2024 , 05-Jun-20 2024	3 , 26-Aug-2023 ec-2023 , 07-Jar	, 07-Sep-2023 , 2 n-2024 , 25-Jan-20	5-Sep-2023 , 124 , 05-Feb-
	Synopsis	•) highlights the NCI Healthcare Delivery Fing and improving interprofessional tean	_		-
1116767	Basic Research in Cancer Health [Allowed)	Disparities (R21 Clinical Trial Not	National Cancer Institute/NIH/DHHS	PAR-21- 323	eb-2023	400,000 USD
	Contact Name	Anu Sharman, Ph.D.				
	Contact Telephone	240-276-6250				
	Contact Email	sharmananu@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	16-Feb-2023 , 16-Mar-2023 , 16-Jun 2024 , 16-Jul-2024	-2023 , 16-Jul-2023 , 16-Oct-2023 , 16-No	ov-2023 , 16-Feb	o-2024 , 16-Mar-20	024 , 16-Jun-



	-		1			_ "
SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Synopsis	into the biological/genetic causes of of studies designed to investigate biologicators associated with cancer dispartistrategies, (2) the development and talso designed to aid and facilitate the in cancer health disparities research with the studies of the stud	s applications from investigators interest cancer health disparities. These research gical/genetic bases of cancer disparities, ities, including those related to basic reseating of new methodologies and mode growth of a nationwide cohort of scient who can expand available resources and	h project grants, such as (1) med search in cancerels, and (3) secontists with a high tools, such as b	(R01) will support chanistic studies or biology or cancer ndary data analyse a level of basic reservices, pati	innovative f biological prevention es. This FOA is earch expertise
114492	RFA-CA-23-002 Innovative Mole echnologies for Basic and Clinica Not Allowed)		National Cancer Institute/NIH/DHHS	RFA-CA- 30-Ja 23-002 [Opt	an-2023 :ional][LOI/Pre-Ap _l	450,000 o] USD
	Contact Name	Kelly Crotty, Ph.D.				
	Contact Telephone	240-760-7997				
	Contact Email	kelly.crotty@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	30-Jan-2023 [Optional][LOI/Pre-App],	. 01-Mar-2023 , 02-Aug-2023 [Optional]	[LOI/Pre-App], (01-Sep-2023	
	Synopsis	on the early-stage development of his basic, clinical, or epidemiological can capabilities involving a high degree of features of cancer biology. Well-suite areas of cancer biology, early detections associated with cancer health widespread applicability but must be Projects proposing the application of target/question being pursued are not	nent (FOA) solicits grant applications proghly innovative technologies offering noter research. The emphasis of this FOA is technical innovation for targeting, prolud applications must offer the potential on and screening, clinical diagnosis, treadisparities. Technologies proposed for defocused on improving molecular and/or existing technologies where the novelty of responsive to this solicitation and will evative Molecular Analysis Technologies	ovel molecular of is on supporting bing, or assessing to accelerate an atment, control, levelopment may resides in the land to be reviewe	or cellular analysis the development of molecular and cond/or enhance research epidemiology, and be intended to leterizations of cancel biological or clinicated. This funding op	capabilities for of novel ellular earch in the d/or address nave eer biology.
11/1/196		pecimen Science Technologies for h (R61 Clinical Trial Not Allowed)	National Cancer Institute/NIH/DHHS	RFA-CA- 30-Ja 23-004 [Opt	an-2023 :ional][LOI/Pre-Ap _l	450,000 o] USD

SPIN ID	Program	Sponsor Name	Sponsor Number	Deadline Date	Funding
SFIIN ID	Title	Sponsor Hame	Sponsor Wulliber	Deadine Date	Amount

Contact Name Kelly Crotty Ph.D.

Contact Telephone 240-760-7997

Contact Email kelly.crotty@nih.gov

Sponsor Website

Program URL Link to program URL

Deadline Dates (ALL) 30-Jan-2023 [Optional][LOI/Pre-App], 01-Mar-2023, 02-Aug-2023 [Optional][LOI/Pre-App], 01-Sep-2023

This Funding Opportunity Announcement (FOA) solicits grant applications proposing exploratory research projects focused on the early-stage development of highly innovative technologies that improve the quality of the samples used for cancer research or clinical care. This includes new capabilities to address issues related to pre-analytical degradation of targeted analytes during the collection, processing, handling, and/or storage of cancer-relevant biospecimens. The overall goal is to support the development of highly innovative technologies capable of maximizing or otherwise interrogating the quality and utility of biological samples used for downstream analyses. This FOA will support the development of tools, devices,

Synopsis instrumentation, and associated methods to preserve or protect sample integrity, or establish verification criteria for quality assessment/quality control and handling under diverse conditions. These technologies are expected to accelerate and/or enhance research in cancer biology, early detection and screening, clinical diagnosis, treatment, or epidemiology, or address issues associated with cancer health disparities, by reducing pre-analytical variations that affect biospecimen sample quality. Projects proposing the application of existing technologies where the novelty resides in the biological or clinical target/question being pursued are not responsive to this solicitation and will not be reviewed. This funding opportunity is part of a broader NCI-sponsored Innovative Molecular Analysis Technologies (IMAT) Program.

RFA-CA-23-003 -- Advanced Development and Validation of Emerging 114495 Molecular and Cellular Analysis Technologies for Basic and Clinical

Cancer Research (R33 Clinical Trial Not Allowed)

National Cancer Institute/NIH/DHHS

RFA-CA- 30-Jan-2023

900,000

23-003 [Optional][LOI/Pre-App] USD

Contact Name Kelly Crotty, Ph.D.

Contact Telephone 240-760-7997

Contact Email kelly.crotty@nih.gov

Sponsor Website

Program URL Link to program URL

Deadline Dates (ALL) 30-Jan-2023 [Optional] [LOI/Pre-App], 01-Mar-2023, 02-Aug-2023 [Optional] [LOI/Pre-App], 01-Sep-2023

|--|

on further development and validation of emerging technologies offering novel capabilities for targeting, probing, or assessing molecular and cellular features of cancer biology for basic, clinical, or epidemiological cancer research. This FOA solicits R33 applications where major feasibility gaps for the technology or methodology have been overcome, as demonstrated with supportive preliminary data, but still requires further development and rigorous validation to encourage adoption by the research community. Well-suited applications must offer the potential to accelerate and/or enhance research in the areas of cancer biology, early detection and screening, clinical diagnosis, treatment, control, epidemiology, and/or address issues associated with cancer health disparities. Technologies proposed for development may be intended to have widespread applicability but must be focused on improving molecular and/or cellular characterizations of cancer. Projects proposing the application of existing technologies where the novelty resides in the biological or clinical target/question being pursued are not responsive to this solicitation and will not be reviewed. This funding opportunity is

This Funding Opportunity Announcement (FOA) invites grant applications proposing exploratory research projects focused

RFA-CA-23-005 -- Advanced Development and Validation of Emerging

114497 Biospecimen Science Technologies for Basic and Clinical Cancer

Synopsis

Research (R33 Clinical Trial Not Allowed)

National Cancer Institute/NIH/DHHS

part of a broader NCI-sponsored Innovative Molecular Analysis Technologies (IMAT) Program.

RFA-CA- 30-Jan-2023

900,000

23-005 [Optional][LOI/Pre-App] USD

Contact Name Kelly Crotty Ph.D.

Contact Telephone 240-760-7997

Contact Email kelly.crotty@nih.gov

Sponsor Website

Program URL Link to program URL

Deadline Dates (ALL) 30-Jan-2023 [Optional] [LOI/Pre-App], 01-Mar-2023, 02-Aug-2023 [Optional] [LOI/Pre-App], 01-Sep-2023

This Funding Opportunity Announcement (FOA) solicits grant applications proposing exploratory research projects focused on further development and validation of emerging technologies that improve the quality of the samples used for cancer research or clinical care. This includes new capabilities to address issues related to pre-analytical degradation of targeted analytes during the collection, processing, handling, and/or storage of cancer-relevant biospecimens. This FOA solicits R33 applications where major feasibility gaps for the technology or methodology have been overcome, as demonstrated with supportive preliminary data, but still require further development and rigorous validation to encourage adoption by the research community. The overall goal is to support the development of highly innovative technologies capable of maximizing or otherwise interrogating the quality and utility of biological samples used for downstream analyses. This FOA will support the development of tools, devices, instrumentation, and associated methods to preserve or protect sample integrity, or establish verification criteria for quality assessment/quality control and handling under diverse conditions. These

Synopsis



	SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
-						

technologies are expected to accelerate and/or enhance research in cancer biology, early detection and screening, clinical diagnosis, treatment, or epidemiology, or address issues associated with cancer health disparities, by reducing pre-analytical variations that affect biospecimen sample quality. Projects proposing to use existing technologies where the novelty resides in the application of the technology or the biological or clinical question being pursued, and not the technical capabilities being developed, are not appropriate for this FOA and will not be reviewed. This funding opportunity is part of a broader NCI-sponsored Innovative Molecular Analysis Technologies (IMAT) Program.

RFA-CA-23-007 -- Revision Applications for Incorporation of Novel NCI-

114499 Supported Technology to Accelerate Cancer Research (U01 Clinical Trial Optional)

National Cancer Institute/NIH/DHHS

RFA-CA- 30-Jan-2023

150.000

23-007 [Optional][LOI/Pre-App] USD

Contact Name Kelly Crotty, Ph.D.

Contact Telephone 240-760-7997

Contact Email kelly.crotty@nih.gov

Sponsor Website

Program URL Link to program URL

Deadline Dates (ALL) 30-Jan-2023 [Optional] [LOI/Pre-App], 01-Mar-2023, 02-Aug-2023, 01-Sep-2023

The purpose of this Funding Opportunity Announcement (FOA) is to encourage revision applications from currently funded NCI U01 research projects. The applicants should propose to expand upon the original research question(s) or otherwise accelerate progress for the parent study by incorporating a new technical approach or instrument developed through Synopsis support from the NCI Innovative Molecular Analysis Technologies (IMAT) program. Awards from this FOA are meant to incentivize independent validation and accelerate the suitability of these emerging technologies for appropriate research communities. As a component of the NCI IMAT program, this FOA aims to promote interdisciplinary collaboration in the

RFA-CA-23-006 -- Revision Applications for Incorporation of Novel NCI-

114498 Supported Technology to Accelerate Cancer Research (R01 Clinical **Trial Optional)**

National Cancer Institute/NIH/DHHS

development of innovative tools and methods that enable cancer research and accelerate scientific discovery.

RFA-CA- 30-Jan-2023

23-006 [Optional][LOI/Pre-App] USD

Contact Name Kelly Crotty, Ph.D.

Contact Telephone 240-760-7997

Contact Email kelly.crotty@nih.gov

Sponsor Website



150,000

SPIN ID Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
Pr	ogram URL Link to p	rogram URL				
			01-Mar-2023 , 02-Aug-2023 [Optional]	l[LOI/Pre-Appl. (01-Sep-2023	
	The purp NCI R01 accelerat Synopsis support incentivity commun	ose of this Funding Opporturesearch projects. The applicate progress for the parent stuffrom the NCI Innovative Moleze independent validation articles. As a component of the	nity Announcement (FOA) is to encoura ants should propose to expand upon the udy by incorporating a new technical ap- ecular Analysis Technologies (IMAT) pro- id accelerate the adoption of these eme NCI IMAT program, this FOA aims to pro- methods that enable cancer research a	age revision appl ne original resear aproach or instru ogram. Awards fi erging technolog omote interdisc	ications from curr rch question(s) or iment developed t rom this FOA are r gies by appropriate iplinary collaborat	otherwise chrough meant to e research cion in the
114502 Supported Technology Trial Optional)		Incorporation of Novel NCI- r Research (P01 Clinical	National Cancer Institute/NIH/DHHS	RFA-CA- 30-Ja 23-009 [Opt	an-2023 ional][LOI/Pre-Ap	150,000 p] USD
Cor	tact Name Kelly Cro	tty, Ph.D.				
Contact	Telephone 240-760-	7997				
Cor	ntact Email <u>kelly.cro</u> t	ty@nih.gov				
Spons	or Website					
Pr	ogram URL Link to p	rogram URL				
Deadline I	Dates (ALL) 30-Jan-20	023 [Optional][LOI/Pre-App]	01-Mar-2023 , 02-Aug-2023 [Optional]	[[LOI/Pre-App], 0	01-Sep-2023	
	NCI P01 accelerat Synopsis support incentiviz commun	program projects proposing to progress for the parent student to the NCI Innovative Moleze independent validation articles. As a component of the	nity Announcement (FOA) is to encoura to expand upon original research questing to by incorporating a new technical application and technical applications. The suitability of these emused in the suitability of the suitability o	ion(s) from spec oproach or instru ogram. Awards fi derging technolog omote interdisc	ific projects or oth iment developed t rom this FOA are r gies for appropria iplinary collaborat	nerwise through meant to te research tion in the
114500 RFA-CA-23-008 Revis Supported Technology Trials Optional)		Incorporation of Novel NCI- r Research (U54 Clinical	National Cancer Institute/NIH/DHHS	RFA-CA- 30-Ja 23-008 [Opt	an-2023 ional][LOI/Pre-Ap	150,000 p] USD
Cor	tact Name Kelly Cro	tty, Ph.D.				



SPIN ID Program Title Sponsor Name Sponsor Number	Deadline Date Funding Amount
---	------------------------------

Contact Telephone 240-760-7997

Contact Email kelly.crotty@nih.gov

Sponsor Website

Program URL Link to program URL

Deadline Dates (ALL) 30-Jan-2023 [Optional][LOI/Pre-App], 01-Mar-2023, 02-Aug-2023 [Optional][LOI/Pre-App], 01-Sep-2023

The purpose of this Funding Opportunity Announcement (FOA) is to encourage revision applications from currently funded NCI U54 Resource-Related Research Projects proposing to expand upon original research question(s) from specific projects or otherwise accelerate progress for the parent study by incorporating a new technical approach or instrument developed through support from the NCI Innovative Molecular Analysis Technologies (IMAT) program. Awards from this FOA are meant

through support from the NCI Innovative Molecular Analysis Technologies (IMAT) program. Awards from this FOA are meant to incentivize independent validation and accelerate the suitability of these emerging technologies for appropriate research communities. As a component of the NCI IMAT program, this FOA aims to promote interdisciplinary collaboration in the development of innovative tools and methods that enable cancer research and accelerate scientific discovery.

National Cancer Institute/NIH/DHHS

RFA-CA- 30-Jan-2023

23-010 [Optional][LOI/Pre-App] USD

RFA-CA-23-010 -- Revision Applications for Incorporation of Novel NCI-

114503 Supported Technology to Accelerate Cancer Research (P50 Clinical

Trial Optional)

Contact Name Kelly Crotty, Ph.D.

Contact Telephone 240-760-7997

Contact Email kelly.crotty@nih.gov

Sponsor Website

Program URL Link to program URL

Deadline Dates (ALL) 30-Jan-2023 [Optional][LOI/Pre-App], 01-Mar-2023, 02-Aug-2023 [Optional][LOI/Pre-App], 01-Sep-2023

The purpose of this Funding Opportunity Announcement (FOA) is to encourage revision applications from currently funded NCI P50 specialized centers proposing to expand upon original research question(s) from specific projects or otherwise accelerate progress for the parent study by incorporating a new technical approach or instrument developed through support from the NCI Innovative Molecular Analysis Technologies (IMAT) program. Awards from this FOA are meant to incentivize independent validation and accelerate the suitability of these emerging technologies for appropriate research

communities. As a component of the NCI IMAT program, this FOA aims to promote interdisciplinary collaboration in the development of innovative tools and methods that enable cancer research and accelerate scientific discovery.

150,000

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
114504	RFA-CA-23-011 Revision Applica Supported Technology to Acceler Trial Optional)	ations for Incorporation of Novel NC ate Cancer Research (U2C Clinical	National Cancer Institute/NIH/DHHS	RFA-CA- 30- 23-011 [Op	Jan-2023 otional][LOI/Pre-Ap	150,000 p] USD
	Contact Name	Kelly Crotty, Ph.D.				
	Contact Telephone					
		kelly.crotty@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Synopsis	The purpose of this Funding Opport NCI U2C Resource-Related Multi-Cofrom specific projects or otherwise instrument developed through supprom this FOA are meant to incentifor appropriate research communit collaboration in the development of	p], 01-Mar-2023, 02-Aug-2023 [Optional] tunity Announcement (FOA) is to encoura omponent Projects and Centers proposing accelerate progress for the parent study I port from the NCI Innovative Molecular A vize independent validation and acceleraties. As a component of the NCI IMAT progof innovative tools and methods that enable	ge revision app to expand upo by incorporatin nalysis Techno e the suitability gram, this FOA	olications from cur on original research ng a new technical logies (IMAT) prog y of these emergin aims to promote i	n question(s) approach or ram. Awards g technologies nterdisciplinary
045115	Short-Term Scientist Exchange Pr	ogram	National Cancer Institute/NIH/DHHS	01-	Mar-2023	Not Specified
	Contact Name	Dr. Vidya Vedham				
	Contact Telephone	240-276-7272				
	Contact Email	NCICenterforGlobalHe@mail.nih.go	<u>ov</u>			
	Sponsor Website	Link to sponsor website				
	Program URL	Link to program URL				
	Deadline Dates (ALL)	01-Mar-2023 , 01-Jul-2023 , 01-Oct	-2023			
	Synopsis		Program (STSEP) at the Center for Global etween researchers at the NCI and foreign			stitute (NCI),
106265	Basic Research in Cancer Health Dallowed	Disparities (R03 Clinical Trial Not	National Cancer Institute/NIH/DHHS	PAR-21- 324 16-	Feb-2023	100,000 USD

SPIN ID Program Title	Sponsor Name	Sponsor Number	ı	Deadline Date	Funding Amount
	ı				
	Anu Sharman, Ph.D.				
Contact Telephon	240-276-6250				
Contact Ema	sharmananu@nih.gov				
Sponsor Websit	e				
Program UR	Link to program URL				
Deadline Dates (ALL) 16-Feb-2023 , 16-Mar-2023 , 16-Ju 2024 , 16-Jul-2024	un-2023 , 16-Jul-2023 , 16-Oct-2023 , 16-N	ov-2023 , 16-Feb-2	2024 , 16-Mar-20)24 , 16-Jun-
Synopsi	basic, mechanistic research into the will support projects on cancer he projects should propose innovative mechanistic studies of biological for the projects and the projects are the projects and the projects are the projects and the projects are the projects a	ncement (FOA) encourages grant application the biological/genetic causes of cancer heal ealth disparities that can be carried out in a vestudies designed to investigate biological factors associated with cancer disparities, in on strategies, (2) the development and test	th disparities. The short period of ti l/genetic bases of ncluding those rel	ese small researc me with limited f cancer disparition ated to basic res	n grants (RO3) resources. The es, such as (1) earch in
106283 Mechanisms that Impact Cancer	Risk after Bariatric Surgery (R21	National Cancer Institute/NIH/DHHS	PAR-21-	b-2023	550,000
Clinical Trial Not Allowed)		National Cancer institute/Nin/Dimis	332	5 2023	USD
Contact Nam	Edward R. Sauter, M.D., Ph.D.				
Contact Telephon	240-276-7657				
Contact Ema	edward.sauter@nih.gov				
Sponsor Websit	2				
Program UR	Link to program URL				
Deadline Dates (ALL	16-Feb-2023 , 16-Mar-2023 , 16-Ju 2024 , 16-Jul-2024	un-2023 , 16-Jul-2023 , 16-Oct-2023 , 16-No	ov-2023 , 16-Feb-2	2024 , 16-Mar-20)24 , 16-Jun-
Synopsi	of investigator-initiated studies ac	y Announcement (FOA), the National Cance ddressing mechanisms by which bariatric su atric surgery to investigate its effects on ca	urgery impacts car	ncer risk, and see	ks to draw in
104709 NCCIH Multi-Site Feasibility Clini Interventions (R01 Clinical Trial I	the state of the s	National Center for Complementary and Integrative Health/NIH/DHHS	PAR-21- 241 21-Fel	b-2023	Not Specified

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	This and interproper demadher Synopsis feas need feas or et com subr	so program URL beb-2023, 10-Mar-2023, 20-Jun-2 Funding Opportunity Announcen ntegrative health approaches with ventions) in NCCIH-designated and ose a multi-site feasibility clinical constrate feasibility of recruitmen rence to the intervention, as well bility of data collection across sith for multi-site feasibility trials is elective bility or acceptability trial(s) or the fectiveness. The data collected sleetitive fully powered multi-site of	023, 22-Jul-2023, 20-Oct-2023, 14-Notent (FOA) invites applications for investing physical and/or psychological theraptes of high research priority. Application trial to assess whether the intervention as retention of participants throughous in preparation for a future fully power perfected to be justified by sufficient properties as the potential to make the potential to	stigator-initiated peutic inputs (oftons submitted un on can be deliver ipants across site ut the study acrosered, multi-site eliminary data frot support clinications as a significant	d clinical trials of co ten called mind an inder this FOA are red with fidelity ac es; demonstrate pa oss sites; and/or do efficacy/ effective rom previous single al trials that determent e necessary to dev impact on public h	omplementary d body expected to ross sites; articipant emonstrate ness trial. The e site mine efficacy elop a nealth Prior to
111/1/11/11	Feasibility Clinical Trials of Mind and Be High Priority Research Topics (R34 Clin		National Center for Complementary and Integrative Health/NIH/DHHS	PAR-21- 240 21-F	eb-2023	450,000 USD
	Contact Name Pete	Murray, Ph.D.				
	Contact Telephone 301-	196-4054				
	Contact Email <u>pete</u>	r.murray@nih.gov				
	Sponsor Website					

Program URL Link to program URL

Deadline Dates (ALL) 21-Feb-2023, 10-Mar-2023, 20-Jun-2023, 22-Jul-2023, 20-Oct-2023, 14-Nov-2023, 20-Feb-2024, 11-Mar-2024

Synopsis The goal of this funding opportunity is to support early phase clinical trials of complementary and integrative health approaches with physical and/or psychological therapeutic inputs (often called mind and body interventions) for conditions

SPIN ID	Program	Sponsor Name	Sponsor Number	Deadline Date	Funding
3FIN ID	Title	Sponsor Name	Sponsor Number	Deadine Date	Amount

that have been identified by NCCIH as high priority research topics. This funding opportunity is intended to support feasibility clinical trials, which will provide data that are critical for the planning and design of a subsequent clinical efficacy or effectiveness study, or a pragmatic trial. The data collected should be used to fill gaps in scientific knowledge necessary to develop a competitive full-scale clinical trial, including, but not limited to the following: examining feasibility and acceptability of interventions lacking published data; adapting an intervention to a specific population; refining the intervention to determine the most appropriate frequency or duration; determining feasibility of recruitment, retention and data collection procedures; refining and assessing the feasibility of protocolized multimodal interventions; or examining acceptability and adherence of control conditions. This FOA will not support randomized clinical trials that test or determine efficacy or effectiveness; nor will this FOA support repetition of feasibility or acceptability research that has been previously conducted in the same or similar patient population with the same or similar intervention. Applications that propose solely to write a protocol or manual of operations or to develop infrastructure for a clinical trial are not appropriate for this announcement. Applications must propose to conduct a feasibility clinical trial. The subsequent larger trial should have the potential to make a significant impact on public health.

Clinical Coordinating Center for NCCIH Multi-Site Investigator-Initiated 104713 Clinical Trials of Mind and Body Interventions (Collaborative UG3/UH3 Clinical Trial Required)

National Center for Complementary and Integrative Health/NIH/DHHS

PAR-21-21-Feb-2023 243

Not Specified

Contact Name Lanay Mudd, Ph.D.

Contact Telephone 301-594-9346

Contact Email lanay.mudd@nih.gov

Sponsor Website

Program URL Link to program URL

Deadline Dates (ALL) 21-Feb-2023, 10-Mar-2023, 20-Jun-2023, 22-Jul-2023, 20-Oct-2023, 14-Nov-2023, 20-Feb-2024, 11-Mar-2024

This Funding Opportunity Announcement (FOA) encourages applications for investigator-initiated multi-site clinical trials (e.g. efficacy, effectiveness or pragmatic trials) to study the effects of complementary and integrative health approaches with physical and/or psychological therapeutic inputs (often called mind and body interventions) in NCCIH designated areas of high research priority. Clinical Coordinating Centers should develop and implement the proposed fully powered multi-site Synopsis clinical trial. The objective of a Clinical Coordinating Center application is to present the scientific rationale and a comprehensive scientific and operational plan for the clinical trial. Clinical Coordinating Center applications are expected to describe plans for project management, participant recruitment and retention strategies, performance milestones, scientific conduct, and dissemination of results. Clinical Coordinating Center applications submitted under this FOA will utilize a twophase, milestone-driven cooperative agreement (UG3/UH3) funding mechanism. In addition, an accompanying Data

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		for the clinical project is required. Both Center (DCC) application need to be the mission, strategic vision, and res (https://nccih.nih.gov/about/plans).	4), submitted under PAR-21-242 proposith a Clinical Coordinating Center applic submitted simultaneously for considera earch priorities of the NCCIH, applicants Applicants are encouraged to contact t y are planning to develop an application	ation and a corre ation by NCCIH. F are encouraged he appropriate th	esponding Data Co or additional info to consult the NO he Scientific/Rese	ordinating rmation about CCIH website:
104712	Data Coordinating Center for NCC Clinical Trials of Mind and Body In Clinical Trial Required)	CIH Multi-Site Investigator-Initiated nterventions (Collaborative U24	National Center for Complementary and Integrative Health/NIH/DHHS	PAR-21- 242 21-F	eb-2023	Not Specified
	Contact Name	Lanay Mudd, Ph.D.				
	Contact Telephone	301-594-9346				
	Contact Email	lanay.mudd@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	21-Feb-2023 , 10-Mar-2023 , 20-Jun-	-2023 , 22-Jul-2023 , 20-Oct-2023 , 14-N	ov-2023 , 20-Feb	-2024 , 11-Mar-20)24
	Synopsis	collaborating Data Coordinating Cen (Phase III and beyond) application su Clinical Coordinating Center (CCC) approvides overall project coordination clinical trial. Both a DCC application is consideration by NCCIH. Trials for what high priority by the Center. For add applicants are encouraged to consultations.	ment (FOA), utilizing the U24 grant functor (DCC) application that accompanies abmitted under PAR-21-243. The DCC application. The objective of the DCC application. The objective of the DCC application. The objective of the DCC application and a corresponding CCC application nearly this FOA applies must be relevant the ditional information about the mission, the NCCIH website: (http://www.nccih.nih.contact for the area of science for which	an investigator-i oplication must be lication is to proper, and biostatistic ed to be submitt to the research metrategic vision, and strategic vision, and strategic vision, and service metrategic vision.	nitiated multi-site e specific to the coose a compreher cal support for the ed simultaneously hission of NCCIH and and research prior s are encouraged t	clinical trial ompanion sive plan that proposed for donsidered ities of NCCIH, o contact the
IIIX/h/I	RFA-HL-23-003 Physician Scient Blood Science Research (R00 - Cli	cist Transition to Independence in nical Trial Optional)	National Heart, Lung, and Blood Institute/NIH/DHHS	RFA-HL- 26-Fo 23-003 [Opt	eb-2023 ional][LOI/Pre-Ap	750,000 o] USD
	Contact Name Contact Telephone	Lisbeth Welniak, PhD 301-435-0050				

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Contact Email	welniakla@mail.nih.gov				
	Sponsor Website					
	·	Link to program URL				
	Deadline Dates (ALL)	26-Feb-2023 [Optional][LOI/Pre-App	o], 28-Mar-2023 , 27-Feb-2024 [Option	al][LOI/Pre-App], 2	28-Mar-2024	
	Synopsis	increase and maintain a strong coho This program is designed to facilitate degree from mentored research pos opportunity for current RFA-HL-20-0 program. In the ROO phase, successfu	thway to Independence in Blood Scien ort of new and talented, NHLBI support a timely transition of outstanding blouitions to independent, tenure-track or 101 or RFA-HL-20-002 K99 awardees to all blood science physician scientist schoupport from this FOA, which will require	ed, independent i od science resear equivalent faculty apply for the inde olars will receive	investigators in blo chers with a clinica y positions. This FC ependent phase (F up to three years o	ood science. al doctorate DA offers the 800) of the of funding to
11174//	RFA-HL-23-004 NHLBI Outstand Clinical Trial Optional)	ling Investigator Award (OIA) (R35	National Heart, Lung, and Blood Institute/NIH/DHHS	RFA-HL- 16-Ja 23-004 [Opt	an-2023 tional][LOI/Pre-Ap	4,900,000 p] USD
	Contact Name	Narasimhan Danthi, Ph.D.				
	Contact Telephone	301-451-5170				
	Contact Email	ndanthi@nhlbi.nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)], 15-Feb-2023 , 26-Mar-2023 [Optiona 24 , 26-Mar-2024 [Optional][LOI/Pre-A		25-Apr-2023 , 16-J	an-2024
	Synopsis	providing long-term support and incommendate currently PD/PIs on at least two litheir ability to make major contribut research program, rather than a reseindividual grant awards. The OIA will OIA will provide investigators increas discoveries in new directions. It will a	ng Investigator Award (OIA) is to prome reased flexibility to experienced Progre NHLBI R01-equivalent awards and who sions to heart, lung, blood and sleep (Hearch project, by providing the primary I support the research program of NHL sed freedom to conduct research that also allow PD/PIs to take greater risks he OIA must be within the scope of the	am Directors/Pring ose outstanding re ILBS) research. The y and most likely s BI-funded investig breaks new groun and to pursue rese	cipal Investigators ecord of research of e OIA is intended to sole source of NHL gators for up to send or extends prevearch that require	(PD/PIs) who demonstrates to support a BI funding on ven years. The ious s a longer

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount

Provide a stable funding environment, thereby improving productivity and facilitating nimble, ambitious, creative research; Accelerate scientific innovation by enabling flexibility in pursuing new research directions as they arise, since PD/PIs will not be bound to specific aims proposed in advance of the studies; Reduce the time researchers spend writing grant applications and managing multiple grant awards, thereby allowing more time to be devoted to conducting research; Facilitate PD/PIs' commitment to research through increased stability of funding; and Enable PD/PIs to devote more time and energy to mentoring students and junior scientists and providing scientific service.

RFA-HL-23-005 -- NHLBI Emerging Investigator Award (EIA) (R35 Clinical Trial Optional

National Heart, Lung, and Blood Institute/NIH/DHHS

RFA-HL- 16-Jan-2023

4.900.000 23-005 [Optional][LOI/Pre-App] USD

Contact Name Narasimhan Danthi, Ph.D.

Contact Telephone 301-451-5170

Contact Email ndanthi@nhlbi.nih.gov

Sponsor Website

Program URL Link to program URL

Deadline Dates (ALL)

16-Jan-2023 [Optional][LOI/Pre-App], 15-Feb-2023, 26-Mar-2023 [Optional][LOI/Pre-App], 25-Apr-2023, 16-Jan-2024 [Optional][LOI/Pre-App], 15-Feb-2024, 26-Mar-2024 [Optional][LOI/Pre-App]

The purpose of the NHLBI Emerging Investigator Award (EIA) is to promote scientific productivity and innovation by providing long-term support and increased flexibility to experienced Program Directors/Principal Investigators (PD/PIs) who are currently PD/PIs on at least two NHLBI R01-equivalent awards and whose outstanding record of research demonstrate their ability to make major contributions to heart, lung, blood and sleep (HLBS) research. The EIA is intended to support a research program, rather than a research project, by providing the primary and most likely sole source of NHLBI funding on individual grant awards. The EIA will support the research program of NHLBI-funded investigators for up to seven years. The EIA will provide investigators increased freedom to conduct research that breaks new ground or extends previous Synopsis discoveries in new directions. It will also allow PD/PIs to take greater risks and to pursue research that requires a longer timeframe. Research supported by the EIA must be within the scope of the NHLBI mission. It is anticipated that the EIA will: Provide a stable funding environment, thereby improving productivity and facilitating nimble, ambitious, creative research; Accelerate scientific innovation by enabling flexibility in pursuing new research directions as they arise, since PD/PIs will not

be bound to specific aims proposed in advance of the studies; Reduce the time researchers spend writing grant applications and managing multiple grant awards, thereby allowing more time to be devoted to conducting research; Facilitate PD/PIs' commitment to research through increased stability of funding; and Enable PD/PIs to devote more time and energy to mentoring students and junior scientists and providing scientific service

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
108325	Notice of Special Interest (NOSI): Clinical Informatics Tools to Enhal	Development and Implementation of nce Patients' Use of Genomic	National Human Genome Research Institute/NIH/DHHS	NOT- HG-22- 07-J 011	an-2023	Not Specified
	Contact Name	Ken Wiley, Jr., Ph.D.				
	Contact Telephone	301-435-5540				
	Contact Email	ken.wiley@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	1	.023 , 16-Feb-2023 , 13-Mar-2023 , 07-I 5-Oct-2023 , 16-Oct-2023 , 07-Jan-2024 124 , 16-Jun-2024 , 07-Sep-2024		•	-
	Synopsis	applications to develop and impleme patient-provider electronic community	rch Institute (NHGRI) is issuing a Notice ent patient-facing genomic-based clinical ication, patient tracking and registry ful tracking, referral tracking, and health ca	al informatics to nctions, patient	ols that facilitate c self-management	or enhance
099483	HIV Vaccine Research and Design	(HIVRAD) Program (P01 Clinical Trial	National Institute of Allergy and	PAR-21-	Mar-2023	12,500,000
099465	Not Allowed)		Infectious Diseases/NIH/DHHS	024	vidi-2025	USD
	Contact Name	Bruce Sundstrom, Ph.D.				
	Contact Telephone	240-669-5045				
	Contact Email	sundstromj@niaid.nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	15-Mar-2023				
	Synopsis		inity Announcement (FOA) is to suppor vant to AIDS prophylactic vaccine discodels may be included.	•	· · ·	
100727	Detection of HIV for Self-Testing ((R61/R33 Clinical Trial Not Allowed)	National Institute of Allergy and Infectious Diseases/NIH/DHHS	PAR-21- 070	Mar-2023	Not Specified

SPIN ID	Program Title	Sponsor Name	Sponsor Number			Funding Amount
	Contact Name	Diane Lawrence, Ph.D.				
	Contact Telephone	240-627-3202				
	Contact Email	lawrencedi@niaid.nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	17-Mar-2023				
		research to inform the development	unity Announcement (FOA) is to support of innovative rapid, sensitive, simple, a e earliest phases of acute infection or o	and cost-effective	e diagnostic techno	
109547 P	•	NIAID Administrative Supplement to untermeasures Against Chemical	National Institute of Allergy and Infectious Diseases/NIH/DHHS	NOT-AI- 22-030 01-N	/lar-2023	100,000 USD
	Contact Name	Dave Yeung, Ph.D.				
	Contact Telephone	301-796-7237				
	Contact Email	dy70v@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	01-Mar-2023 , 01-Mar-2024				
		the research and early development their MCM research focus into this c	upplement applications from current N of medical countermeasures (MCMs) a ritical field. There must be sufficient pr roposed supplemental activities must	against chemical to	threats to allow the rent project to justi	em to expand fy the
114076	ntegrated Preclinical/Clinical AID PCAVD) (U19 Clinical Trial Not Al	S Vaccine Development Program llowed)	National Institute of Allergy and Infectious Diseases/NIH/DHHS	PAR-23- 13-F 033 [Opt	eb-2023 ional][LOI/Pre-App	Not] Specified
	Contact Name	Sujata Vijh, Ph.D.				
	Contact Telephone	301-761-7713				
	Contact Email	sujata.vijh@nih.gov				



			i viii i aiiaii į	3 Opportunities			
SPIN ID	Program Title	Sp	ponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Sponsor Website						
	Program URL	Link to progr	ram URL				
	Deadline Dates (ALL)		3 [Optional][LOI/Pre-App], .OI/Pre-App], 14-Mar-2025	15-Mar-2023 , 14-Feb-2024 [Option	al][LOI/Pre-App],	15-Mar-2024 , 13-	Feb-2025
	The purpose of this Funding Opportunity Announcement (FOA) is to support translation of advanced HIV-1 vaccine candidates from pre-clinical studies through different phases of process and product development, Current Good Manufacturing Practice (CGMP) manufacturing and regulatory filing to the point of clinical testing. The FOA will support technology transfer, preclinical immunogenicity and optimization studies, process development, analytical assay development, qualification, validation, testing, small scale pilot or engineering runs, CGMP manufacture in partnership Pharma/Biotech/Contract Manufacturing Organizations (CMO), quality assurance/quality control oversight, fill-finish activities, product release and storage, generation of reference standard, drug substance and drug product stability test programs, Investigational New Drug (IND)-enabling studies, and regulatory submission preparation.						
77/17/11	RFA-AI-22-069 Cooperative Cer Clinical Trial Optional)	nters on Huma		National Institute of Allergy and nfectious Diseases/NIH/DHHS	RFA-AI- 08-1 22-069 [Op ²	Mar-2023 tional][LOI/Pre-Ap	12,500,000 p] USD
	Contact Name	Chao Jiang, F	Ph.D.				
	Contact Telephone	301-761-780	02				
	Contact Email	chao.jiang@	nih.gov				
	Sponsor Website	!					
	Program URL	Link to progr	ram URL				
	Deadline Dates (ALL)	08-Mar-2023	3 [Optional][LOI/Pre-App],	07-Apr-2023			
	Synopsis	Cooperative studies to dis	e Centers on Human Immur iscover novel molecules, m Ithy and vulnerable popula	ent (FOA) seeks to solicit application nology (CCHI) program. The program echanisms, or regulatory pathways tions (i.e., across lifespan, organ/tiss lated to prevention or treatment of	n supports mechal governing functio sue transplant rec	nistic and hypothe n of the human im ipients, pregnant v	sis-testing nmune system women).



benefits.

pathogenesis/sequelae associated with infectious disease, and/or immune-mediated diseases. This FOA also supports technology development to advance studies of the human immune system. The overarching goal of the CCHI is to provide foundational information on human immune system function to support translation of immunology research into clinical

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	NIAID Research Opportunities for Promote Workforce Diversity (R0	New and "At-Risk" Investigators to 1 Clinical Trial Optional)	National Institute of Allergy and Infectious Diseases/NIH/DHHS	PAR-22- 241	7-Jan-2023	Not Specified
	Contact Name	Diane Adger-Johnson, MPH				
	Contact Telephone					
	Contact Email	AlTrainingHelpDesk@niaid.nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	2023 , 07-Jan-2024 , 05-Feb-2024 , 0	.2023 , 07-May-2023 , 05-Jun-2023 , 05- 5-Mar-2024 , 07-May-2024 , 05-Jun-202 25 , 05-Mar-2025 , 07-May-2025 , 05-Ju	24 , 05-Jul-202	24 , 07-Sep-2024 , 05	-Oct-2024 , 05-
	Synopsis	mission. This FOA seeks to support e successfully for substantial, indepen- support as a PD/PI on a substantial in grant award in the current fiscal yea	unity announcement is to encourage ap either (a) a New Investigator (NI), an ind dent funding from NIH, or (b) are an 'At independent research award and unless r, will have no substantial research grar e from groups underrepresented in the	ividual who h -Risk' investig successful in at funding in t	as not previously corgator, an individual w securing a substantia he following fiscal ye	npeted ho had prior al research
112878	NIAMS Clinical Trial Planning Gran	nt (R34) - Clinical Trial Not Allowed	National Institute of Arthritis and Musculoskeletal and Skin Diseases/NIH/DHHS		11-Feb-2023 Optional][LOI/Pre-Ap	300,000 p] USD
	Contact Name	NIAMS Clinical Research Team				
	Contact Telephone					
	Contact Email	NIAMSclinicaltrials@mail.nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	01-Feb-2023 [Optional][LOI/Pre-App [Optional][LOI/Pre-App], 03-Nov-202], 03-Mar-2023 , 02-Jun-2023 [Optional 23][LOI/Pre-App	o], 02-Jul-2023 , 04-O	ct-2023
	Synopsis	trials. The R34 planning grant is design	ment (FOA) will support planning grants gned to enable the necessary planning, itiated clinical trials. Completion of the	design, and p	reparation of docum	entation prior

Program					Funding	
SPIN ID Title	Sponsor Name	Sponsor Number		Deadline Date	Amount	
	clinical trial implementation applica	been addressed is required prior to sub tion that will support the actual implem rial that is hypothesis-driven, milestone IIAMS.	entation and cond	duct of the study	. The planning	
100720 Clinical Observational (CO) Studi Skin Diseases (R01 Clinical Trial N	es in Musculoskeletal, Rheumatic, and Not Allowed)	National Institute of Arthritis and Musculoskeletal and Skin Diseases/NIH/DHHS	PAR-21- 053 03-M	lar-2023	475,000 USD	
Contact Name	e Yan Wang, M.D., Ph.D.					
Contact Telephone	e 301-594-5032					
Contact Ema	il wangy1@mail.nih.gov					
Sponsor Website	е					
Program UR	L Link to program URL					
Deadline Dates (ALL	.) 03-Mar-2023 , 02-Jul-2023 , 03-Nov	-2023				
Synopsi	Deadline Dates (ALL) O3-Mar-2023 , 02-Jul-2023 , 03-Nov-2023 This Funding Opportunity Announcement (FOA) is to encourage Research Project Grant (R01) applications to pure observational (CO) studies to obtain data necessary for designing clinical studies for musculoskeletal, rheumatic diseases or conditions. A future clinical study may include a clinical trial or an observational study. Research data observational studies supported by this FOA can enhance clinical study design by providing essential information disease symptoms, stages, and timing of disease progression; comorbid conditions; availability of potential research participants; and outcomes that are important to patients. They also can facilitate efforts to develop and/or valobjective biomarkers or subjective outcome measures for use in a future clinical study. Applicants to this FOA a encouraged to propose studies that address significant obstacles or questions in the design of a clinical project, determining the appropriate primary or secondary outcome measures or identifying the stages of disease during patients are most likely to respond to an intervention. Only observational studies will be supported through this					
100718 NIAMS Clinical Trial Implemental Clinical Trial Required)	tion Cooperative Agreement (U01	National Institute of Arthritis and Musculoskeletal and Skin Diseases/NIH/DHHS	PAR-21- 036	ar-2023	Not Specified	
Contact Name	e					
Contact Telephone	e					
Contact Ema	il NIAMSclinicaltrials@mail.nih.gov					



					_	
SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Sponsor Website					
	-	Link to program URL				
	Deadline Dates (ALL)	03-Mar-2023 , 02-Jul-2023 , 03-Nov-	2023			
	Synopsis	investigator-initiated interventional normally expected to go through a trapplication for the UO1 (Part 2). Investher means may apply for a NIAMS	ment (FOA) solicits cooperative agreem clinical trials (all phases). Applications for wo-part process, which begins with an stigators who have completed all necest U01 without an awarded R34. The NIA ithin the research mission of the NIAM	or clinical trials son clinical trials son R34 planning phassary pre-trial plass MS expects trials	ubmitted to the N ase (Part 1) followe anning and prepar	IAMS are ed by an ation through
	Exploratory Clinical Trial Grants in Skin Diseases (R21 Clinical Trial Re	n Arthritis and Musculoskeletal and equired)	National Institute of Arthritis and Musculoskeletal and Skin Diseases/NIH/DHHS	PAR-21- 045	Лаr-2023	400,000 USD
	Contact Name	Yan Wang, M.D., Ph.D.				
	Contact Telephone	301-594-5032				
	Contact Email	wangy1@mail.nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	03-Mar-2023 , 02-Jul-2023 , 03-Nov-	2023			
	Synopsis	timeframe and budget. A broad rang	ment (FOA) is designed to facilitate cling of e of types of exploratory studies may be ssion and goals of the NIAMS and may ral or rehabilitation therapies.	e submitted to t	his FOA. The trials	must address
	Notice of Special Interest (NOSI): on HIV/AIDS in NIAMS	Promoting Research Opportunities	National Institute of Arthritis and Musculoskeletal and Skin Diseases/NIH/DHHS	NOT- AR-23- 07-J: 004	an-2023	Not Specified
	Contact Name	Heiyoung Park, Ph.D.				
	Contact Telephone	301-594-5032				



Contact Email parkh1@mail.nih.gov

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Sponsor Website					
	Program URL <u>Linl</u>	k to program URL				
	202 16- Deadline Dates (ALL) Aug , 05 202 The	23, 07-Aug-2023, 07-Sep-2023, 07-Seb-2024, 04-Apr-2024, 07-May Feb-2024, 04-Apr-2024, 07-May 24, 06-Dec-2024, 07-Jan-2025, 0 g-2025, 07-Sep-2025, 05-Oct-202 5-Jun-2026, 16-Jun-2026, 07-Sep 27, 05-Jun-2027, 16-Jun-2027, 0 e purpose of this announcement i	2023, 03-Mar-2023, 06-Apr-2023, 07-M 05-Oct-2023, 16-Oct-2023, 03-Nov-2023, 02-2024, 05-Jun-2024, 16-Jun-2024, 06-Apr-2025, 16-Feb-2025, 09-Apr-2025, 05-Dec-2025, 07-Jan-20-2026, 05-Oct-2026, 16-Oct-2026, 07-Jan-20-2026, 05-Oct-2026, 16-Oct-2027, 16-Oct-2027, s to inform potential applicants to the National Special interest in HIV/AIDS-associat	3 , 06-Dec-2023 .ug-2024 , 07-Se , 07-May-2025 2026 , 05-Feb-2 an-2027 , 05-Fe , 07-Jan-2028 ational Institute	, 07-Jan-2024 , 05- ep-2024 , 05-Oct-20 , 05-Jun-2025 , 16- 026 , 16-Feb-2026 , eb-2027 , 16-Feb-20	Feb-2024 , 024 , 16-Oct- Jun-2025 , 06- , 07-May-2026 027 , 07-May- usculoskeletal
	mis	ssion.				
1 1 3 1 1 2 1 1 1	RFA-HD-23-025 Physiomimetics and Health (R21 Clinical Trial Not Allowed		National Institute of Child Health and Human Development/NIH/DHHS	HD-33-	Feb-2023 tional][LOI/Pre-App	275,000 b] USD
	Contact Name Ray	vi Ravindranath, DVM, PhD				
	Contact Telephone 301	L-435-6889				
	Contact Email <u>rav</u>	<u>indrn@mail.nih.gov</u>				
	Sponsor Website					
	Program URL <u>Lin</u> l	k to program URL				
	Deadline Dates (ALL) 28-	Feb-2023 [Optional][LOI/Pre-App], 29-Mar-2023			
	Synopsis exp risk	ture systems for studies of the fe cover factors responsible for gyne ploratory/developmental research k/high reward projects that lack p	ment (FOA) invites grant applications to male reproductive tract and gametogene ecological conditions and infertility. The Food in the early and continuing support for the early and continuing the most appropriated in RO1 mechanism (RFA-HD-23-024).	esis (both male R21 grant mech conceptual stag	and female) that ca anism is intended t es of project develo	an be used to o encourage opment. High
1131137	RFA-HD-23-024 Physiomimetics and Health (R01 Clinical Trial Not Allowed		National Institute of Child Health and Human Development/NIH/DHHS	HD-23-	Feb-2023 tional][LOI/Pre-App	Not o] Specified

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Contact Name	Ravi Ravindranath, DVM, PhD				
	Contact Telephone					
		ravindrn@mail.nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	•	28-Feb-2023 [Optional][LOI/Pre-App], 29-Mar-2023			
	Synopsis	culture systems for studies of the fer uncover factors responsible for gyne further development of projects who	ment (FOA) invites grant applications to male reproductive tract and gametogene cological conditions and infertility. This lere preliminary data supports the feasible o apply to the companion R21 FOA (RFA	esis (both male a FOA is intended lity of the line o	and female) that ca to provide suppor	an be used to
	Catalyzing Innovation in Pediatric I and Resource Access (X01 Clinical	Pharmacology Clinical Trial Design Trial Not Allowed)	National Institute of Child Health and Human Development/NIH/DHHS	PAR-20- 161	1ar-2023	Not Specified
	Contact Name	Perdita Taylor-Zapata, MD				
	Contact Telephone	301-496-9584				
	Contact Email	taylorpe@mail.nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	17-Mar-2023				
	Synopsis .	resource for planning activities and of address gaps in pediatric drug develon Act (BPCA) Program. The FOA will suthat require non-traditional designs Investigators will have access to the	nity announcement (FOA) is to provide in concept development for single or multipopment and that align with priorities ide poort the development of clinical trials of in pediatric therapeutics with the opport expertise in pediatric drug development its Network (PTN) and the BPCA Data Control of the province of the pr	site investigator ntified in the Be concepts of futur tunity to expand trial designs by	r initiated clinical t st Pharmaceutical re well-designed c I novelty and/or in utilizing the consu	rials that s for Children linical trials inovation.
113423	Advancing Methods for Safe, Noni Placenta Development and Function	nvasive, Real Time Assessment of on Across Pregnancy (R21 Clinical	National Institute of Child Health and Human Development/NIH/DHHS	PAR-22- 236 16-Fe	eb-2023	275,000 USD



	Program Title	Sponsor Name	Sponsor Number		II)eadline I)ate II	Funding Amount
	Comtost Name	Douid Wainhaus DhD				
	Contact Name i	David Weinberg, PhD				
	·	weinbergd@mail.nih.gov				
	Sponsor Website	wembergue man.mi.gov				
	,	Link to program URL				
			2023 , 16-Nov-2023 , 16-Oct-2024 , 16-N	lov-2024		
	Synopsis (•	ement (FOA) invites grant applications the levelopment of safe, real-time, non-invate human placenta across pregnancy.		•	
113425 P	-	nvasive, Real Time Assessment of on Across Pregnancy (R01 Clinical	National Institute of Child Health and Human Development/NIH/DHHS	PAR-22- 237	5-Feb-2023	Not Specified
	Contact Name	David Weinberg, PhD				
	Contact Telephone	<u> </u>				
	Contact Email	weinbergd@mail.nih.gov				
	Sponsor Website					
	Program URL I	Link to program URL				
	Deadline Dates (ALL)	05-Feb-2023 , 05-Mar-2023 , 05-Oct-	-2023 , 05-Nov-2023 , 05-Oct-2024 , 05-N	lov-2024		
	Synopsis	•	ement (FOA) invites grant applications the levelopment of safe, real-time, non-invate human placenta across pregnancy.		•	
112//10	FA-HD-24-002 Development of lethods (R61/R33 - Clinical Trial N	Novel Nonsteroidal Contraceptive Not Allowed)	National Institute of Child Health and Human Development/NIH/DHHS	HD-2//-	7-Feb-2023 Optional][LOI/Pre-App]	Not Specified
	Contact Name I	Daniel S. Johnston, PhD				
	Contact Telephone	301-827-4663				
	Contact Email	daniel.johnston@nih.gov				
	Sponsor Website					



SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Program URL	Link to program URL				
	=	27-Feb-2023 [Optional][LOI/Pre-Ap	p], 29-Mar-2023			
		The purpose of this funding opports approaches for the development of	unity announcement (FOA) is to support a novel nonsteroidal contraceptive produc on innovative and validated methods for	cts for men and v	women that act p	
TTZUUN -	RFA-HD-24-001 Pediatric Critica Development Program (K12 Clinic		National Institute of Child Health and Human Development/NIH/DHHS	RFA- HD-24- 29-N 001	1ar-2023	650,000 USD
	Contact Name	Tessie October, MD, MPH				
	Contact Telephone	301-451-4295				
	Contact Email	tessie.october@mail.nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	29-Mar-2023				
		development and training in resear Pediatric Critical Care and Trauma S trained investigators and advance r This Funding Opportunity Announce investigator of an independent clini	ement (FOA) invites applications to support ch for junior faculty in pediatric critical call scientist Development Program (PCCTSDP) esearch in the clinically demanding fields ement (FOA) allows appointment of Scho cal trial; or proposing a separate ancillary nother investigator, as part of their resea	re medicine and) was developed of pediatric criti lars (K12)] propo	I pediatric trauma I to fuel the pipelical care and trau osing to serve as t proposing to gair	surgery. The ne of well- ma surgery. he lead
113756	NCMRR Early Career Research Aw	ard (R03 Clinical Trial Optional)	National Institute of Child Health and Human Development/NIH/DHHS	PAR-23- 029 28-N	1ar-2023	200,000 USD
	Contact Name	Maria Nurminskaya, PhD				
	Contact Telephone	240-591-9986				
	Contact Email	Maria.nurminskaya@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	'					



SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Deadline Dates (ALL)		ar-2025 habilitation Research (NCMRR) Early Ca arch from rehabilitation scientists who	· · · · · · · · · · · · · · · · · · ·	•	
	Synopsis	The research must be focused on o to the NIH Research Plan on Rehabirehab-plan). The NCMRR ECR Awarexisting data; small, self-contained outcomes research; and development	ne or more of the areas within the miss litation for strategic priorities (https://wd R03 grant mechanism supports variouresearch projects; development of reseant of new technology. Irrespective of tor(s)/Principal Investigator(s) (PD(s)/P	ion of NCMRR: Ap www.nichd.nih.go is types of project: arch methodology he type of project,	plicants are encory/ newsroom/news including second r; translational res r, the intent of the	uraged to refer vs/110121-NIH- dary analysis of search; NCMRR ECR
III/hx-	Continuation or Revision of NIDC Cooperative Agreement (UH3 Clir		National Institute of Dental and Craniofacial Research/NIH/DHHS	PAR-22- 068	/lar-2023	Not Specified
	Contact Name	Dena Fischer, DDS, MSD, MS				
	Contact Telephone					
	Contact Email	<u>301-594-4876</u>				
	Sponsor Website	Link to sponsor website				
	Program URL	Link to program URL				
	Deadline Dates (ALL)	07-Mar-2023 , 06-Jul-2023 , 03-Nov	-2023 , 06-Mar-2024			
	Synopsis	ongoing clinical trials supported by ongoing clinical trial through a com complete the trial or when an exter revisions will be supported when the Applicants are strongly encouraged	ement (FOA) will accept applications fo the National Institute of Dental and Cra peting renewal application will be supp nded period of follow-up is well justified here is compelling justification for modit to contact the appropriate Scientific/R ng renewal or competitive revision prior	nniofacial Research orted when there d to assess longer fying the scope of esearch contact fo	n (NIDCR). Extensi is need for addition term outcomes. Continued the ongoing clinical the ongoing clirical the ong	on of an on an
106245	NIDCR Behavioral and Social Inter Implementation Cooperative Agre Required)	rvention Clinical Trial Planning and eement (UG3/UH3 Clinical Trial	National Institute of Dental and Craniofacial Research/NIH/DHHS	PAR-21- 317	an-2023	Not Specified
	Contact Name	Melissa W. Riddle, PhD				



1	SPIN ID	Program	Sponsor Name	Sponsor Number	Deadline Date	Funding	
١	SPIN ID	Title	Sponsor Name	Sponsor Number	Deadine Date	Amount	

Contact Telephone 301-451-3888

Contact Email riddleme@mail.nih.gov

Sponsor Website

Program URL Link to program URL

07-Jan-2023, 07-Feb-2023, 07-Mar-2023, 07-May-2023, 06-Jun-2023, 06-Jul-2023, 07-Sep-2023, 03-Oct-2023, 03-Nov-Deadline Dates (ALL) 2023 , 07-Jan-2024 , 06-Feb-2024 , 06-Mar-2024 , 07-May-2024

The purpose of this Funding Opportunity Announcement (FOA) is to encourage UG3/UH3 phased cooperative agreement research applications to plan and implement behavioral and social intervention clinical trials. Studies appropriate for this FOA include clinical trials to develop and test behavior change interventions related to dental, oral, or craniofacial conditions. Applications for NIDCR support of clinical trials research are expected to identify research proposals using the NIH Stage Model framework, described in detail here and incorporate an experimental medicine approach. Awards made under this FOA will initially support a milestone-driven UG3 planning phase for up to 2 years, with possible transition to a UH3 clinical trial implementation phase (UH3) of up to five years. The UG3 phase for behavioral and social intervention clinical trials will permit both scientific and operational planning activities. Scientific planning activities include small-scale data collection to assess the feasibility and/or acceptability of a planned behavioral or social intervention and associated study procedures (e.g., acceptability of study content or mode of delivery; feasibility of proposed data collection procedures; preliminary testing of intervention training and fidelity monitoring procedures). Operational planning activities include, at a minimum, development of: the final clinical protocol; the intervention manual or equivalent; the data management system and other tools for data and quality management, safety and operational oversight plans; recruitment and retention strategies; and other essential documents. The UH3 phase will support the conduct of investigator-initiated intervention research at all stages, from early mechanistic research and intervention development (e.g., Stages 0/ I) through implementation and health services research (Stages IV/V). This FOA may also support basic behavioral experimental studies with humans that are considered clinical trials based on the NIH's revised clinical trial definition (please see Clinical Trial

Synopsis

RFA-DK-22-039 -- Toward ElucidAting MechanismS of HIV 113833 Pathogenesis within the Mission of the NIDDK (Pathogenesis TEAMS) (R01 Clinical Trial Optional)

National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS

RFA-DK- 15-Feb-2023 2,500,000 22-039 [Optional][LOI/Pre-App] USD

Contact Name Peter J. Perrin, Ph.D. Contact Telephone 301-451-3759 Contact Email Peter.Perrin@nih.gov

Requirements for Grants and Contracts for guidance).

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount	
	1100						
	Sponsor Website						
	Program URL	Link to program URL					
	Deadline Dates (ALL)	15-Feb-2023 [Optional][LOI/Pre-App], 15-Mar-2023				
	Synopsis	expertise in HIV and pathobiology, pa specific interest to the National Instit comprehensively interrogate fundam	ment (FOA) seeks to support multidiscip athophysiology, and/or metabolism in o tute of Diabetes and Digestive and Kidn nental biological mechanisms underlyin ssion of the NIDDK and advance progre	organs, tissues, a ey Diseases (NID g HIV-associated	nd/or biological sy DK). These teams v comorbidities, co-	stems of will infections,	
112542	RFA-DK-22-018 Human Islet Re Knowledgebase Program (PanKba	search Network (HIRN) Pancreas ase) (U24 - Clinical Trial Not Allowed)	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	RFA-DK- 28-F6 22-018 [Opti	eb-2023 ional][LOI/Pre-App	Not o] Specified	
	Contact Name	Ann A. Jerkins, Ph.D.					
	Contact Telephone	301-594-2242					
	Contact Email	ann.jerkins@nih.gov					
	Sponsor Website						
	Program URL	Link to program URL					
	Deadline Dates (ALL)	28-Feb-2023 [Optional][LOI/Pre-App], 31-Mar-2023				
	Synopsis	This Funding Opportunity Announcement (FOA) invites applications to develop a centralized resource of the human pancreas for diabetes research that will provide access to deeply curated high-quality datasets, knowledge in computab forms, and advanced data science tools and workflows; and enable open and reproducible multidisciplinary collaboratic toward accelerating biomarker and therapeutic target development. The program will become a component of the Hum Islet Research Network or HIRN (https://hirnetwork.org/).					
III/nxn	RFA-DK-21-030 New Investigato T1D Research (R03 Clinical Trial N	or Gateway Awards for Collaborative lot Allowed)	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	RFA-DK- 20-F6 21-030 [Opti	eb-2023 ional][LOI/Pre-App	200,000 b] USD	
	Contact Name	Kristin M. Abraham, Ph.D					
	Contact Telephone	301-451-8048					
	Contact Email	abrahamk@mail.nih.gov					



SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Sponsor Website					
	Program URL	<u>Link to program URL</u>				
	Deadline Dates (ALL)	20-Feb-2023 [Optional][LOI/Pre-App], 20-Mar-2023			
		investigators will continue to embarl research, the Gateway program provpursue their studies within the intell programs. Embedding awardees witl opportunities for New andEarly Stag and to establish unique and potential	ed in T1D Research is designed to ensur k on successful careers in T1D research vides an opportunity for new Program [ectual environment of a select number hin an established scientific framework e Investigators to increase their unders ally long-lasting collaborations that will support needed to enhancethe success research.	. In addition to properties. In addition to properties. In addition to properties. In addition to propel their cares.	roviding support for all Investigators (PI g collaborative res consortia will provuestions in the fiel ers forward. It is a	or preliminary D/PIs) to earch vide unique d, to network nticipated th
11/160	NIDDK Central Repository Non-rei	newable Sample Access (X01 Clinical	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	PAR-22- 171 02-N	Лаr-2023	Not Specified
	Contact Name	Rebecca M. Rodriguez, Ph.D				
	Contact Telephone	301-451-0323				
	Contact Email	rebecca.rodriguez2@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	02-Mar-2023 , 29-Jun-2023 , 26-Oct-	2023, 01-Mar-2024, 27-Jun-2024, 29-	Oct-2024 , 04-Ma	ar-2025 <i>,</i> 25-Jun-2	025
	Synopsis	initiative allows investigators to appl about the samples available can be f	es valuable biological samples and data ly for access to non-renewable samples found at the Repository's website. Appl Central Repository with the X01 Applica	from one or mor icants must includ	re of these studies de a volume and i	a. Information mpact
	RFA-DK-21-033 KUH Predoctora Award (F99/K00 - Independent Cli	al to Postdoctoral Fellow Transition inical Trial Not Allowed)	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	RFA-DK- 21-033	Лаr-2023	Not Specified
	Contact Name	Christine Maric-Bilkan, Ph.D				



SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Sponsor Website	christine.maric-bilkan@nih.gov				
	Deadline Dates (ALL)	30-Mar-2023 , 01-Aug-2023 , 30-No	v-2023 , 02-Apr-2024 , 01-Aug-2024 , 0	3-Dec-2024 , 01-A	pr-2025	
	Synopsis	recruit truly exceptional graduate st research, and provide them a stable Strong candidates will bring novel al statistics, data science, imaging, bio U, or H research are not eligible for National Research Service Award (N are strongly encouraged to contact This Funding Opportunity Announce	or Hematology (KUH) Predoctoral to Poudents, who are currently not involved transition into a postdoctoral research pproaches and diverse perspectives from the chemistry, neuroscience and genetics. This F99/K00 award and are instead energy in the NIDDK Program Official early in the ement (FOA) does not allow applicants are research experience in a clinical trial	I in Kidney, Urolog n experience focus om fields including, Graduate students couraged to apply (Parent F31, PA-2 process to discuss to propose to lead	y or Hematology (sed on K, U, or H ro, but not limited to so who are already for the Ruth L. King 1-051). Prospectives eligibility and productions and independent of the selections.	(K, U or H) esearch. o, engineering involved in K, rschstein ve applicants ogram goals.
11/4/5/4	RFA-DK-22-017 NIDDK Informat dkNET-CU (U24 Clinical Trial Not A		National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	RFA-DK- 28-Fe 22-017 [Opti	eb-2023 ional][LOI/Pre-Ap	Not p] Specified
	Contact Name	Xujing Wang, Ph.D.				
	Contact Telephone	301-451-2862				
	Contact Email	xujing.wang@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				

Synopsis

Deadline Dates (ALL) 28-Feb-2023 [Optional][LOI/Pre-App], 31-Mar-2023

The purpose of this Funding Opportunity Announcement (FOA) is to continue development and expansion of the NIDDK Information Network (dkNET) under the direction of the dkNET Coordinating Unit (dkNET-CU). dkNET supports the NIDDK community's needs in data science by providing an information portal that connects users to data, analytical tools, and other biomedical research resources. Additionally, dkNET supports researchers by providing a hub for data-driven hypothesis generation; a suite of tools that assist users in FAIR (Findable, Accessible, Interoperable, Reusable) practice, and in improving rigor and reproducibility in research; and a variety of programs to enhance community engagement and workforce

SPIN ID Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	development. The dkNET-CU will be management to advance dkNET goa	responsible for providing the scientific ls.	direction, vision, and administra	iive
113279 <u>Limited Competition: Small Gran</u> K01/K08/K23/K25 Recipients (R0		National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	PAR-22- 129 07-Jan-2023	150,000 USD
Contact Name	Lisa M. Spain, Ph.D.			
Contact Telephone	301-451-9871			
Contact Emai	SpainL@niddk.nih.gov			
Sponsor Website	9			
Program UR	Link to program URL			
Deadline Dates (ALL) 2023 , 07-Jan-2024 , 16-Feb-2024 , 1	-2023 , 07-May-2023 , 16-Jun-2023 , 16- .6-Mar-2024 , 07-May-2024 , 16-Jun-202 25 , 16-Mar-2025 , 07-May-2025 , 16-Ju	24 , 16-Jul-2024 , 07-Sep-2024 , 1	6-Oct-2024 , 16-
Synopsi	supported K01, K08, K23, and K25 re the award period of their K award. T K01, K08, K23, and K25 award recipi s investigator status. The R03 grant m secondary analysis of existing data; development of new research techn	nd Digestive and Kidney Diseases (NIDD) ecipients the opportunity to apply for Sribrough the use of this mechanism, the ents to conduct research as they complectanism supports different types of presmall, self-contained research projects; tology. The RO3 is, therefore, intended the nited resources and that may provide present the second	mall Grant (R03) support during t NIDDK is seeking to enhance the ete their transition to fully indep rojects, including pilot and feasib development of research metho o support research projects that	he latter years of capability of its endent ility studies; dology; and can be carried
RFA-DK-22-027 Fostering Rese 114404 Development (FORWARD) Urolo Allowed)	arch With Additional Resources and gy Centers (P20 Clinical Trial Not	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	RFA-DK- 08-Feb-2023 22-027 [Optional][LOI/Pre- <i>A</i>	750,000 (pp] USD
Contact Name	Julia Barthold, M.D.			
Contact Telephone	301-594-9655			
Contact Emai	l julia.barthold@nih.gov			
Sponsor Website	2			



|--|

Program URL Link to program URL

Deadline Dates (ALL) 08-Feb-2023 [Optional] [LOI/Pre-App], 08-Mar-2023, 19-Oct-2023

The overall goal of the Fostering Research with Additional Resources and Development (FORWARD) Urology Centers program is to foster and expand the urology (excluding cancer) research community. The objective of each FORWARD Urology Center will be to support a Research Project designed and conducted by a collaborative, multidisciplinary team comprising primarily of junior investigators with at least one Early Stage Investigator (ESI) and/or researcher new to urology. Research Project data are expected to support one or more follow-on independent grant applications (e.g., R01s) submitted by Research Project Team investigators. The Center PD(s)/PI(s) will lead an Administrative (Project Support) Core to provide guidance to the Research Project Team to help ensure the research aims are met and to aid them in their successful integration into the broader urologic research field. The Center will leverage intra- and extra-institutional resources, collaborations and facilities and engage as a member of NIDDK's CAIRIBU (Collaborating for the Advancement of Interdisciplinary Research in Benign Urology) Program.

RFA-ES-22-010 -- Environmental Health Sciences Core Centers (EHSCC) National Institute of Environmental 114249

RFA-ES- 19-Mar-2023

3,400,000

(P30 Clinical Trial Optional)

Health Sciences/NIH/DHHS

22-010 [Optional][LOI/Pre-App] USD

Contact Name Claudia Thompson, Ph.D.

Contact Telephone 984-287-3330

Contact Email thomps14@niehs.nih.gov

Sponsor Website

Program URL Link to program URL

Deadline Dates (ALL) 19-Mar-2023 [Optional] [LOI/Pre-App], 19-Apr-2023, 19-Mar-2024 [Optional] [LOI/Pre-App], 19-Apr-2024

This Funding Opportunity Announcement (FOA) invites grant applications for Environmental Health Sciences Core Centers (EHS CC). As intellectual hubs for environmental health science research, the EHS CC is expected to be the thought leaders for the field and advance the goals of the NIEHS Strategic Plan (http://www.niehs.nih.gov/about/strategicplan/). The Core Centers provide critical research infrastructure, shared facilities, services and/or resources, to groups of investigators Synopsis conducting environmental health sciences research. An EHS CC enables researchers to conduct their independently-funded individual and/or collaborative research projects more efficiently and/or more effectively. The overall goal of an EHS CC is to identify and capitalize on emerging issues that advance improving the understanding of the relationships among environmental exposures, human biology, and disease. The EHS CC supports community engagement and translational research as key approaches to improving public health.

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
108465	Notice of Special Interest (NOSI): Curriculum or Training Activities to the Training Environment	Administrative Supplements for to Enhance Wellness and Resiliency in	National Institute of General Medical Sciences/NIH/DHHS	NOT- GM-22- 15-N 015	Mar-2023	80,000 USD
	Contact Name	Laurie Stepanek, Ph.D.				
	Contact Telephone					
	Contact Email	laurie.stepanek@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	15-Mar-2023				
	Synopsis	institutional career development (Konverwhelming and lead to stress, an evidence-informed curricular or trait to enhance wellness and resiliency is	GMS institutional training (T32, T34), cert 12) awards. Navigating the biomedical re exiety and self-doubt. The funds will supp ining activities to provide trainees and pa in the training environment. Together with ability of individuals to be successful in the	search training ort the develop rticipating facu :h promoting sa	pathway can seen oment and implem Ity with the knowl afe and inclusive e	n eentation of edge and skills nvironments,
108464	Notice of Special Interest (NOSI): Curriculum or Training Activities t Research Training Environment		National Institute of General Medical Sciences/NIH/DHHS	NOT- GM-22- 15-N 014	Mar-2023	80,000 USD
	Contact Name	Kenneth Gibbs, Ph.D.				
	Contact Telephone	,				
	·	kenneth.gibbs@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)					
	Synopsis	Supplements to institutions with NIC research education program (R25, s	edical Sciences (NIGMS) announces the a GMS institutional training (T32, T34), inst ee below)awards. The supplement award at through the development of evidence-i	itutional career Is will provide f	r development (K1 funds to enhance r	2), or certain mentor training

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		• •	r these training materials should be resear ugh use of the materials to also build skills		•	
108461	Notice of Special Interest (NOSI): Curriculum or Training Modules t Biomedical Research Training		National Institute of General Medical Sciences/NIH/DHHS	NOT- GM-22- 15-N 012	1ar-2023	80,000 USD
	Contact Telephone Contact Email Sponsor Website	Link to program URL				
	Synopsis	Supplements to institutions with ur	Nedical Sciences (NIGMS) announces the andergraduate NIGMS institutional training ort the development and implementation	(T34) or certain	research educat	ion (R25, see
108463	Notice of Special Interest (NOSI): Enhance Program Evaluation Cap		National Institute of General Medical Sciences/NIH/DHHS	NOT- GM-22- 15-N 013	1ar-2023	80,000 USD
	Contact Telephone Contact Email Sponsor Website	kenneth.gibbs@nih.gov				



Biomedical Research Training Environments Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL) The National Institute of General Medical Sciences (NIGMS) announces the availability of funds for Administrative Supplements to institutions with NIGMS institutional training (T32, T34), institutional career development (K12), or certain Synopsis curricular or training activities to provide trainees and participating faculty with the knowledge and skills to enhance laboratory safety and to promote a culture of safety in the training environment. Notice of Special Interest (NOSI): Administrative Supplements for Curriculum or Training Modules to Promote Safe and Inclusive Biomedical Research Training Environments Contact Name Contact Telephone Contact Telephone Contact Telephone Contact Email alison.gammie@nih.gov					
activities and are expected to disseminate their outcomes to the broader community. The supplement awards will provide funds to enhance the institutional evaluation capacity to help meet these expectations for program evaluation. Plans for sustainability of the enhanced evaluation capacity beyond the funding period should be included in the supplement application Notice of Special Interest (NOSI): Administrative Supplements to Enhance Laboratory Safety Curriculum and a Culture of Safety in Biomedical Research Training Environments Contact Name Contact Name Contact Email Sponsor Website Program URL Link to program URL Deadline Dates (ALL) 15-Mar-2023 The National Institute of General Medical Sciences (NIGMS) announces the availability of funds for Administrative Supplements to institutions with NIGMS institutional training (T32, T34), institutional career development (K12), or certain research education program (R25, see below) awards. The funds will support the development and implementation of curricular or training activities to provide trainees and participating faculty with the knowledge and skills to enhance laboratory safety and to promote a culture of safety in the training environment. Notice of Special Interest (NOSI): Administrative Supplements for Curriculum or Training Modules to Promote Safe and inclusive Biomedical Research Training Environments Contact Telephone Contact Telephone Contact Email Alison Gammie, Ph.D. Contact Telephone Contact Email alison, gammie@nih.gov	SPIN II)	Sponsor Name	Sponsor Number	Deadline Date	
108458 Enhance Laboratory Safety Curriculum and a Culture of Safety in Biomedical Research Training Environments Contact Name Contact Telephone Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL) The National Institute of General Medical Sciences/NIH/DHHS Michelle R. Bond, Ph.D. Link to program URL Deadline Dates (ALL) The National Institute of General Medical Sciences (NIGMS) announces the availability of funds for Administrative Supplements to institutions with NIGMS institutional training (T32, T34), institutional career development (K12), or certain research education program (R25, see below) awards. The funds will support the development and implementation of curricular or training activities to provide trainees and participating faculty with the knowledge and skills to enhance laboratory safety and to promote a culture of safety in the training environment. Notice of Special Interest (NOSI): Administrative Supplements for Curriculum or Training Modules to Promote Safe and Inclusive Biomedical Research Training Environments Contact Name Contact Telephone Contact Telephone Contact Email alison.gammie@nih.gov		activities and are expected to disse funds to enhance the institutional sustainability of the enhanced eval	eminate their outcomes to the broader cor evaluation capacity to help meet these ex	mmunity. The supplement award pectations for program evaluation	ls will provide on. Plans for
Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL) Deadline Dates (ALL) The National Institute of General Medical Sciences (NIGMS) announces the availability of funds for Administrative Supplements to institutions with NIGMS institutional training (T32, T34), institutional career development (K12), or certain Synopsis research education program (R25, see below) awards. The funds will support the development and implementation of curricular or training activities to provide trainees and participating faculty with the knowledge and skills to enhance laboratory safety and to promote a culture of safety in the training environment. Notice of Special Interest (NOSI): Administrative Supplements for Curriculum or Training Modules to Promote Safe and Inclusive Biomedical Research Training Environments National Institute of General Medical Sciences/NIH/DHHS Notice of Special Interest (NOSI): Administrative Supplements for Sciences/NIH/DHHS Notice of Special Interest (NOSI): Administrative Supplements for Sciences/NIH/DHHS Notice of Special Interest (NOSI): Administrative Supplements for Sciences/NIH/DHHS Notice of Special Interest (NOSI): Administrative Supplements for Sciences/NIH/DHHS Notice of Special Interest (NOSI): Administrative Supplements for Sciences/NIH/DHHS Notice of Special Interest (NOSI): Administrative Supplements for Sciences/NIH/DHHS Notice of Special Interest (NOSI): Administrative Supplements for Sciences/NIH/DHHS Notice of Special Interest (NOSI): Administrative Supplements for Sciences/NIH/DHHS Notice of Special Interest (NOSI): Administrative Supplements for Sciences/NIH/DHHS Notice of Special Interest (NOSI): Administrative Supplements for Sciences/NIH/DHHS Notice of Special Interest (NOSI): Administrative Supplements for Sciences/NIH/DHHS Notice of Special Interest (NOSI): Administrative Supplements for Sciences/NIH/DHHS Notice of Special Interest (NOSI): Administrative Supplements for Sciences/NIH/DHHS Notice of Special Interest (NOSI): Administrat	108458 Enhance Laboratory Safety (Curriculum and a Culture of Safety in		GM-22- 15-Mar-2023	80,000 USI
Contact Email Sponsor Website Program URL Deadline Dates (ALL) Deadline Dates (ALL) The National Institute of General Medical Sciences (NIGMS) announces the availability of funds for Administrative Supplements to institutions with NIGMS institutional training (T32, T34), institutional career development (K12), or certain synopsis research education program (R25, see below) awards. The funds will support the development and implementation of curricular or training activities to provide trainees and participating faculty with the knowledge and skills to enhance laboratory safety and to promote a culture of safety in the training environment. Notice of Special Interest (NOSI): Administrative Supplements for Curriculum or Training Modules to Promote Safe and Inclusive Biomedical Research Training Environments Contact Name Contact Telephone Contact Telephone Contact Email Alison Gammie, Ph.D.		·			
Sponsor Website Program URL Deadline Dates (ALL) The National Institute of General Medical Sciences (NIGMS) announces the availability of funds for Administrative Supplements to institutions with NIGMS institutional training (T32, T34), institutional career development (K12), or certain research education program (R25, see below) awards. The funds will support the development and implementation of curricular or training activities to provide trainees and participating faculty with the knowledge and skills to enhance laboratory safety and to promote a culture of safety in the training environment. Notice of Special Interest (NOSI): Administrative Supplements for Curriculum or Training Modules to Promote Safe and Inclusive Biomedical Research Training Environments Contact Name Contact Telephone Contact Telephone Contact Email alison.gammie@nih.gov	·				
Program URL Deadline Dates (ALL) 15-Mar-2023 The National Institute of General Medical Sciences (NIGMS) announces the availability of funds for Administrative Supplements to institutions with NIGMS institutional training (T32, T34), institutional career development (K12), or certain research education program (R25, see below) awards. The funds will support the development and implementation of curricular or training activities to provide trainees and participating faculty with the knowledge and skills to enhance laboratory safety and to promote a culture of safety in the training environment. Notice of Special Interest (NOSI): Administrative Supplements for Curriculum or Training Modules to Promote Safe and Inclusive Biomedical Research Training Environments Notice of Special Interest (NOSI): Administrative Supplements for Sciences/NIH/DHHS Notice of Special Interest (NOSI): Administrative Supplements for Sciences/NIH/DHHS Notice of Special Interest (NOSI): Administrative Supplements for Sciences/NIH/DHHS Notice of Special Interest (NOSI): Administrative Supplements for Sciences/NIH/DHHS Notice of Special Interest (NOSI): Administrative Supplements for Sciences/NIH/DHHS Notice of Special Interest (NOSI): Administrative Supplements for Sciences/NIH/DHHS Notice of Special Interest (NOSI): Administrative Supplements for Special Interes					
Deadline Dates (ALL) The National Institute of General Medical Sciences (NIGMS) announces the availability of funds for Administrative Supplements to institutions with NIGMS institutional training (T32, T34), institutional career development (K12), or certain research education program (R25, see below) awards. The funds will support the development and implementation of curricular or training activities to provide trainees and participating faculty with the knowledge and skills to enhance laboratory safety and to promote a culture of safety in the training environment. Notice of Special Interest (NOSI): Administrative Supplements for Curriculum or Training Modules to Promote Safe and Inclusive Biomedical Research Training Environments Contact Name Contact Telephone Contact Telephone Contact Telephone Contact Email alison.gammie@nih.gov	·				
The National Institute of General Medical Sciences (NIGMS) announces the availability of funds for Administrative Supplements to institutions with NIGMS institutional training (T32, T34), institutional career development (K12), or certain research education program (R25, see below) awards. The funds will support the development and implementation of curricular or training activities to provide trainees and participating faculty with the knowledge and skills to enhance laboratory safety and to promote a culture of safety in the training environment. Notice of Special Interest (NOSI): Administrative Supplements for Curriculum or Training Modules to Promote Safe and Inclusive Biomedical Research Training Environments Notice of Special Interest (NOSI): Administrative Supplements for Sciences/NIH/DHHS National Institute of General Medical Sciences/NIH/DHHS Sciences/NIH	•				
Supplements to institutions with NIGMS institutional training (T32, T34), institutional career development (K12), or certain research education program (R25, see below) awards. The funds will support the development and implementation of curricular or training activities to provide trainees and participating faculty with the knowledge and skills to enhance laboratory safety and to promote a culture of safety in the training environment. Notice of Special Interest (NOSI): Administrative Supplements for Curriculum or Training Modules to Promote Safe and Inclusive Biomedical Research Training Environments Contact Name Contact Telephone Contact Telephone Contact Telephone alison.gammie@nih.gov	Deadline Dates				
108459 Curriculum or Training Modules to Promote Safe and Inclusive Biomedical Research Training Environments Contact Name Contact Telephone Contact Email alison.gammie@nih.gov	Syn	Supplements to institutions with Nopsis research education program (R25, curricular or training activities to p	IIGMS institutional training (T32, T34), inst see below) awards. The funds will support provide trainees and participating faculty w	itutional career development (K the development and impleme ith the knowledge and skills to e	12), or certain ntation of
Contact Telephone Contact Email alison.gammie@nih.gov	108459 Curriculum or Training Mod	ules to Promote Safe and Inclusive		GM-22- 15-Mar-2023	80,000 USI
Contact Email <u>alison.gammie@nih.gov</u>	Contact N	Name Alison Gammie, Ph.D.			
	Contact Telep	hone			
Spansor Walsita	Contact	Email alison.gammie@nih.gov			
Sporisor website	Sponsor We	ebsite			
Program URL Link to program URL	Program	n URL Link to program URL			
Deadline Dates (ALL) 15-Mar-2023	Doodling Dates				



					_	
SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Synopsis	Supplements to institutions with NIC research education (R25, see below	edical Sciences (NIGMS) announces the a GMS institutional training (T32, T34), ins) awards. The funds will support the dev and inclusive biomedical research training	titutional career elopment and in	development (K1	2), or certain
	Notice of Special Interest (NOSI): Support Undergraduate Summer		National Institute of General Medical Sciences/NIH/DHHS	NOT- GM-22- 15-N 009	Лar-2023	Not Specified
	Contact Name Contact Telephone Contact Email Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	15-Mar-2023 , 15-Mar-2024				
	Synopsis	Supplements to NIGMS-funded R01	edical Sciences (NIGMS) announces the a , R35, and R37 awards. These funds are a edical research careers by providing auth ummer.	intended for sup	port of undergrad	uate students
	Data Harmonization, Curation and Clinical Datasets (R61/R33 Clinica		National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-22- 055	⁄lar-2023	Not Specified
	Contact Name	Christine Swanson-Fischer, PhD				
	Contact Telephone	301-496-5680				
	Contact Email	christine.swanson-fischer@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	14-Mar-2023 , 14-Mar-2024				
	Synopsis	analysis, using existing datasets fror	ment invites applications from multidisc n two or more multi-site clinical researc veness research. Secondary analyses sho	h projects, includ	ding clinical trials,	natural history



SPIN ID	Program Title	Sponsor Name	Sponsor Number			Funding Amount
		data harmonization and curation, assexisting clinical data. Consistent with	pplications are required to systemation is sessed using go/no-go data-quality months the FAIR (findable, accessible, interoalloging of the processes and tools use	cally and comprehe etrics, prior to perf perable and reusal	ensively perform cr forming secondary ble) data principles	oss-project analyses of , this funding
103697	RFA-NS-21-012 NIH Blueprint a Specialized Predoctoral to Postdo (D-SPAN) Award (F99/K00 Clinical	ctoral Advancement in Neuroscience	National Institute of Neurological Disorders and Stroke/NIH/DHHS	RFA-NS- 15-N 21-012 [Opt	//ar-2023 ional][LOI/Pre-App	Not Specified
	Contact Name	Michelle Jones-London, PhD				
	Contact Telephone	301-451-7966				
	Contact Email	jonesmiche@ninds.nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	15-Mar-2023 [Optional][LOI/Pre-App], 14-Apr-2023 , 15-Nov-2023 [Optior	nal][LOI/Pre-App],	15-Dec-2023	
	Synopsis	Award is to support a defined pathw including those from groups underre completion of the doctoral dissertati postdoctoral positions, and will provibecoming independent neuroscience	ersity Specialized Predoctoral to Post ay across career stages for outstandir presented in biomedical and behavio on and transition of talented graduat de career development opportunities e researchers. This Funding Opportuni inical trial, but does allow applicants	ng graduate studen ral sciences. This to e students to stror s relevant to their l ity Announcement	nts from diverse bac wo-phase award wing ng neuroscience res long-term career go (FOA) does not allo	ckgrounds, Il facilitate earch oal of ow applicant
IIX5XX/I		ement of Chronic Conditions (R21	National Institute of Nursing	PAR-19-	eb-2023	400,000
	Clinical Trial Optional)		Research/NIH/DHHS	382		USD
	Contact Name	Karen Huss, PhD, RN, APRN-BC, FAAN	I, FAAAAI			
	Contact Telephone	301-594-5970				
	Contact Email	hussk@mail.nih.gov				
	Sponsor Website					



SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Title					Amount
	Program URL	Link to program URL				
	_	16-Feb-2023 , 16-Mar-2023 , 07-May	y-2023			
	Synopsis	The purpose of this Funding Opport patient activation on self-manageme	unity Announcement is to encourage ont of chronic conditions.	e grant applications	that address the	influence of
1106001 -	Patient Activation for Self-Manag Clinical Trial Optional)	ement of Chronic Conditions (R01	National Institute of Nursing Research/NIH/DHHS	PAR-19- 381	eb-2023	Not Specified
	Contact Name	Karen Huss, PhD, RN, APRN-BC, FAAN	N, FAAAAI			
	Contact Telephone	301-594-5970				
	Contact Email	hussk@mail.nih.gov				
	Sponsor Website					
	· ·	<u>Link to program URL</u>				
	Deadline Dates (ALL)	05-Feb-2023 , 05-Mar-2023 , 07-May				
	Synopsis	The purpose of this Funding Opport patient activation on self-manageme	unity Announcement is to encourage ent of chronic conditions.	e grant applications	that address the	influence of
	NINR Areas of Emphasis for Resea Health Equity (R01 Clinical Trial O	arch to Optimize Health and Advance ptional)	National Institute of Nursing Research/NIH/DHHS	PAR-22- 230	an-2023	Not Specified
	Contact Name	David L. Tilley, MPH, MS, CPH				
	Contact Telephone	301-827-6014				
	Contact Email	david.tilley@nih.gov				
	Sponsor Website					
	Program URL	<u>Link to program URL</u>				
	Deadline Dates (ALL)	07-Jan-2023 , 05-Feb-2023 , 05-Mar- 2023 , 07-Jan-2024 , 05-Feb-2024 , 0	5-Mar-2024 , 07-May-2024 , 05-Jun-2		•	-
		Nov-2024 , 07-Jan-2025 , 05-Feb-202	5 , 05-Mar-2025 , 07-May-2025			



SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		nation's most pressing and persister study designs to inform practice and	nt health challenges with a solutions orierd policy.	ntation, and em _l	ploy innovative ar	nd rigorous
	NINR Areas of Emphasis for Resea Health Equity (R21 Clinical Trial O	arch to Optimize Health and Advance ptional)	National Institute of Nursing Research/NIH/DHHS	PAR-22- 231	n-2023	200,000 USD
	Contact Telephone Contact Email Sponsor Website Program URL	david.tilley@nih.gov Link to program URL 07-Jan-2023 , 16-Feb-2023 , 16-Mar	-2023 , 07-May-2023 , 16-Jun-2023 , 16-Ju 16-Mar-2024 , 07-May-2024 , 16-Jun-2024 25 , 16-Mar-2025 , 07-May-2025	•		
	Synopsis	are consistent with the research fra Strategic Plan. This research will be	s R21 grant applications that propose exp mework detailed in the 2022-2026 Nation rooted in nursing's holistic, contextualize ressing and persistent health challenges was to inform practice and policy.	nal Institute of N d approach to u	lursing Research (nderstanding peo	NINR) ple and their
113465	Notice of Special Interest (NOSI): Diagnosis and Clinical Studies in A Related Dementias (ADRD)	The state of the s	National Institute on Aging/NIH/DHHS	NOT- AG-22- 05-Ja 032	nn-2023	Not Specified
	Contact Name	Lorenzo M. Refolo, Ph.D.				
	Contact Telephone	301-594-7576				
	Contact Email	refolol@nia.nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	2023 , 07-Sep-2023 , 05-Oct-2023 , 3	2023 , 10-Mar-2023 , 05-Apr-2023 , 07-M 13-Nov-2023 , 05-Jan-2024 , 05-Jan-2024 024 , 09-Jul-2024 , 05-Sep-2024 , 07-Sep-2 y-2025 , 05-Jun-2025 , 05-Sep-2025	, 07-Jan-2024 , (05-Feb-2024 , 11-	Mar-2024 , 05-



SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Synopsis	Positron Emission Tomography (PET)	invites applications for research grants to for use in Alzheimer's disease (AD) and a gical process or molecular pathways tha odegeneration.	AD-related dem	nentias (ADRD) res	cers for earch
108282	Notice of Special Interest (NOSI): Epidemiology of Alzheimer's Disea Dementias (AD/ADRD) and Cognit	ase and Alzheimer's Disease-Related	National Institute on Aging/NIH/DHHS	NOT- AG-21- 10-M 045	Лаr-2023	Not Specified
	Contact Telephone	Dallas W. Anderson, Ph.D. 301-402-6693 dallas.anderson@nih.gov				
	Sponsor Website Program URL Deadline Dates (ALL)	Link to program URL 10-Mar-2023 , 10-Jul-2023 , 13-Nov-2 This Notice of Special Interest (NOSI) relevant to AD/ADRD and cognitive re	023 , 11-Mar-2024 , 09-Jul-2024 , 12-No encourages investigator-initiated resear esilience, but identifies specific areas tha ied in the 2018 and 2021 Alzheimer's D	rch on all aspect at build on curre	ent efforts suppor	0,
108279	Sponsor Website Program URL Deadline Dates (ALL)	Link to program URL 10-Mar-2023, 10-Jul-2023, 13-Nov-2 This Notice of Special Interest (NOSI) relevant to AD/ADRD and cognitive rewell as gaps and opportunities identif	encourages investigator-initiated resear silience, but identifies specific areas that	rch on all aspect at build on curre isease Research NOT-	ent efforts suppor	0,



SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		biology that have not been adeq	e complex biology of AD to fill critical know uately addressed in the past. Applicants a I to integrate the use of human data and b	re encouraged to	use or develop sta	te-of-the-art
	Notice of Special Interest (NOSI): Vulnerability in Aging and Alzheir		National Institute on Aging/NIH/DHF	NOT- IS AG-21- 10- 040	Mar-2023	Not Specified
	Contact Name	Bradley C. Wise, Ph.D.				
	Contact Telephone	301-496-9350				
	Contact Email	WiseB@mail.nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	10-Mar-2023 , 10-Jul-2023 , 13-N	lov-2023 , 11-Mar-2024 , 09-Jul-2024 , 12-	Nov-2024		
	Synopsis	(e.g., neurons and glia), neural action (or resistant) in brain aging and Asignatures of different types of nand in different stages of AD will types by physiological measures networks will provide a functional generate sophisticated data on networks.	Interest (NOSI) is to stimulate research to ctivity and circuits, structural and function AD and the mechanisms underlying such securons and glial cells across the adult lifes implicate cell processes and pathways mesuch as electrophysiology and connectivitial index of selective vulnerability. Application cells and on sechanisms underlying selective vulnerability develop effective therapies.	al networks, and elective vulnerab pan, in AD comp ediating selective y and manipulatints are encourage structure and fun	brain regions that ility. Genetic and nared to other dem vulnerability in AD neural activity in ded to use new apprection of brain circu	are vulnerable nolecular entias of agin b. Defining celen circuits and oaches to lits and
	Notice of Special Interest (NOSI): Studying Clinical Alzheimer's Dise	Novel Approaches to Diagnosing a case and Related Dementias	and National Institute on Aging/NIH/DHF	NOT- IS AG-21- 10- 036	Mar-2023	Not Specified
	Contact Name	John Hsiao, M.D.				



Contact Telephone 301-496-9350

Sponsor Website

Contact Email jhsiao@mail.nih.gov

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	-	The goal of this NOSI is to encourage	2023 , 11-Mar-2024 , 09-Jul-2024 , 12-No the development of novel approaches to		ing, diagnosing, and	predicting
IIIX/X	Notice of Special Interest (NOSI): and Services for Persons with Der	Dementia Care Research: Programs	National Institute on Aging/NIH/DHHS	NOT- AG-21- 10 046)-Mar-2023	Not Specified
	Contact Telephone Contact Email Sponsor Website	Elena Fazio, Ph.D. 301-496-3136 elena.fazio@nih.gov Link to program URL				
	_		2023 , 11-Mar-2024 , 09-Jul-2024 , 12-No	v-2024		
	Synopsis	areas as set forth by the National Ins discussions from the NIH 2020 Deme	n-priority Alzheimer's disease (AD) and A titute on Aging's Division of Behavioral a entia Care Summit, the NASEM Decadal S /ADRD research implementation milesto	nd Social Res urvey of Beha	earch. The NOSI is b	ased on exper
	Notice of Special Interest (NOSI): Areas in Dementia Care Partner/C	Behavioral and Social Science Priority Caregiver Research	National Institute on Aging/NIH/DHHS	NOT- AG-21- 10 047)-Mar-2023	Not Specified
	Contact Name	Melissa S. Gerald, Ph.D.				
	Contact Telephone	301-496-3136				
		melissa.gerald@nih.gov				
	Sponsor Website					
		Link to program URL				
	Deadline Dates (ALL)		2023 , 11-Mar-2024 , 09-Jul-2024 , 12-No			_
	Synopsis		mer's disease (AD) and AD-related deme titute on Aging's Division of Behavioral a			



SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		The state of the s	ion milestones and are based on expert on the NASEM Decadal Survey of Behavioration			
	Notice of Special Interest (NOSI): as Predictors of Preclinical Alzhei	Sensory and Motor System Changes mer's Disease	National Institute on Aging/NIH/DHHS	NOT- AG-21- 044	10-Mar-2023	Not Specified
	Contact Name	Coryse St. Hillaire-Clarke, Ph.D.				
	Contact Telephone	301-827-6944				
	Contact Email	sthillaireclacn@mail.nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	-		2023 , 11-Mar-2024 , 09-Jul-2024 , 12-No	v-2024		
	Synopsis	· · · · · · · · · · · · · · · · · · ·	I Interest (NOSI) is to encourage applicati dies that investigate how functional chan ssion of Alzheimer's disease.		•	
	Notice of Special Interest (NOSI): of Alzheimer's Disease	Deciphering the Glycosylation Code	National Institute on Aging/NIH/DHHS	NOT- AG-21- 042	10-Mar-2023	Not Specified
	Contact Name	Austin Yang, Ph.D.				
	Contact Telephone	301-496-9350				
	Contact Email	yangj13@mail.nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	10-Mar-2023 , 10-Jul-2023 , 13-Nov-	2023 , 11-Mar-2024 , 09-Jul-2024 , 12-No	v-2024		
	Synopsis		erest (NOSI) is to invite research projects d the potential impact of glycosylation or			
111X X11 / -	Notice of Special Interest (NOSI): Alzheimer's Disease and Related		National Institute on Aging/NIH/DHHS	NOT- AG-21- 038	10-Mar-2023	Not Specified



SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Contact Telephone : Contact Email Sponsor Website Program URL	jhsiao@mail.nih.gov Link to program URL			
	Synopsis	This Notice of Special Interest (NOSI)	2023 , 11-Mar-2024 , 09-Jul-2024 , 12-No has two aims: To study in vivo synaptic dementias (ADRD), and To advance the	structure and function in Alzhein	
108315	Notice of Special Interest (NOSI): Deliving with Alzheimer's Disease and Dementias (AD/ADRD)	Dementia Care Workforce for Those of Alzheimer's Disease-Related	National Institute on Aging/NIH/DHHS	NOT- AG-21- 10-Mar-2023 049	Not Specified

Contact Name John W. R. Phillips, Ph.D.

Contact Telephone 301-496-3136

Contact Email john.phillips@nih.gov

Sponsor Website

Program URL Link to program URL

Deadline Dates (ALL) 10-Mar-2023 , 10-Jul-2023 , 13-Nov-2023 , 11-Mar-2024 , 09-Jul-2024 , 12-Nov-2024

This Notice of Special Interest (NOSI) is intended to promote behavioral and social research on the dementia care workforce and the impact of workforce factors on outcomes for persons living with Alzheimer's disease or Alzheimer's disease-related dementia (AD/ADRD) and their families. Applications focused on care of persons living with dementia and the systems that provide care may cite NOT-AG-21-046, and applications focused solely on unpaid dementia care partners/caregivers may cite NOT-AG-21-047 in the Agency Routing Identifier field (box 4B). PLEASE NOTE: Applications proposing clinical trials will

Synopsis cite NOT-AG-21-047 in the Agency Routing Identifier field (box 4B). PLEASE NOTE: Applications proposing clinical trials will not be considered a high priority for this NOSI. Studies proposing dementia care intervention research are encouraged to explore whether PAR-21-307 Dementia Care and Caregiver Support intervention Research (R01 – Clinical Trial Required) or PAR-21-308 Pragmatic Trials for Dementia Care and Caregiver Support (R61/R33 – Clinical Trial Required) would be more appropriate.



SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
10X4/4	Notice of Special Interest (NOSI): In Disease	nfectious Etiology of Alzheimer's	National Institute on Aging/NIH/DHHS	NOT- AG-21- 043	10-Mar-2023	Not Specified
	Contact Name	Miroslaw 'Mack' Mackiewicz, Ph.D.				
	Contact Telephone	301-496-9350				
	Contact Email	mirolsaw.mackiewicz@nih.gov				
	Sponsor Website					
	Program URL <u>I</u>	Link to program URL				
	Deadline Dates (ALL)	10-Mar-2023 , 10-Jul-2023 , 13-Nov	-2023 , 11-Mar-2024 , 09-Jul-2024 , 12-No	ov-2024		
			aging existing cohorts with available sam, to address the possible links between in			fluid (CSF), and
	Notice of Special Interest (NOSI): F Disease Genetic Variants	Human Cell Biology of Alzheimer's	National Institute on Aging/NIH/DHHS	NOT- AG-21- 052	10-Mar-2023	Not Specified
	Contact Name	Bradley Wise, Ph.D.				
	Contact Telephone	301-496-9350				
	Contact Email	wiseb@mail.nih.gov				
	Sponsor Website					
	Program URL <u>I</u>	Link to program URL				
	Deadline Dates (ALL)	10-Mar-2023 , 10-Jul-2023 , 13-Nov	-2023 , 11-Mar-2024 , 09-Jul-2024 , 12-No	ov-2024		
	Synopsis	,	erest (NOSI) is to encourage research thang factors contributing to AD using human		•	
11/1/164	NIA Multi-site Clinical Trial Implem Required)	nentation Grant (R01 Clinical Trial	National Institute on Aging/NIH/DHHS	PAR-23- 057	07-Mar-2023	Not Specified
_	Contact Name	Sergei Romashkan, M.D., Ph.D.				
	Contact Telephone	301-435-3047				
	Contact Email	romashks@mail.nih.gov				



SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	07-Mar-2023 , 05-Jun-2023 , 05-Oct 2025	-2023 , 05-Feb-2024 , 05-Jun-2024 , 05-O	ct-2024 , 05-F	eb-2025 , 05-Jun-20)25 , 05-Oct-
	Synopsis	interventional clinical trials (all phas	ement (FOA) invites applications for imple es). The trials should be hypothesis-drive t NIA's mission can be found on the NIA w	n, milestone-	-	
108313 D	otice of Special Interest (NOSI): etection and Monitoring of Alzh ementias	 	National Institute on Aging/NIH/DHHS	NOT- AG-21- 10 048	-Mar-2023	Not Specified
	Contact Name	Yuan Luo, Ph.D.				
	Contact Telephone	301-496-9350				
	Contact Email	yuan.luo@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	10-Mar-2023 , 10-Jul-2023 , 13-Nov-	-2023 , 11-Mar-2024 , 09-Jul-2024 , 12-No	ov-2024		
	Synopsis) encourages research on the use of digit nal decline in persons with Alzheimer's di			
111X X / /	otice of Special Interest (NOSI): hanges in Alzheimer's Disease	Role of Age-Associated Metabolic	National Institute on Aging/NIH/DHHS	NOT- AG-21- 10 053	-Mar-2023	Not Specified
	Contact Name	Yih-Woei Fridell, Ph.D.				
	Contact Telephone	01-496-7847				
	Contact Email	<u>yih-woei.fridell@nih.gov</u>				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	10-Mar-2023 , 10-Jul-2023 , 13-Nov-	-2023 , 11-Mar-2024 , 09-Jul-2024 , 12-No	ov-2024		



SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Synopsis pe	nis Notice of Special Interest (NOSI) eripheral tissues or in the brain affe	is aimed at improving our understandir ct the onset and/or progression of Alzho	ng of how age-a	associated metabol e (AD).	ic changes in
108114	Notice of Special Interest (NOSI): Ge Trafficking as a Pathological Hub in A Alzheimer's Disease-Related Demen	Alzheimer's Disease and	National Institute on Aging/NIH/DHHS	NOT- AG-21- 10- 034	Mar-2023	Not Specified
	Contact Telephone 30	arilyn Miller, Ph.D. 01-496-9350 illerm@nia.nih.gov				
	Program URL <u>Lii</u> Deadline Dates (ALL) 10 Th m	ne goals of this Notice of Special Int olecular, cellular, and physiological	2023, 11-Mar-2024, 09-Jul-2024, 12-No erest (NOSI) are to encourage basic and processes associated with the endoson anded under this topic will support resea	translational r	ent in AD and Alzhei	imer's disease-
		nhancing our understanding of how athophysiological changes associate	the genetic underpinnings of endosomed with the disease.	al trafficking in	AD/ADRD may act	as a hub in the
108556	Investigational New Drug (IND)-enabor Medications to Treat Alcohol Use Organ Damage (UT1/UT2 Clinical Tri	disorder and Alcohol-Associated	National Institute on Alcohol Abuse and Alcoholism/NIH/DHHS	PAR-22- 103	Mar-2023	Not Specified
	Contact Telephone 30 Contact Email <u>je</u>	nica Patterson, Ph.D. 01-827-6166 nica.patterson@nih.gov				
	Deadline Dates (ALL) 27	nk to program URL 7-Mar-2023 , 04-Dec-2023 , 27-Mar			(CTTD)	
	Synopsis bu	usiness concerns (SBCs) that propos	nent (FOA) supports Small Business Tec e the development of therapeutic agen in damage (AAOD). As a starting point, e	ts for the treat	ment of alcohol us	e disorder



SPIN ID	Program	Sponsor Name	Sponsor Number	Deadline Date	Funding
3FIN ID	Title	Sponsor Name	Sponsor Number	Deadine Date	Amount

candidate with a robust body of background data in the basic science and early discovery phases to be ready for transition to the preclinical and clinical phases of development. Data may include having sufficient bioactivity, stability, manufacturability, bioavailability, in vivo efficacy and/or target engagement, and other favorable properties that are consistent with the desired clinical application. Projects responsive to this announcement could be undertaken at any point along the drug development continuum, from late discovery (i.e., lead optimization/early safety) up to early-stage clinical trials. For small molecules, the earliest stage of eligibility for this Award is already having small-molecule compounds with proof of desired pharmacological activity. For biologics, the profiling of promising product candidates in animal models of AUD or AAOD will be allowed as the earliest entry point. The ultimate purpose and goal of this FOA is to advance molecules closer to U.S. Food and Drug Administration (FDA) approval. Milestones will be commensurate with the project proposed and the purpose of this FOA. This FOA supports early-phase clinical trials, although these are not required. Women-owned and socially or economically disadvantaged small businesses are encouraged to apply.

Investigational New Drug (IND)-enabling and Early-Stage Development 108554 of Medications to Treat Alcohol Use disorder and Alcohol-Associated Organ Damage (U43/U44 Clinical Trial Optional)

National Institute on Alcohol Abuse and Alcoholism/NIH/DHHS

PAR-22-27-Mar-2023 102

Not Specified

Contact Name Jenica Patterson, Ph.D.

Contact Telephone 301-827-6166

Contact Email jenica.patterson@nih.gov

Sponsor Website

Program URL Link to program URL

Deadline Dates (ALL) 27-Mar-2023, 04-Dec-2023, 27-Mar-2024, 04-Dec-2024

This Funding Opportunity Announcement (FOA) supports Small Business Innovation Research (SBIR) applications from small business concerns (SBCs) that propose the development of therapeutic agents for the treatment of alcohol use disorder (AUD) and/or alcohol associated organ damage (AAOD). As a starting point, eligible applicants must identify a therapeutic candidate with a robust body of background data in the basic science and early discovery phases to be ready for transition to the preclinical and clinical phases of development. Data may include having sufficient bioactivity, stability, manufacturability, Synopsis bioavailability, in vivo efficacy and/or target engagement, and other favorable properties that are consistent with the desired clinical application. Projects responsive to this announcement could be undertaken at any point along the drug development continuum, from late discovery (i.e., lead optimization/early safety) up to early-stage clinical trials. For small molecules, the earliest stage of eligibility for this Award is already having small-molecule compounds with proof of desired pharmacological activity. For biologics, the profiling of promising product candidates in animal models of AUD or AAOD will be allowed as the earliest entry point. The ultimate purpose and goal of this FOA is to advance molecules closer to U.S. Food

P	Program					Funding
	Fitle	Sponsor Name	Sponsor Number		Deadline Date	Amount
			proval. Milestones will be commensu whase clinical trials, although these a business are encouraged to apply.		• •	
103057	tting-Edge Basic Research Awa tional)	rds (CEBRA) (R21 Clinical Trial	National Institute on Drug Abuse/NIH/DHHS	PAR-21- 208	Mar-2023	275,000 USD
	Contact Name	Amy C. Lossie, Ph.D.				
	Contact Telephone	301-827-6092				
	Contact Email	lossieac@mail.nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	08-Mar-2023 , 10-Aug-2023 , 08-M	ar-2024			
	Synopsis	innovative or conceptually creative use disorders (SUDs). It supports hi NIDA's current portfolio that has thadapt, revolutionary techniques or	se (NIDA) Cutting-Edge Basic Research related to the etiology, par gh-risk and potentially high-impact rate potential to transform SUD resear methods for addiction research or to tive and significant hypothesis for what the surrent thinking.	thophysiology, preveresearch that is under ch. The proposed res that show promising f	ention, or treatment rrepresented or no search should: 1. d future applicability	nt of substance of included in levelop, and/o
1 1 1111X	havioral & Integrative Treatme	nt Development Program (R34	National Institute on Drug Abuse/NIH/DHHS	PAR-22- 183 21-N	Mar-2023	450,000 USD
	Contact Name	Will M. Aklin, Ph.D.				
	Contact Telephone	301-827-5909				
	Contact Email	aklinwm@mail.nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	21-Mar-2023 , 10-Aug-2023 , 21-M	ar-2024 , 09-Aug-2024 , 21-Mar-202	5		
	Synopsis	The purpose of this Funding Oppor development and testing of behavi	tunity Announcement (FOA) is to en oral and integrative treatments for s	courage research gra substance use and de	ant applications on ependence. This FC	the OA reaffirms



SPIN ID	Program	Sponsor Name	Sponsor Number	Deadline Date	Funding
SFIN ID	Title	Sponsor Warne	Sponsor Number	Deadine Date	Amount

the continued commitment of NIDA to major programs of research on behavioral and integrative treatments. The term behavioral treatments" is used here in a broad sense and includes but is not limited to psychotherapies, cognitive, relapse" prevention, remediative, rehabilitative, skills training, counseling, family, and exercise therapies. Screening, brief, computerized, adherence, prevention interventions for HIV risk behaviors, and interventions that target therapist training and fidelity also are included. Integrative refers to combinations with other treatments, including pharmacotherapies or other complementary approaches. The development and testing of putative targets and mechanisms of behavior change, as well as the use and development of valid and reliable assessment tools are crucial to the three stages of treatment research supported under this initiative: Stage I (treatment generation, refinement) encompasses all activities related to the creation of a new behavioral intervention. This stage also includes the modification, adaptation, or refinement of an existing intervention (Stage IA). Stage I culminates in feasibility and pilot testing (Stage 1B). For example, one can conduct Stage I studies in research settings, with research therapists and research subjects, or in community settings with community providers. Stage II ("Efficacy") research consists of experimental testing of promising behavioral interventions in research settings, with research-based therapists/providers. Stage III ("Efficacy in Real-World") research consists of experimental testing of promising behavioral interventions in community settings, with community-based therapists/providers and patients, while maintaining a high level of control necessary to establish internal validity. Stages I, II, and III all include a focus on theory-derived, targets/putative moderators, mediators, and change mechanisms that underlie the treatment, and studies that optimize combined, sequential, or integrated behavioral/pharmacological treatments.

111016 Behavioral & Integrative Treatment Development Program (R01 Clinical Trial Optional)

National Institute on Drug Abuse/NIH/DHHS PAR-22-182 21-Mar-2023 Not Specified

Contact Name Will M. Aklin, Ph.D.

Contact Telephone 301-827-5909

Contact Email aklinwm@mail.nih.gov

Sponsor Website

Program URL Link to program URL

Deadline Dates (ALL) 21-Mar-2023, 10-Aug-2023, 21-Mar-2024, 09-Aug-2024, 21-Mar-2025

The purpose of this Funding Opportunity Announcement (FOA) is to encourage research grant applications on the development and testing of behavioral and integrative treatments for drug and alcohol use, abuse, and dependence. This FOA reaffirms the continued commitment of NIDA to major programs of research on behavioral and integrative treatments. The term "behavioral treatments" is used here in a broad sense and includes but is not limited to psychotherapies, cognitive, relapse prevention, remediative, rehabilitative, skills training, counseling, family, and exercise therapies. Screening, brief, computerized, adherence, prevention interventions for HIV risk behaviors, and interventions that target therapist training

Synopsis

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	------------------	--------------	----------------	---------------	-------------------

and fidelity are included. Integrative refers to combinations with other treatments, including pharmacotherapies or other complementary approaches. The development and testing of putative targets and mechanisms of behavior change, as well as the use and development of valid and reliable assessment tools are crucial to the three stages of treatment research supported under this initiative: Stage I (treatment generation, refinement) encompasses all activities related to the creation of a new behavioral intervention. This stage also includes the modification, adaptation, or refinement of an existing intervention (Stage IA). Stage I culminates in feasibility and pilot testing (Stage 1B). For example, one can conduct Stage I studies in research settings, with research therapists and research subjects, or in community settings with community providers. Stage II ("Efficacy") research consists of experimental testing of promising behavioral interventions in research settings, with research-based therapists/providers. Stage III ("Efficacy in Real-World") research consists of experimental testing of promising behavioral interventions in community settings, with community-based therapists/providers and patients, while maintaining a high level of control necessary to establish internal validity. Stages I, II, and III all include a focus on theory-derived, targets/putative moderators, mediators, and change mechanisms that underlie the treatment, and studies that optimize combined, sequential, or integrated behavioral/pharmacological treatments.

Exploratory Clinical Neuroscience Research on Substance Use 082413 Disorders (R61/R33 Clinical Trial Optional)

National Institute on Drug Abuse/NIH/DHHS

PAR-19-10-Mar-2023 282

Not Specified

Contact Name Vani Pariyadath, Ph.D.

Contact Telephone 301-443-3209

Contact Email vani.pariyadath@nih.gov

Sponsor Website

Program URL Link to program URL

Deadline Dates (ALL) 10-Mar-2023, 07-May-2023

This Funding Opportunity Announcement (FOA) uses a R61/R33 Phased Innovation Award mechanism to support clinical research applications that are exploratory and developmental in nature and focus on understanding the neurobiological Synopsis mechanisms underlying Substance Use Disorders (SUD), including fundamental brain function relevant to substance use. For projects not requiring a phased research approach, applicants are encouraged to apply under a different funding mechanism (e.g., Neuroscience Research on Drug Abuse (R01 Clinical Trial Optional).

104639 NIDA Animal Genomics Program (U01 – Clinical Trial Not Allowed)

National Institute on Drug Abuse/NIH/DHHS

PAR-21-02-Mar-2023 244

Not Specified

Contact Name Amy C. Lossie, PhD Contact Telephone 301-827-6092



	SPIN ID	Program	Sponsor Name	Sponsor Number	Deadline Date	Funding
,	or iiv ib	Title	Sponsor ivallie	Sponsor Wulliber	Deadine Date	Amount

Contact Email lossieac@mail.nih.gov

Sponsor Website

Program URL Link to program URL

Deadline Dates (ALL) 02-Mar-2023, 26-Jul-2023, 04-Mar-2024

The purpose of the NIDA Animal Genetics Program is to identify genetic, genomic, and molecular (epi)genetic variants that underlie: 1. Phenotypes associated with addictive behaviors and/or vulnerability to distinct stages along the substance use disorder (SUD) trajectory (e.g. initial/acute use, escalation of use, acquisition of tolerance, dependence, uncontrolled use, abstinence and relapse or recovery); 2. Behaviors associated with SUD (e.g. impulsivity, novelty seeking, delayed discounting, and other genetically-associated phenotypes); and 3. Comorbidities that demonstrate genetic correlations with phenotypes and behaviors linked with SUD (e.g. anxiety, stress, poor maternal care, social defeat, and other paradigms). Applications may examine any type of variant, including single nucleotide variants (SNVs), indels, large and small structural variants, and all types of mobile DNA. NIDA encourages applications that take genomics, multi-omics, and/or data-based approaches that integrate multi-level 'omics data, delineate gene networks, and/or uncover the function of known or newly discovered genetic or epigenetic variants. NIDA expects these studies to uncover novel mechanisms that contribute to SUD and facilitate the discovery of targets for intervention and guide the development of individualized therapeutics to treat these different aspects of SUD.

Эупора.

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Extracellular RNA Carrier Subclasses in Processes Relevant to Substance Use Disorders or HIV infection (R21- Clinical Trial Not Allowed)	National Institute on Drug Abuse/NIH/DHHS	PAR-20- 148	07-Jan-2023	275,000 USD

Contact Name John Satterlee, Ph.D

Contact Telephone 301-435-1020

Contact Email satterleej@nida.nih.gov

Sponsor Website

Program URL Link to program URL

Deadline Dates (ALL) 07-Jan-2023, 15-Mar-2023, 07-May-2023

The purpose of this FOA is to encourage research investigating the roles of extracellular RNA (exRNA) carrier subclasses in biological processes relevant to substance use disorders (SUDs) and/or HIV infection, latency, or pathogenesis in the CNS.

SPIN ID	Program Title	Sponsor Name	ponsor Number		Deadline Date	Funding Amount
		Applicants may propose to investigate biol improved technologies to investigate extra	_		subclasses, or propose to	develop
091068	Extracellular RNA Carrier Subclass Disorders or HIV infection (R01- C	ses in Processes Relevant to Substance Use Clinical Trial Not Allowed)	National Institute on Drug Abuse/NIH/DHHS	PAR-20- 147	07-Jan-2023	Not Specified
	Contact Telephone Contact Email Sponsor Website Program URL	Link to program URL 07-Jan-2023 , 15-Mar-2023 , 07-May-2023 The purpose of this FOA is to encourage re	use disorders (SUDs) and/or H ogical mechanisms involving e	IV infection, xRNA carrier	latency, or pathogenesis in	the CNS.
113957		racterization of Genes or Variants rders (R21/R33 Clinical Trial Not Allowed)	National Institute on Drug Abuse/NIH/DHHS	PAR-23- 041	02-Mar-2023	Not Specified
	Contact Telephone Contact Email Sponsor Website Program URL	<u>Link to program URL</u> 02-Mar-2023, 26-Jul-2023, 04-Mar-2024,	projects that functionally valid		haracterize genes or variar	its involved
114007	RFA-DA-24-004Targeting Inflam Clinical Trial Not Allowed)	nmasomes in Substance Abuse and HIV (R21	National Institute on Drug Abuse/NIH/DHHS	RFA-DA- 24-004	16-Feb-2023 [Optional][LOI/Pre-App]	275,000 USD
	Contact Name	Shang-Yi Anne Tsai, PhD				



SPIN ID	Program Title	Sponsor Name	Sponsor Number		ו מדבנו מחווחבמנוו	Funding Amount
	Contact Telephone	301-827-5842				
	·	stsai@nih.gov				
	Sponsor Website					
	·	Link to program URL				
	· ·	16-Feb-2023 [Optional][LOI/Pre-App], 16-	Mar-2023			
	Synopsis	The scientific objective of this Funding Op inflammasome activation, humoral immu immune functions in people with HIV and the mechanisms of inflammasomes in viruimmune cells associated with HIV-1 infect may lead to development of novel therap and immune dysregulation aroused in the	ne reaction and potential antibo substance use disorders (SUDs). us and drug-induced immune act ion or disease progression amon ies that target inflammasome ac	dy-mediated enh This FOA suppor ivation, or (2) ide g individuals with	ancement, and their ts studies to either (ntify molecular marl n SUD. Success of the	link to 1) elucidate kers and CN ese projects
	RFA-DA-24-003 Targeting Inflam	nmasomes in Substance Abuse and HIV (RC	1 National Institute on Drug	RFA-DA- 16-	Feb-2023	2,500,000
	Clinical Trial Not Allowed)		Abuse/NIH/DHHS	24-003 [Op	tional][LOI/Pre-App]	USD
	Contact Name	Shang-Yi Anne Tsai, PhD				
	Contact Telephone	301-827-5842				
	Contact Email	stsai@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	16-Feb-2023 [Optional][LOI/Pre-App], 16-	Mar-2023			
	Synopsis	The goal of this Funding Opportunity Anninflammasome activation, humoral immu immune functions in people with HIV and the mechanisms of inflammasomes in viruimmune cells associated with HIV-1 infect may lead to development of novel therap and immune dysregulation in people with	ne reaction and potential antibo substance use disorders (SUDs). us and drug-induced immune act ion or disease progression amon ies that target inflammasome ac	dy-mediated enh This FOA suppor ivation, or (2) ide g individuals with	ancement, and their ts studies to either (ntify molecular marl n SUD. Success of the	1) elucidate kers and CN ese projects
14003	Notice of Special Interest (NOSI): Addiction and Substance Use Disc	Targeting Epigenetic Regulators for Treation or Treati	ng National Institute on Drug Abuse/NIH/DHHS	NOT-DA- 24-004	Jan-2023	Not Specified



SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount		
	Contact Name	Sam Ananthan, Ph.D.						
	Contact Telephone	301-435-2199						
	Contact Email	sam.ananthan@nih.gov						
	Sponsor Website							
	Program URL	Link to program URL						
	Deadline Dates (ALL)	7-Jan-2023, 05-Feb-2023, 12-Feb-2023, 16-Feb-2023, 08-Mar-2023, 08-Apr-2023, 07-May-2023, 05-Jun-2023, 12-Jun- 023, 16-Jun-2023, 08-Aug-2023, 10-Aug-2023, 07-Sep-2023, 05-Oct-2023, 12-Oct-2023, 16-Oct-2023, 08-Dec-2023, 07- 03, 16-Jun-2024, 05-Feb-2024, 12-Feb-2024, 16-Feb-2024, 08-Mar-2024, 08-Apr-2024, 07-May-2024, 05-Jun-2024, 12-Jun-2024, 08-Aug-2024, 07-Sep-2024, 07-Sep-2024, 05-Oct-2024, 12-Oct-2024, 16-Oct-2024, 08-Dec-2024, 07-Jan-2025, 05-Feb- 025, 12-Feb-2025, 16-Feb-2025, 08-Apr-2025, 07-May-2025, 05-Jun-2025, 12-Jun-2025, 16-Jun-2025, 08-Aug-2025, 07-Sep-2025, 05-Oct-2025, 12-Oct-2025, 16-Oct-2025, 08-Dec-2025, 07-Jan-2026						
	Synopsis	The National Institute on Drug Abuse (NIII) NIDA's special interest in innovative reseabligenetic regulators and mechanisms for	arch that uses chemical and pha	rmacological appro	aches to identify a			
114048	Notice of Special Interest (NOSI): of Targets and Therapeutics to Tr	Chemoproteomic Approaches for Discovereat Substance Use Disorders	National Institute on Drug Abuse/NIH/DHHS	NOT-DA- 24-005	eb-2023	Not Specified		
	Contact Name	Sam Ananthan, Ph.D.						
	Contact Telephone	301-435-2199						
	Contact Email	sam.ananthan@nih.gov						
	Sponsor Website							
	Program URL	Link to program URL						
	Deadline Dates (ALL)	05-Feb-2023 , 12-Feb-2023 , 16-Feb-2023 , 2023 , 08-Aug-2023 , 10-Aug-2023 , 07-Se Feb-2024 , 12-Feb-2024 , 16-Feb-2024 , 08-Aug-2024 , 07-Sep-2024 , 05-Oct-2022 , 2025 , 16-Feb-2025 , 08-Apr-2025 , 07-M 05-Oct-2025 , 12-Oct-2025 , 16-Oct-2025	ep-2023 , 05-Oct-2023 , 12-Oct-2 8-Mar-2024 , 08-Apr-2024 , 07-I 24 , 12-Oct-2024 , 16-Oct-2024 , ay-2025 , 05-Jun-2025 , 12-Jun-2	2023 , 16-Oct-2023 May-2024 , 05-Jun-2 08-Dec-2024 , 07-Ja	, 08-Dec-2023 , 07 2024 , 12-Jun-2024 an-2025 , 05-Feb-2	-Jan-2024 , 05- 4 , 16-Jun-2024 2025 , 12-Feb-		

	Program					Funding
SPIN ID	Title	Sponsor Name	Sponsor Number		Deadline Date	Amount
	Synopsis in	ne purpose of this Notice is to inform p terest in supporting basic research on evelopment of drugs to treat addiction	the application of chemoproteon			•
107619	Notice of Special Interest (NOSI): Re Pharmacology of Addictive Drugs	search in the Chemistry and	National Institute on Drug Abuse/NIH/DHHS	NOT-DA- 23-002	07-Jan-2023	Not Specified
		·				
	Sponsor Website					
	07 Deadline Dates (ALL)	nk to program URL 7-Jan-2023 , 05-Feb-2023 , 12-Feb-202 023 , 07-Sep-2023 , 05-Oct-2023 , 16-C 5-Jun-2024 , 16-Jun-2024 , 07-Sep-202	oct-2023 , 07-Jan-2024 , 05-Feb-20	•	•	
	ar gu all Synopsis er sy de ag	ne mission of the Division of Neuroscie nimal and human research aimed at id uide treatment strategies. As a compor I aspects of the chemistry and pharma neompassing research on substance us enthetic and biosynthetic methodologic etermination of 3D structures of ligance gents, and 3) discover and advance the verdose, emphasizing the pre-clinical s	entifying the causes and consequent of the Division, the Chemistrated cology of addictive drugs. The Brace disorders (SUD) and overdose ces, structure-activity relationships is bound to biological targets, 2) or pre-clinical development of new	ences of drug a y and Pharmac anch develops a lesigned to: 1) o s, pharmacolog develop new re- pharmacother	iddiction across the lift cology Branch supports and oversees a broad elucidate mechanisms by and toxicity of addiction ceptor type and subty apies for the treatmen	espan and to s research on portfolio s of action, ctive drugs, and ope specific
111673	Notice of Special Interest (NOSI): Hig Neuroscience Branch in the Division		National Institute on Drug Abuse/NIH/DHHS	NOT-DA- 22-058	07-Jan-2023	Not Specified
	Contact Telephone 30 Contact Email <u>Ol</u> Sponsor Website	livier Berton, Ph.D. 01-827-7771 livier.berton@nih.gov nk to program URL				



SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Deadline Dates (ALL)	07-Jan-2023, 05-Feb-2023, 12-Feb-2023, 2023, 10-Aug-2023, 07-Sep-2023, 05-CFeb-2024, 08-Mar-2024, 07-May-2024, 16-Oct-2024, 07-Jan-2025, 05-Feb-2022, 16-Jun-2025, 07-Sep-2025, 05-O	oct-2023 , 12-Oct-2023 , 16-Oct-20 , 05-Jun-2024 , 12-Jun-2024 , 16-J 25 , 12-Feb-2025 , 16-Feb-2025 , 0 ct-2025 , 12-Oct-2025 , 16-Oct-20	023 , 07-Jan-2024 , un-2024 , 07-Sep-2 07-May-2025 , 07-N 025 , 07-Jan-2026	05-Feb-2024 , 12- 2024 , 05-Oct-2024 Лау-2025 , 05-Jun-	Feb-2024 , 16- 4 , 12-Oct-2024 -2025 , 12-Jun-
	Synopsis	The mission of the Division of Neuroscie human research aimed at identifying the across the lifespan and to guide treatme research on the cellular mechanisms and covers: 1) the regulation and plasticity o exposure to, and/or withdrawal from, ac interactions and their modification by su substance use and SUD, and 5) neuroim induced neuroinflammation.	e causes and consequences of subsent strategies. The Integrative New discretive that underlie substance of neurotransmitter and neuromoud dictive substances, 2) the study of	ostance use and suluroscience (IN) Brade use and SUD. Residuatory systems in of substance-inductions and sulations and substance-inductions and substance-inductions and substance and s	ostance use disord nch within DNB su earch supported b duced by chronic d ed neurotoxicity, s n of neural system	lers (SUD) pports by the Branch or intermittent B) neuron-glia is in relation to
	Accelerating the Pace of Drug Abo Clinical Trial Optional)	use Research Using Existing Data (R21	National Institute on Drug Abuse/NIH/DHHS	RFA-DA- 22-038 07-N	/lar-2023	Not Specified
	Contact Name	Marsha F. Lopez, Ph.D., M.H.S.				
	Contact Telephone	· ·				
	Contact Email	marsha.lopez@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	07-Mar-2023 , 09-Aug-2023 , 15-Nov-20	23 , 04-Mar-2024 , 05-Aug-2024 ,	15-Nov-2024		
	Synopsis	The purpose of this Funding Opportunity existing social science, behavioral, admir substance using behaviors (defined as all prevention of substance use and HIV, an other extant community-based or clinical trajectories of substance using behaviors development of psychopathology, strated quality, effective and efficient services for collection is not allowed for applications.	nistrative, and neuroimaging data cohol, tobacco, prescription, and id health service utilization. This F al datasets to their full potential in s and their consequences including egies to guide the development, to or the prevention and treatment	to study the etiolo other substances) OA encourages the n order to increase ng morbidity and m esting, implementa	ogy and epidemiol and related disorce analyses of publi our knowledge of ortality, risk and ration, and delivery	ogy of ders, c use and etiology, esilience in the of high

			, - 1-1			
SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
11124/111	RFA-DA-22-037 Accelerating the Existing Data (R01 Clinical Trial O	e Pace of Drug Abuse Research Using ptional)	National Institute on Drug Abuse/NIH/DHHS	RFA-DA- 22-037	07-Mar-2023	Not Specified
	Contact Name	Marsha F. Lopez, Ph.D., M.H.S.				
	Contact Telephone	' '				
	Contact Email	marsha.lopez@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	07-Mar-2023 , 09-Aug-2023 , 15-Nov-2	023 , 04-Mar-2024 , 05-Aug-2024 ,	, 15-Nov-202	4	
	Synopsis	substance using behaviors (defined as a prevention of substance use and HIV, a other extant community-based or clinic trajectories of substance using behavior development of psychopathology, straquality, effective and efficient services collection is not allowed for application	nd health service utilization. This local datasets to their full potential in rs and their consequences including tegies to guide the development, the for the prevention and treatment	FOA encourag n order to ind ng morbidity testing, imple	ges the analyses of publ crease our knowledge o and mortality, risk and mentation, and delivery	ic use and f etiology, resilience in tl / of high
		Development Program Award in Substa Research (K12 Clinical Trial Optional)	nce National Institute on Drug Abuse/NIH/DHHS	PAR-20- 249	01-Mar-2023	2,500,00 USD
	Contact Name	Aria Davis Crump, Sc.D.				
	Contact Telephone	301-435-0881				
	Contact Email	acrump@nida.nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	01-Mar-2023 , 02-Aug-2023 , 15-Nov-2	023			
	Synopsis	This funding opportunity announcement programs that propose to support inte (Scholars) leading to research independent	nsive supervised research and car	eer developn and substan	nent experiences for cli ce use disorder researc	nician scientis n. For this FO



clinician scientists may include (but are not limited to) physicians, clinical psychologists, epidemiologists, doctoral level social

SPIN ID	Program Title	Sponsor Name	Sponsor Number		I DOGRIDO LIGADO L	Funding Amount
		workers, pharmacists, and behavioral sci month appointments. Candidates selecte months (equivalent to 75% of full-time p associated with the proposed program T of an independent clinical trial; or proposed experience in a clinical trial led by another	ed for support as scholars must he rofessional effort) to conducting his FOA allows appointment of some a separate ancillary study to	nold a doctorate and clinical research ar cholars proposing to an existing trial; or	d commit a minimulated career developm o serve as the lead in proposing to gain in	m of 9 persor ent activities investigator
	NIDA Research Education Program (R25 Clinical Trial Not Allowed)	m for Clinical Researchers and Clinicians	National Institute on Drug Abuse/NIH/DHHS	PAR-21- 320 15-N	1ar-2023	1,750,000 USD
	Contact Telephone	acrump@nida.nih.gov				
	·	Link to program URL				
	-	15-Mar-2023 , 10-Aug-2023 , 15-Nov-202	23 . 15-Mar-2024 . 09-Aug-2024			
		The NIH Research Education Program (R2 arching goal of this NIDA R25 program is workforce to meet the nation's biomedic education activities that enhance the known program is intended for those in clinically providers, clinical researchers, or optima research-related clinical training. To account activities with a primary focus on Course education programs must include both or research experiences. Proposed courses enhance skills development.	25) supports research education to support educational activities cal, behavioral and clinical research whedge of substance use (SU) any focused careers and/or those tally a combination of the two. The supplies the stated over-arching sets for Skills Development and Recourses for skills development and	s that complement and needs. This FOA and substance use di raining for careers a sis mechanism may negoal, this FOA will subsearch Experiences di research experier	and/or enhance the is intended to supp sorder (SUD) resear so clinicians/health not be used to supp upport creative edu. The proposed researces with primary en	e training of a port research rch. The service ort non- cational earch mphasis on
114171		dies to Investigate Mechanisms of HIV d/or Pathogenesis in the Context of 3 - Clinical Trial Not Allowed)	National Institute on Drug Abuse/NIH/DHHS		eb-2023 ional][LOI/Pre-App]	Not Specified
	Contact Name Contact Telephone	Shang-Yi Anne Tsai, Ph.D. 301-827-5842				

SPIN ID	Program Title	Sponsor Name	Sponsor Number		11)eadline Date	Funding Amount
	Title					Amount
	Contact Email	stsai@nih.gov				
	Sponsor Website	-				
	Program URL I	Link to program URL				
	Deadline Dates (ALL)	23-Feb-2023 [Optional][LOI/Pre-App], 23-	Mar-2023			
	Synopsis i	The purpose of this FOA is to support exploypotheses to investigate mechanistic quence neuroHIV) in the context of Substance Uses signaling pathways that are involved in CN investigate the underlying molecular mechand to determine how addictive substance reservoirs.	estions in HIV infection, replication in HIV infection, replication in HIV infection, replication is HIV establishment and expansion in HIV infection in HIV in	ion, latency, and/o e focuses on explo sion. The FOA aim is initiated, establi	or pathogenesis (inc ration and characte s to promote resear shed, and maintain	luding rization of ch to ed in the CNS
		revention Effectiveness Research Among	National Institute on Drug	RFA-DA- 15-I	Feb-2023	Not
		elfare System (R61/R33 Clinical Trial	Abuse/NIH/DHHS		tional][LOI/Pre-App	
	Required)					•
		Barbara Oudekerk, PhD				
	Contact Telephone					
		barbara.oudekerk@nih.gov				
	Sponsor Website					
		Link to program URL				
		15-Feb-2023 [Optional][LOI/Pre-App], 15-				
	Synopsis I	The purpose of this Funding Opportunity aprevent substance misuse or use disorder with risk for involvement in the child welf practices and critical components of preventions involved in the child welfare supported through exploratory/developmyears of funding for scientific and operations	among youth, caregivers (includance) are system. Of interest are projective interventions to develop system, and have potential for selection phased awards (R61/R33)	ding foster parents ects that strategica prevention strateg cale-up and sustai that may not exce	s), and/or families ir ally adapt or build up gies that are well-su nability. Research w eed 5 years, allocatio	nvolved in or oon promisin ited for ill be ng up to two

intervention or service.

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	unding amount
114735		Prevention Effectiveness Research Among Velfare System (R01 Clinical Trial Required)	National Institute on Drug Abuse/NIH/DHHS	RFA-DA- 24-012	15-Feb-2023 [Optional][LOI/Pre-App]	Not Specified
	Contact Name	Barbara Oudekerk, PhD				
	Contact Telephone	240-328-7936				
	Contact Email	<u>barbara.oudekerk@nih.gov</u>				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	15-Feb-2023 [Optional][LOI/Pre-App], 15-	Mar-2023			
	Synopsis	The purpose of this Funding Opportunity aprevent substance misuse or use disorder with risk for involvement in the child welf practices and critical components of prevents of	among youth, caregivers (includate are system. Of interest are project entive interventions to develop	ding foster pa ects that stra prevention st	arents), and/or families inv tegically adapt or build upo trategies that are well-suit	volved in, or on promising
114633	-	on of Epidemiological Findings into ce Use and Addiction (R61/R33 Clinical Tria	National Institute on Drug Abuse/NIH/DHHS	RFA-DA- 24-010	15-Feb-2023 [Optional][LOI/Pre-App]	Not Specified
	Contact Name	Alexa Romberg, PhD				
	Contact Telephone	-				
	Contact Email	alexa.romberg@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	15-Feb-2023 [Optional][LOI/Pre-App], 15-	Mar-2023			
	Synopsis	This Funding Opportunity Announcement epidemiological research into intervention mechanism is used to support exploratory required to use a Multiple-Principal Invest the R61 phase will inform intervention res	ns to prevent substance use and //developmental research with t tigator (MPI) structure and clear	addiction. The potential	he R61/R33 Phased Innovator for high impact. Application	ntion Award ons are
102690	RFA-OD-21-004 Maximizing the Collections (R21 Clinical Trial Not	Scientific Value of Existing Biospecimen Allowed)	National Institutes of Health/DHHS	RFA-OD- 21-004	07-Jan-2023 [Optional][LOI/Pre-App]	275,000 USD

SPIN ID	Program	Sponsor Name	Sponsor Number	Deadline Date	Funding
SPIN ID	Title	Sponsor Warne	Sponsor Number	Deadine Date	Amount

Contact Name Rachel Grana Mayne, PhD

Contact Telephone 240-276-5899

Contact Email granar@nih.gov

Sponsor Website

Program URL Link to program URL

Deadline Dates (ALL) 07-Jan-2023 [Optional][LOI/Pre-App], 08-Mar-2023

The purpose of this Funding Opportunity Announcement (FOA) is to invite R21 applications to stimulate exploratory research relevant to the mission of the Food and Drug Administration (FDA) - Center for Tobacco Products (CTP) using existing (publicly available) biospecimens currently stored in repositories in the United States. This will include, but not be limited to, collections associated with the Population Assessment of Tobacco and Health (PATH) Study, the National Health and Nutrition Examination Survey (NHANES), the National Heart, Lung and Blood Institute's (NHLBI) Biologic Specimen and Data Repository Information Coordinating Center (BioLINCC), and the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. Proposed research should seek to maximize the scientific value of these stored collections and to provide Synopsis researchers with an opportunity to generate preliminary data for subsequent research proposals. Other publicly available datasets would be considered, depending on analyses to be conducted. These applications need to provide justification why the data set is unique, and the research questions cannot be answered from a publicly available, nationally representative, data set. The awards under this FOA will be administered by NIH using funds that have been made available through FDA-CTP and the Family Smoking Prevention and Tobacco Control Act (P.L. 111-31). Research results from this FOA are expected to generate findings and data that are directly relevant in informing the FDA's regulation of the manufacture, distribution,

and marketing of tobacco products to protect public health. Research Projects must address the research priorities related

RFA-OD-21-003 -- Secondary Analyses of Existing Datasets of Tobacco Use and Health (R21 Clinical Trial Not Allowed)

National Institutes of Health/DHHS

to the regulatory authority of the Food and Drug Administration (FDA) - Center for Tobacco Products (CTP).

RFA-OD-21-003

07-Jan-2023

[Optional][LOI/Pre-App]

275,000 USD

Contact Name Rachel Grana Mayne, PhD

Contact Telephone 240-276-5899

Contact Email granar@nih.gov

Sponsor Website

Program URL Link to program URL

Deadline Dates (ALL) 07-Jan-2023 [Optional][LOI/Pre-App], 08-Mar-2023



102689

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	------------------	--------------	----------------	---------------	-------------------

The purpose of this Funding Opportunity Announcement (FOA) is to invite R21 applications proposing the innovative analysis of existing (publicly available) nationally representative U.S. cross-sectional and longitudinal data, to investigate novel scientific ideas and/or to generate new models, systems, tools, methods, or technologies that have the potential for significant impact on biomedical or biobehavioral research in areas relevant to the Food and Drug Administration (FDA) -Center for Tobacco Products (CTP). Other publicly available data sets would be considered depending on the analyses to be conducted; however, nationally representative analyses will receive priority. Applications not using nationally representative data sets will need to provide justification why the data set is unique, and why the research questions cannot be answered from a (publicly available) nationally representative data set. This FOA encourages the analyses of public use datasets that may inform tobacco regulatory actions in the United States (U.S.). The awards under this FOA will be administered by NIH using funds that have been made available through FDA-CTP and the Family Smoking Prevention and Tobacco Control Act (P.L. 111-31). Research results from this FOA are expected to generate findings and data that are directly relevant in informing the FDA's regulation of the manufacture, distribution, and marketing of tobacco products to protect public health. Research Projects must address the research priorities related to the regulatory authority of the Food and Drug Administration (FDA) - Center for Tobacco Products (CTP).

International Research Scientist Development Award (IRSDA) (K01) Independent Clinical Trial Required

National Institutes of Health/DHHS

PAR-21-105

08-Mar-2023

700,000 USD

Contact Name Christine Jessup, Ph.D.

Synopsis

Contact Telephone 301-496-1653

Contact Email Christine.Jessup@nih.gov

Sponsor Website

Program URL Link to program URL

Deadline Dates (ALL) 08-Mar-2023

The purpose of the International Research Scientist Development Award (IRSDA) is to provide support and protected time (three to five years) to advanced postdoctoral U.S. research scientists and recently-appointed U.S. junior faculty (applicants must be at least two years beyond conferral of doctoral degree) for an intensive, mentored research career development experience in a low- or middle-income country (LMIC), as defined by the World Bank

Synopsis (http://data.worldbank.org/about/country-classifications/country-and-lending-groups), including "low-income," "lowermiddle-income," and "upper-middle-income" countries) leading to an independently-funded research career focused on global health. This Funding Opportunity Announcement (FOA) invites applications from postdoctoral research scientists and junior faculty from any health-related discipline who propose career development activities and a research project that is relevant to the health priorities of the LMIC under the mentorship of LMIC and U.S. mentors. This Funding Opportunity



101454

Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	clinical trial, a clinical trial feasibility study development. Applicants not planning an	y, or a separate ancillary clinic independent clinical trial, or	cal trial, as part proposing to ga	of their research and ca	reer
Summer Research Education Expension	erience Program (R25 Clinical Trial Not	National Institutes of Health/DHHS	PAR-21- 168	17-Mar-2023	625,000 USD
Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL)	301-451-8507 laura.kwako@nih.gov Link to program URL 17-Mar-2023 , 08-May-2023 , 19-Mar-202 The NIH Research Education Program (R2 overarching goal of this R25 program is to	5) supports research education support educational activities	es that compler	nent and/or enhance th	e training of a
, ,	goal, this FOA will support creative educa	tional activities with a primar	y focus on: Res	earch Experiences for hi	_
		National Institutes of Health/DHHS	RFA-HL- 23-006	15-Mar-2023	Not Specified
Contact Telephone Contact Email Sponsor Website Program URL	301-402-3833 david.schopfer@nih.gov Link to program URL	14. 16 May 2024			
	Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL) Synopsis RFA-HL-23-006 Stimulating Accordependent Clinical Trial Not Allo Contact Name Contact Telephone Contact Telephone Contact Email Sponsor Website Program URL	Announcement (FOA) is designed specific clinical trial, a clinical trial feasibility study development. Applicants not planning an led by another investigator, must apply to summer Research Education Experience Program (R25 Clinical Trial Not Allowed) Contact Name Laura E. Kwako, Ph.D. Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL) Deadline Dates (ALL) The NIH Research Education Program (R2 overarching goal of this R25 program is to workforce to meet the nation's biomedicate goal, this FOA will support creative educated students, undergraduate students, and/or RFA-HL-23-006 Stimulating Access to Research in Residency (StARR) (R38 Independent Clinical Trial Not Allowed) Contact Name Contact Telephone Contact Telephone Contact Telephone Contact Telephone Contact Email Sponsor Website Program URL Link to program URL	Announcement (FOA) is designed specifically for applicants proposing clinical trial, a clinical trial feasibility study, or a separate ancillary clinic development. Applicants not planning an independent clinical trial, or led by another investigator, must apply to companion FOA (PAR-21-10 Idea by another investigator, must apply to companion FOA (PAR-21-10 Idea by another investigator, must apply to companion FOA (PAR-21-10 Idea by another investigator, must apply to companion FOA (PAR-21-10 Idea by another investigator, must apply to companion FOA (PAR-21-10 Idea by another investigator, must apply to companion FOA (PAR-21-10 Idea by another investigator, must apply to companion FOA (PAR-21-10 Idea by another investigator, must apply to companion FOA (PAR-21-10 Idea by another investigator, must apply to companion FOA (PAR-21-10 Idea by another investigator, must apply to companion FOA (PAR-21-10 Idea by another investigator, must apply to companion FOA (PAR-21-10 Idea by another investigator, must apply to companion FOA (PAR-21-10 Idea by another investigator, must apply to companion FOA (PAR-21-10 Idea by another investigator, must apply to companion FOA (PAR-21-10 Idea by another investigator, must apply to companion FOA (PAR-21-10 Idea by another investigator, must apply to companion FOA (PAR-21-10 Idea by another	Announcement (FOA) is designed specifically for applicants proposing to serve as the clinical trial, a clinical trial, a clinical trial, a clinical trial, as part development. Applicants not planning an independent clinical trial, or proposing to go led by another investigator, must apply to companion FOA (PAR-21-104). Summer Research Education Experience Program (R25 Clinical Trial Not National Institutes of Health/DHHS 168 Contact Name Laura E. Kwako, Ph.D.	Announcement (FOA) is designed specifically for applicants proposing to serve as the lead investigator of an inclinical trial, a clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial, as part of their research and can development. Applicants not planning an independent clinical trial, or proposing to gain research experience led by another investigator, must apply to companion FOA (PAR-21-104). Summer Research Education Experience Program (R25 Clinical Trial Not Health/DHHS 168 17-Mar-2023 Contact Name Laura E. Kwako, Ph.D. Contact Telephone 301-451-8507 Contact Email Laura.kwako@nih.gov Sponsor Website Program URL Deadline Dates (ALL) 17-Mar-2023 , 08-May-2023 , 19-Mar-2024 , 07-May-2024 The NIH Research Education Program (R25) supports research education activities in the mission areas of the overarching goal of this R25 program is to support educational activities that complement and/or enhance the Synopsis workforce to meet the nation's biomedical, behavioral and clinical research needs. To accomplish the stated of goal, this FOA will support creative educational activities with a primary focus on: Research Experiences for his students, undergraduate students, and/or science teachers during the summer academic break. REA-HL-23-006 - Stimulating Access to Research in Residency (StARR) (R38 National Institutes of Health/DHHS 23-006 15-Mar-2023 15-Mar-2023 10-Mar-2023 10-Mar-202



SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		can provide outstanding mentored researchindividual career development research research conducted by Resident-Investig milestones.	awards. The program will supp	ort institutions	to provide support for	up to 2 years
101453	International Research Scientist Dindependent Clinical Trial Not Alle	Development Award (IRSDA) (K01) owed	National Institutes of Health/DHHS	PAR-21- 104	08-Mar-2023	700,000 USD
	Contact Telephone Contact Email Sponsor Website Program URL	Christine.Jessup@nih.gov Link to program URL				
	Deadline Dates (ALL) Synopsis	The purpose of the International Researd (three to five years) to advanced postdomust be at least two years beyond confeexperience in a low- or middle-income c (http://data.worldbank.org/about/counmiddle-income," and "upper-middle-income global health. This Funding Opportunity junior faculty from any health-related direlevant to the health priorities of the LN Announcement (FOA) is designed specifical trial, a clinical trial feasibility study propose research experience in a clinical ancillary study to an ongoing clinical trial	ctoral U.S. research scientists a cral of doctoral degree) for an ountry (LMIC), as defined by the try-classifications/country-andome" countries) leading to an information and the countries appoins the mentorship of LN cally for applicants proposing rely, or an ancillary study to a cliral led by a mentor or co-me	nd recently-apintensive, mene World Bank lending-groups of the world Bank lending-groups of the world Bank lending and U.S. mesearch that de lical trial. Applicant	pointed U.S. junior facu tored research career d s), including "low-incom funded research career m postdoctoral research ivities and a research pr entors. This Funding Op oes not involve leading a cants to this FOA are pe	lty (applicants evelopment e," "lower- focused on a scientists and roject that is portunity an independent of all or an
		s to Integrate Basic Behavioral, Biomedica (K18 Basic Experimental Studies with	National Institutes of Health/DHHS	PAR-20- 226	17-Mar-2023	Not Specified
	Contact Name Contact Telephone	William Elwood, PhD 301-402-0116				



SPI	N ID	Program	Sponsor Name	Sponsor Number	Deadline Date	Funding
•	., .,	Title				Amount

Contact Email william.elwood@nih.gov

Sponsor Website

Program URL Link to program URL

Deadline Dates (ALL) 17-Mar-2023

This Funding Opportunity Announcement (FOA) invites applications from investigators who strive to expand their research trajectories through the acquisition of new knowledge and skills in the areas of basic psychological processes, sociological processes, and/or biomedical pathways—expertise that is beyond and enhances their current areas of expertise. The program will support career development experiences and a small-scale research project that will provide experienced investigators with the scientific competencies required to conduct independent research projects that more thoroughly investigate interrelationships among behavioral, biological, endocrine, epigenetic, immune, inflammatory, neurological, psychological, and/or social processes. Eligible candidates are independent investigators at mid-career faculty rank or level. Applicants may propose research career development projects that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical and/or behavioral outcomes in humans to understand fundamental aspects of phenomena (see, NOT-OD-18-212). These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should submit under this FOA include Synopsis studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Applicants who plan to gain research experience within an existing clinical trial or basic experimental study with humans led by another investigator, or who propose to gain research experience in purely basic human or model animal research, or in data sciences, must apply to companion FOA, PAR--20-211, Independent Clinical Trials Not Allowed. This Funding Opportunity Announcement is for basic science experimental studies involving humans, referred to inNOT-OD-18-212as "prospective basic science studies involving human participants." These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should submit under this FOA include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards

Mid-Career Enhancement Awards to Integrate Basic Behavioral, Biomedical, 095511 and/or Social Scientific Processes (K18 No Independent Clinical Trials)

National Institutes of Health/DHHS

PAR-20-211

17-Mar-2023

Not Specified

Contact Name William Elwood, PhD Contact Telephone 301-402-0116

processes or products in mind.



		_	• •				
SPIN ID	Program Title	Sponsor Name	Sponsor Number		I Deadline Date	Funding Amount	
	Contact Email willia	m.elwood@nih.gov					
	Sponsor Website						
	Program URL Link t	o program URL					
	Deadline Dates (ALL) 17-M	ar-2023					
This Funding Opportunity Announcement (FOA) invites applications from investigators who strive to expand their resea trajectories through the acquisition of new knowledge and skills in the areas of basic psychological processes, sociologic processes, and/or biomedical pathways—expertise that is beyond and enhances their current areas of expertise. The program will support career development experiences and a small-scale research project that will provide experienced investigators with the scientific competencies required to conduct independent research projects that more thoroughly investigate interrelationships among behavioral, biological, endocrine, epigenetic, immune, inflammatory, neurological, synopsis psychological, and/or social processes. Applicants may propose research that involves non-human animals, secondary of analyses, or other career development projects that do not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical trial. Applicants are permitted to propose research experience within a clinical trial led by a mentor or co-mentor. Eligible candidates are independent investigators at mid-career faculty rank of level. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that doe involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical trial. Applicants proposing Basic Experimental Studies with Humans (BESH) should apply to the companion FOA PAR-20-226.							
100349	RFA-Al-20-076 New Technologies for Therapeutics for an HIV Cure (R01 Clini		National Institutes of Health/DHHS	RFA-AI-20- 15- 076 [O _I	-Feb-2023 ptional][LOI/Pre-App	Not Specified	
	Contact Name Betty	Poon, Ph.D.					
	Contact Telephone 240-6						
	Contact Email poon	b@niaid.nih.gov					
	Sponsor Website						
	Program URL <u>Link t</u>	o program URL					
	Deadline Dates (ALL) 15-Fe	b-2023 [Optional][LOI/Pre-App], 1	7-Mar-2023				
		urpose of this Funding Opportunit ative strategies to deliver anti-HIV				validation of	
108568	Notice of Special Interest (NOSI): Admin Purchases for Select NIGMS-Funded Av		ent National Institutes of Health/DHHS	NOT-GM- 22-017	-Mar-2023	250,000 USD	

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Contact Name						
	Contact Telephone						
	Contact Email						
	Sponsor Website						
	Program URL	Link to pr	ogram URL				
	Deadline Dates (ALL)	01-Mar-2	023				
	Synopsis		onal Institute of General Medical ents to NIGMS-funded R01, R15,		•		
	Notice of Special Interest (NOSI):			National Institutes of	NOT-AI-		100,000
	Collaborative Science to Synergiz		l Medical Countermeasures	Health/DHHS	22-029	01-Mar-2023	USD
	Discovery and Early Development	<u>-</u> I					
	Contact Name		<u> </u>				
	Contact Telephone	301-796-	7237				
	Contact Email	dy70v@n	<u>ih.gov</u>				
	Sponsor Website						
	Program URL	Link to pr	ogram URL				
	Deadline Dates (ALL)	01-Mar-2	023 , 01-Mar-2024				
NIAID announces the availability of funds for Administrative Supplements to a subset of existing NIAID-funded/co-Chemical Countermeasures Research Program (CCRP) grants and cooperative agreements across the NIH. These further intended to stimulate ongoing research by providing CCRP-supported researchers the opportunities to form new collaborations with each other that were not anticipated at the time of submission, review, and funding of the paraward.						e funds are w	
111XX54	RFA-NS-22-021 HEAL Initiative:					07-Feb-2023	5,000,000
	Coordination and Integration Cer	<u>iter (U24 (</u>	Clinical Trial Not Allowed)	Health/DHHS	22-021 [Optional][LOI/Pre-App]] USD
	Contact Name	D.P. Moh	apatra, PhD				
	Contact Telephone	301-496-	9964				
	Contact Email	dp.moha	oatra@ni.gov				
	Sponsor Website						



SPIN ID	Program	Sponsor Name	Sponsor Number	Deadline Date	Funding
SPIN ID	Title	Sponsor Name	Sponsor Number	Deadine Date	Amount

Program URL Link to program URL

Deadline Dates (ALL) 07-Feb-2023 [Optional][LOI/Pre-App], 09-Mar-2023

The goal of this funding opportunity announcement is to support a Human Pain-associated Genes & Cells Data Coordination and Integration Center as part of the NIH HEAL Initiative's Program to Reveal and Evaluate Cells-to-gene Information that Specify Intricacies, Origins, and the Nature of Human Pain (PRECISION Human Pain). The Data Coordination and Integration Center will curate, harmonize, and integrate comprehensive -omics and cellular function datasets generated by companion U19 Centers for Discovery and Functional Evaluation of Human Pain-associated Genes & Cells, which include the characterization of functional genetic elements, epigenetic signatures, and molecular/cellular pathways that underlie human Synopsis pain signal transduction, transmission and processing. The Human Pain-associated Genes & Cells Data Coordination and Integration Center will lead efforts to establish spatial and semantic standards for managing heterogeneous human painassociated data types and information, collect and register multimodal human pain-associated data to common neural tissue coordinate systems, and establish a web-accessible information system that can be widely used throughout the research community. A central goal of the PRECISION Human Pain network is to generate comprehensive, integrated datasets, maps, and other resources on human genes and cellular function phenotypes underlying the heterogeneity,

RFA-NS-22-018 -- HEAL Initiative: Discovery and Functional Evaluation of 108852 Human Pain-associated Genes & Cells (U19 Clinical Trial Not Allowed)

National Institutes of Health/DHHS

RFA-NS-07-Feb-2023 22-018

7,500,000 [Optional][LOI/Pre-App] USD

Contact Name D.P. Mohapatra, PhD

Contact Telephone 301-496-9964

Contact Email dp.mohapatra@ni.gov

Sponsor Website

Program URL Link to program URL

Deadline Dates (ALL) 07-Feb-2023 [Optional][LOI/Pre-App], 09-Mar-2023

pathogenesis and susceptibility to specific pain conditions.

The purpose of this funding opportunity announcement is to support research that uses human tissue or cells to generate comprehensive datasets for the discovery and characterization of functional genetic elements, epigenetic signatures, and molecular/cellular pathways that underlie human pain transduction, transmission, and processing. This FOA will support Synopsis|concerted multidisciplinary team science efforts that apply large-scale high-throughput approaches on tissues involved in human pain processing as part of the NIH HEAL Initiative's Program to Reveal and Evaluate Cells-to-gene Information that Specify Intricacies, Origins, and the Nature of Human Pain (PRECISION Human Pain). U19 Centers will operate as a

cooperative network to promote collaboration and coordination of research activities. U19 Centers will also coordinate with



SPIN ID	Program Title	Sponsor Name	ponsor Number		Deadline Date	Funding Amount
		the U24 HEAL Initiative: Human Pain-assoc harmonize, and integrate datasets generat			Integration Center that	
105351	<u>Dyadic Interpersonal Processes a</u> <u>Trials Not Allowed)</u>	nd Biopsychosocial Outcomes (R01 Clinical	National Institutes of Health/DHHS	PAR-21- 281	05-Mar-2023	Not Specified
	Contact Telephone Contact Email Sponsor Website Program URL	william.elwood@nih.gov Link to program URL 05-Mar-2023 , 07-May-2023 This funding opportunity announcement (I or measure independent and interdependent of two individuals whose interactions networks. Both animal and human subject	ent health-related effects with and influences on one anothe s research projects are welcor al studies involving humans, c ies involving human participal FOA PAR-21-280" Dyadic Intel	nin dyads. For r are nested on me. Types of por existing/syr nts (i.e., expe	the purpose of this FOA within larger social conterprojects submitted undenthesized datasets studie imentally manipulate in	., a dyad is a exts and r this FOA es. Researcher dependent
105350	Dyadic Interpersonal Processes a Experimental Studies with Human	nd Biopsychosocial Outcomes (R01 - Basic ns)	National Institutes of Health/DHHS	PAR-21- 280	05-Mar-2023	Not Specified
	Contact Telephone Contact Email Sponsor Website Program URL	william.elwood@nih.gov Link to program URL 05-Mar-2023, 07-May-2023 This funding opportunity appouncement (FOA) invites basic and/or metl	nodological re	esearch projects that illu	minate and/or



SPIN ID	Program Title	Sponsor Name	ponsor Number		Deadline Date	Funding Amount
		purpose of this FOA, a dyad is a unit of two larger social contexts and networks. Dyads bidirectional influences on physical and mothat affect each member of the dyad indiveffects are those that affect one member of the individual is part of a dyad but also becas well).	are social relationships that ental health. For the purpose idually (i.e., by nature of bein of the dyad contingent upon	extend beyond of this FOA, ind g part of the dy the other memb	the individual and have ependent effects are tl ad), whereas interdepe per of the dyad (i.e., no	e strong hose effects endent t only because
103486	Notice of Special Interest (NOSI): Later in Life	Early-life Factors and Cancer Development	National Institutes of Health/DHHS	NOT-CA- 21-074	07-Jan-2023	Not Specified
	Contact Name Contact Telephone Contact Email Sponsor Website					
	· ·	Link to program URL 07-Jan-2023, 05-Feb-2023, 16-Feb-2023, 2023, 16-Oct-2023, 05-Nov-2023, 07-Jan	07-Mar-2023 , 07-May-2023 -2024 , 05-Feb-2024 , 16-Feb	, 05-Jun-2023 , -2024 , 07-Mar-:	16-Jun-2023 , 07-Sep-2 2024	.023 , 05-Oct-
		The purpose of this Notice of Special Interesting (maternal-paternal, in utero, birth and infalife.	est (NOSI) is to stimulate rese	earch focused or	n the roles of early-life	
11177/18	Notice of Special Interest (NOSI): Related Cardiotoxicity	Improving Outcomes in Cancer Treatment-	National Institutes of Health/DHHS	NOT-CA- 22-001	07-Jan-2023	Not Specified
	Contact Name	Crystal Wolfrey				
	Contact Telephone	240-276-6277				
	Contact Email	wolfreyc@mail.nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	07-Jan-2023 , 25-Jan-2023 , 05-Feb-2023 , 2023 , 07-Sep-2023 , 05-Oct-2023 , 09-Oct-Mar-2024 , 07-May-2024 , 05-Jun-2024 , 0	-2023 , 16-Oct-2023 , 05-Nov	-2023 , 07-Jan-2	024 , 05-Feb-2024 , 16	



SPIN ID	Program	Sponsor Name	Sponsor Number		IDEAUINE DATE	Funding		
	Title					Amount		
	Synopsis	The purpose of this Notice of Special Integration cardiovascular dysfunction while optimized cardiotoxicity and translating the finding	zing cancer outcomes by under	standing the m	echanisms of cancer trea	tment-related		
		Development and Validation of Non- nin (R01 Clinical Trial Not Allowed)	National Institutes of Health/DHHS	RFA-NS- 22-070	05-Feb-2023 [Optional][LOI/Pre-App	3,750,000] USD		
	Contact Name							
	Contact Telephone							
	Contact Email	HEALanimalmodels@nih.gov						
	Sponsor Website							
	Program URL	Link to program URL						
	Deadline Dates (ALL)	5-Feb-2023 [Optional][LOI/Pre-App], 07-Mar-2023 , 06-Jun-2023 [Optional][LOI/Pre-App], 06-Jul-2023 , 08-Oct-2023 Optional][LOI/Pre-App], 07-Nov-2023 , 05-Feb-2024 [Optional][LOI/Pre-App], 06-Mar-2024						
	Synopsis	This funding opportunity announcement mammalian models of pain, associated or research for effective pain management behavioral, and/or cognitive aspects of hexpected to provide well-validated modinterventions with little or no addiction	outcome measures and/or end . These models are expected to numan pain disorders and conc els and measures that facilitate	points that will o recapitulate m litions. Researcl	significantly advance tran nolecular, cellular, pathol h supported under this FO	nslational ogical, DA is		
108837	Notice of Special Interest (NOSI): Hardship to Improve Patient Outo	Addressing Cancer-Related Financial comes	National Institutes of Health/DHHS	NOT-CA- 22-045	07-Jan-2023	Not Specified		
	Contact Name	Kathleen Castro, RN, MS, AOCN						
	Contact Telephone							
	Contact Email	kathleen.castro@mail.nih.gov						
	Sponsor Website							
	Program URL	Link to program URL						
	Deadline Dates (ALL)	07-Jan-2023 , 25-Jan-2023 , 05-Feb-2023 2023 , 25-Sep-2023 , 05-Oct-2023 , 07-O Feb-2024 , 16-Feb-2024		•				



SPIN ID	Program	Sponsor Name	ponsor Number		Deadline Date	Funding	
51 114 10	Title	Sponsor Name	polisor Number		Deadinic Date	Amount	
	Synopsis	The purpose of this Notice of Special Interapplications that aim to study ways to mit patients receiving cancer treatment, surviv	igate financial hardship for ir				
100480		periences to Enhance Diversity in the Next I Addiction Scientists (R25 Clinical Trials Not	National Institutes of Health/DHHS	PAR-20- 236	.5-Mar-2023	1,250,000 USD	
	Contact Name	Albert Avila, PhD					
	Contact Telephone	301-496-8804					
	Contact Email	aavila@nida.nih.gov					
	Sponsor Website						
	Program URL	Link to program URL					
	Deadline Dates (ALL)	15-Mar-2023 , 10-Aug-2023 , 15-Nov-2023	}				
	The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The overarching goal of this R25 program is to support educational activities that encourage individuals from diverse backgrounds, including those from groups underrepresented in the biomedical and behavioral sciences, to pursue furth studies or careers in research. To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on: Research Experiences Courses for Skills Development						
112420	Notice of Special Interest (NOSI): Screening in Diverse Populations	Increasing Uptake of Evidence-Based Across the Lifespan	National Institutes of Health/DHHS	NOT-OD- 22-178	7-Jan-2023	Not Specified	
	Contact Name	Melissa C. Green Parker, PhD					
	Contact Telephone	301-480-1161					
	Contact Email	melissa.greenparker@nih.gov					
	Sponsor Website						
	Program URL	Link to program URL					
	Deadline Dates (ALL)	07-Jan-2023, 05-Feb-2023, 07-Feb-2023, 2023, 06-Jun-2023, 07-Jun-2023, 15-Jun-0ct-2023, 16-Oct-2023, 17-Oct-2023, 05-May-2024, 05-Jun-2022024, 07-Jan-2025, 05-Feb-2025, 16-Feb-	2023 , 16-Jun-2023 , 19-Jun- -Nov-2023 , 07-Jan-2024 , 05 4 , 07-Jun-2024 , 16-Jun-202	2023 , 07-Sep-202 -Feb-2024 , 06-Fel	3 , 03-Oct-2023 , 05-0 b-2024 , 15-Feb-2024	Oct-2023 , 09- , 16-Feb-2024	

SPIN ID Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
Synopsis	The Office of Disease Prevention (ODP) a (ICs) are issuing this Notice of Special Interventions to improve the uptake of e but not limited to, those experiencing he effectiveness, dissemination and implem screening are encouraged.	erest (NOSI) to encourage appl vidence-based screening servically alth disparities and those that	ications proposices across the lif	ng to test multilevel st espan and in populatio d. Studies addressing e	rategies and ons including, fficacy,
112421 Notice of Special Interest (NOSI):	Addressing Evidence Gaps in Screening	National Institutes of Health/DHHS	NOT-OD- 22-179	07-Jan-2023	Not Specified
	Melissa C. Green Parker, PhD				
Contact Telephone					
	melissa.greenparker@nih.gov				
Sponsor Website					
Program URI	Link to program URL				
Deadline Dates (ALL	07-Jan-2023, 05-Feb-2023, 07-Feb-2023 2023, 06-Jun-2023, 07-Jun-2023, 15-Jun Oct-2023, 16-Oct-2023, 17-Oct-2023, 0 , 07-Mar-2024, 07-May-2024, 05-Jun-20 2024, 07-Jan-2025, 05-Feb-2025, 16-Fe	n-2023 , 16-Jun-2023 , 19-Jun-2 5-Nov-2023 , 07-Jan-2024 , 05- 124 , 07-Jun-2024 , 16-Jun-2024	2023 , 07-Sep-20 -Feb-2024 , 06-F	023 , 03-Oct-2023 , 05-0 eb-2024 , 15-Feb-2024	Oct-2023 , 09- , 16-Feb-2024
Synopsis	The Office of Disease Prevention (ODP) a (ICs) are issuing this Notice of Special Interpreventive screening services where the cannot be determined. This NOSI encour to close high priority evidence gaps to elerecommendation.	erest (NOSI) to solicit application evidence is lacking, of poor quages the development and use	ons proposing to ality, conflicting of innovative a	o strengthen the evider , or the balance of ben nd rigorous methods a	nce base for efits and harms
112325 Notice of Special Interest (NOSI): Improve Health Outcomes	Research on Addressing Violence to	National Institutes of Health/DHHS	NOT-OD- 22-167	07-Jan-2023	Not Specified
Contact Name	Dara R. Blachman, Ph.D.				
Contact Telephone	301-496-8522				
Contact Emai	Dara.blachman-demner@nih.gov				



SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	07-Jan-2023, 05-Feb-2023, 07-Feb-2023 2023, 16-Jun-2023, 10-Jul-2023, 07-Sep- Feb-2024, 16-Feb-2024, 11-Mar-2024, 0 , 16-Oct-2024, 12-Nov-2024, 07-Jan-2029 2025, 05-Oct-2025	-2023 , 05-Oct-2023 , 16-Oct-202 7-May-2024 , 05-Jun-2024 , 16-J	23 , 13-Nov-2023 , (un-2024 , 09-Jul-20	07-Jan-2024 , 05-F 024 , 07-Sep-2024	eb-2024 , 06- , 05-Oct-2024
		The purpose of this Notice is to highlight i violence-related screening and intervention focused on addressing exposure to violen dating violence, elder mistreatment, peer processes and outcomes.	ons into health care settings. Thi ce - including but not limited to	s Notice is to enco child maltreatmen	urage interventior t, intimate partner	research violence/teen
104865	Notice of Special Interest (NOSI): Lost in Transition	Navigating Pediatric to Adult Health Care:	National Institutes of Health/DHHS	NOT-HD- 21-027 07-Ja	an-2023	Not Specified
	Contact Name	Sonia Lee, PhD				
	Contact Telephone	301-594-4783				
	Contact Email	leesonia@mail.nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	07-Jan-2023 , 05-Feb-2023 , 16-Feb-2023 2023 , 16-Oct-2023 , 05-Nov-2023 , 07-Jar		95-Jun-2023 , 16-Ju	ın-2023 , 07-Sep-2	023 , 05-Oct-
	Synopsis	The purpose of this Notice of Special Interpediatric health care transition for youth Research applications that will advance or care transitions (HCT) from pediatric to ac encouraged. The ultimate goal is to impro	with chronic physical/medical cour understanding of promising public sare settings as well as barri	anditions or intelled ractices designed t ers and facilitators	ctual/developmen to facilitate success to such transition	tal disabilities. sful health are
107763	•	Electronic Nicotine Delivery Systems (END acco Delivery Systems: Population, Clinical sms of Health Effects	National Institutes of	NOT-OD- 22-023	an-2023	Not Specified



SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Title					Amount
	Contact Name	Rachel Grana Mayne, PhD, MPH				
	Contact Telephone	240-276-5899				
	Contact Email	rachel.mayne@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)		b-2023 , 07-Mar-2023 , 10-Mar-2023 , , 07-Jan-2024 , 05-Feb-2024 , 16-Feb-	-		.023 , 05-Oct-
The Office of Disease Prevention and participating ICOs are issuing this Notice to communicate our interest in electronic nicotine delivery systems (ENDS). Research on alternative nicotine and tobacco delivery systems [e. tobacco products (also called heat-not-burn)] will also be considered. Research with a focus on other non-com Synopsis nicotine and tobacco products will be considered on a case-by-case basis. Studies should examine population-and applied prevention of disease, including etiology and epidemiology of use, potential risks, benefits and im tobacco use behavior among different populations. Studies exclusively examining smokeless tobacco or comb products (e.g., cigarettes, cigars) will be considered non-responsive.						
	Notice of Special Interest (NOSI):	Electronic Nicotine Delivery System	ns (ENDS) National Institutes of	NOT-OD-		Not
107787		oacco Delivery Systems: Basic Mecha	Health/DHHS	22-022 07-J	lan-2023	Specified
	Health Effects	1	, 			<u>'</u>
		Ron Johnson, Ph.D.				
	Contact Telephone					
		rjohnso2@mail.nih.gov				
	Sponsor Website					
	_	Link to program URL				
	Deadline Dates (ALL)		b-2023 , 10-Mar-2023 , 07-May-2023			
	Synopsis	examining how electronic nicotine organs, and behaviors. Research o	and participating ICOs are issuing this I e delivery systems (ENDS) affect normal on alternative nicotine and tobacco de considered. Studies exclusively exami will be considered non-responsive.	al and disease state livery systems [e.g.,	es relevant to huma , heated tobacco pr	n cells, tissues oducts (also



SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
108660		<u>Salidation of Digital Health and Artificial</u> Sessment in Epidemiological, Clinical, and	National Institutes of Health/DHHS	NOT-CA- 22-037	28-Dec-2022	Not Specified
	Contact Name	Dana Wolff-Hughes, PhD				
	Contact Telephone 2	240-620-0673				
	Contact Email c	dana.wolff@nih.gov				
	Sponsor Website					
	Program URL <u>L</u>	ink to program URL				
	Deadline Dates (ALL) S T Synopsis in	28-Dec-2022, 05-Jan-2023, 07-Jan-2023, 2023, 05-Apr-2023, 26-Apr-2023, 07-Massep-2023, 07-Sep-2023, 05-Oct-2023, 09-Dec-2023, 05-Jan-2024, 07-Jan-2024. The purpose of this Notice of Special Interstility and validity of digital health and arrestervention research. The intent is to suppresently developed but not yet validated software as a medical device (SaMD), and	ny-2023, 05-Jun-2023, 07-Jun- 9-Oct-2023, 16-Oct-2023, 17-0 1, 05-Feb-2024, 15-Feb-2024, rest (NOSI) is to encourage gra tificial intelligence (AI) tools an oport the addition of new meas digital health and AI tools such	2023 , 16-Jun- Oct-2023 , 01- 16-Feb-2024 nt application d technologie surement mod	-2023, 10-Jul-2023, 26- Nov-2023, 05-Nov-2023, 07-Mar-2024 s to support the evaluat s in epidemiological, clir dalities to evaluate exist	Aug-2023, 05- 3, 13-Nov-2023 ion of the nical, and ing and
108318	Notice of Special Interest (NOSI): Some Disease and Alzheimer's Disease-Ro	ex and Gender Differences in Alzheimer's elated Dementias (AD/ADRD)	National Institutes of Health/DHHS	NOT-AG- 21-050	10-Mar-2023	Not Specified
	Contact Name	Amelia Karraker, Ph.D.				
	Contact Telephone 3	301-496-3131				
		amelia.karraker@nih.gov				
	Sponsor Website	-				
	Program URL L	ink to program URL				
	-	LO-Mar-2023 , 10-Jul-2023 , 13-Nov-2023	, 11-Mar-2024 , 09-Jul-2024 , 1	L2-Nov-2024		
	Synopsis t	This NOSI promotes multidisciplinary reserting and clinical presentation of Alzohat examine sex and gender differences AD/ADRD as well as AD/ADRD caregiving-	heimer's disease (AD) and Alzh in outcomes (e.g., clinical, func	eimer's diseas tional, well-be	se-related dementias (Al eing) among people livin	ORD). Studies g with

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		hormonal, genetic, metabolic, comorbidi physical activity, substance use, social en status, educational attainment, socioeco functioning, socio-emotional functioning provider knowledge and attitudes about that separately, or together, may drive o gender. Studies that account for method of interest.	gagement), social (e.g., history nomic and employment status and self-regulation, stress read dementia) and healthcare syst bserved differences by sex and	of maltreatment), psychological ctivity, personal em-level (e.g., and gender and/or	nt or adversity, parenth (e.g., depression, cogn ity), healthcare profess access to care) factors a may operate differentl	nood, marital itive ion (e.g., and processes y by sex and
111858	· · · · · · · · · · · · · · · · · · ·	Preventive Interventions to Address opulations that Experience Health	National Institutes of Health/DHHS	NOT-OD- 22-154	07-Jan-2023	Not Specified
	Contact Name	Jennifer Alvidrez, PhD				
	Contact Telephone	301-827-0071				
	Contact Email	Jennifer.alvidrez@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	07-Jan-2023, 05-Feb-2023, 07-Feb-2023 2023, 06-Jun-2023, 07-Jun-2023, 16-Jun Nov-2023, 07-Jan-2024, 05-Feb-2024, 0 2024, 16-Jun-2024, 07-Sep-2024, 05-Oo May-2025	n-2023 , 07-Sep-2023 , 05-Oct-2 06-Feb-2024 , 16-Feb-2024 , 07	2023 , 06-Oct-20 -Mar-2024 , 07-	023 , 09-Oct-2023 , 16- May-2024 , 05-Jun-202	Oct-2023 , 05- 4 , 07-Jun-
	Synopsis	The purpose of this NOSI is to solicit proj populations that experience health dispa		ns that address	cardiometabolic risk fa	ctors in
114750 -	railblazer Award for New and Ea Optional)	rrly Stage Investigators (R21 Clinical Trial	National Institutes of Health/DHHS	PAR-24- 022	16-Jan-2023	400,000 USD
	Contact Name	Randy King, Ph.D.				
	Contact Telephone	301-451-0707				
	Contact Email	Randy.King@nih.gov				
	Sponsor Website					



SPIN ID	Program Title	Sponsor Name	Sponsor Number		11)eadline I)ate	Funding Amount
	,					
		Link to program URL				
	Deadline Dates (ALL)	16-Jan-2023 , 16-Mar-2023 , 07-May-2023 2024 , 16-Feb-2024 , 16-Mar-2024 , 07-Ma 07-Jan-2025 , 16-Feb-2025 , 16-Mar-2025 2025 , 07-Jan-2026	ay-2024 , 16-Jun-2024 , 16-Jul-2	024 , 07-Sep-2024 ,	16-Oct-2024 , 16-N	lov-2024,
	Synopsis	This Trailblazer Award is an opportunity for (https://grants.nih.gov/policy/early-invest integrate engineering and the physical scie exploratory, developmental, proof of conditiven, or hypothesis-driven. Importantly, preliminary data. A distinct feature for this if available, minimal preliminary data are a independently produced and not yet publi limited to one-half page, which may includ one figure will be considered noncomplian	eigators/index.htm) to pursue re ences with the life and/or biom eept, or high risk-high impact, a applicants must propose resea is FOA is that no preliminary data allowed. Preliminary data are defished in a peer-reviewed journated de one figure. Applications inclu	esearch programs of edical sciences. A T nd may be technolor rch approaches for ta are required, exp efined as material val. All preliminary da uding data more tha	railblazer project mogy design-directed which there are mi ected, or encouragivhich the applicant ta should be clearly an one-half page or	ay be , discovery- nimal or no ed. However, has marked and
114331		Data and Specimen Collections to Advance Research (R21 - Clinical Trial Not Allowed)	National Institutes of Health/DHHS		eb-2023 ional][LOI/Pre-App]	275,000 USD
	Contact Name	Eric Lorenzo, PhD				
	Contact Telephone	301-443-4993				
	Contact Email	eric.lorenzo@nih.gov				
	Sponsor Website	-				
	Program URL	Link to program URL				
	Deadline Dates (ALL)	27-Feb-2023 [Optional][LOI/Pre-App], 29-I	Mar-2023			
		The purpose of this Funding Opportunity A collections to generate new research questinical manifestations, and HIV-associated	Announcement (FOA) is to utilize stions and findings related to ex	oidemiology, pathog	genesis, treatment,	
114481	Notice of Special Interest (NOSI): Care	Advancing the Science of Geriatric Palliativ	National Institutes of Health/DHHS	NOT-AG- 22-048	eb-2023	Not Specified
	Contact Name	Basil Eldadah, M.D., Ph.D.				



SPIN ID	Program Title	Sponsor Name	Sp	oonsor Number		Deadline Date	Funding Amount
	Contact Telephone	301-496-6761					
	·	eldadahb@nia.nih.gov					
	Sponsor Website						
	Program URL	Link to program URL					
	Deadline Dates (ALL)	16-Feb-2023 , 10-Mar-2023 , 07-M	ay-2023	, 05-Jun-2023 , 16-Jun-2023 , 1	.0-Jul-2023 <i>,</i> 07-9	Sep-2023	
	Synopsis	This Notice of Special Interest (NO: populations. This NOSI covers stud specialty medical or surgical wards clinics and doctors' offices, patient healthcare or community settings. and medical records, claims data, c specimen repositories, and other e observational approaches, quasi-ex	ies in a v s, intensives' homes This NOS or other sexisting re	ariety of settings including hose we care units, and emergency defended and other residential settings. So encourages both prospective sources. Leveraging ongoing consearch resources and infrastructures.	pitals (and speci lepartments), po , long-term care e studies and and shorts, interventi ucture is encoura	fic sites within hosp st-acute care setting facilities, hospices, a llyses of existing dat ion studies, network	tals including gs, outpatient and other asets, health s, data and
114797	•	Administrative Supplements to Sup euroscience Pilot Research Projects in Minority Institutions		National Institutes of Health/DHHS	NOT-MD- 23-001	-Mar-2023	500,000 USD
	Contact Name	Rina Das, PhD.					
	Contact Telephone	301-496-3996					
	Contact Email	dasr2@mail.nih.gov					
	Sponsor Website						
	Program URL	Link to program URL					
	Deadline Dates (ALL)	02-Mar-2023					
		This Notice of Special Interest (NOS Minority Institutions (RCMI) U54 are investigators (NIs) focused on rese funded careers. It is expected that grant or career development applies	wards to arch on s pilot pro	support pilot research project substance use, addiction, and/o ject PIs will work with their ins	s led by early-sta or neuroscience, titutions to prep	nge investigators (ES as a bridge to indep pare and submit follo	ls) and new endently w-up research
114765	Notice of Special Interest (NOSI): Research	Firearm Injury and Mortality Prever	<u>ntion</u>	National Institutes of Health/DHHS	NOT-OD- 23-039 07	-Jan-2023	Not Specified



SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Contact Name Contact Telephone	Dara R. Blachman, Ph.D.				
	•	Dara.blachman-demner@nih.gov				
	Deadline Dates (ALL)	2023, 03-May-2023, 07-May-202 10-Jul-2023, 22-Jul-2023, 26-Aug 2023, 20-Oct-2023, 13-Nov-2023 Feb-2024, 20-Feb-2024, 11-Mar- 2024, 09-Jul-2024, 07-Sep-2024 Feb-2025, 07-May-2025, 05-Jun- The purpose of this Notice is to hi injury, the identification of those accidental injury), the developme	eb-2023, 16-Feb-2023, 17-Feb-2023, 23, 26-May-2023, 05-Jun-2023, 15-Ja-2023, 07-Sep-2023, 08-Sep-2023, 3, 14-Nov-2023, 28-Dec-2023, 07-Ja-2024, 11-Mar-2024, 03-May-2024, 08-Sep-2024, 05-Oct-2024, 16-Oct-2025, 16-Jun-2025, 07-Sep-2025, 0 aghlight interest in research to improvat risk of firearm injury (including selent, piloting, and testing of innovative es to improve the implementation of	lun-2023 , 16-Jui 26-Sep-2023 , 0 n-2024 , 11-Jan- 07-May-2024 , 0 -2024 , 12-Nov-2 5-Oct-2025 , 16- ve understandin f- and other-dire	n-2023, 20-Jun-2023, 2 5-Oct-2023, 16-Oct-202 2024, 05-Feb-2024, 15 05-Jun-2024, 16-Jun-20 2024, 07-Jan-2025, 05- Oct-2025, 07-Jan-2026 g of the determinants o ected, victims and perpe	11-Jun-2023, 23, 17-Oct- 3-Feb-2024, 16 24, 21-Jun- Feb-2025, 16- , 05-Feb-2026 f firearm etrators,
111641 [Notice of Special Interest (NOSI):	Climate Change and Health	National Institutes of Health/DHHS	NOT-ES- 22-006	07-Jan-2023	Not Specified
	Contact Name	Claudia L. Thompson				
	Contact Telephone	984-287-3330				
	Contact Email	thompso1@niehs.nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	2023, 08-Apr-2023, 07-May-2023 Jul-2023, 03-Aug-2023, 08-Aug-2 03-Nov-2023, 13-Nov-2023, 15-N 2024, 16-Feb-2024, 20-Feb-2024	b-2023, 12-Feb-2023, 16-Feb-2023 3, 25-May-2023, 05-Jun-2023, 12-Ju 2023, 07-Sep-2023, 25-Sep-2023, 05 Nov-2023, 08-Dec-2023, 11-Dec-202 4, 11-Mar-2024, 08-Apr-2024, 07-M I-2024, 15-Jul-2024, 08-Aug-2024, (un-2023 , 16-Jun 5-Oct-2023 , 12-(3 , 07-Jan-2024 ay-2024 , 25-Ma	-2023 , 19-Jun-2023 , 10 Oct-2023 , 16-Oct-2023 , 25-Jan-2024 , 05-Feb-2 y-2024 , 05-Jun-2024 , 2	0-Jul-2023 , 13- , 19-Oct-2023 2024 , 12-Feb- 12-Jun-2024 ,



SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Synopsis	2024, 16-Oct-2024, 21-Oct-2024, 12-No Feb-2025, 12-Feb-2025, 16-Feb-2025, 1 The National Institute of Environmental H National Institute of Minority Health and Health and Human Development (NICHD) (NINR), National Heart Blood and Lung Insteading an NIH-wide Climate Change and climate change across the lifespan; improclimate change impacts; and building health content increasing health equity. As a part of this on health and well-being over the life couglobally.	9-Feb-2025, 08-Apr-2025, 07-Nealth Science (NIEHS), in partner Health Disparities (NIMHD), Europarties (NIMHD), Europarties (NHBLI) and National Institute (NHBLI) and NHBLI (N	May-2025 ership with Fogarty nice Kennedy Shrive ealth (NIMH), Natio titute of Allergy and goals of: reducing are at increased risk , communities, natio	International Center National Instituted Institute of Number 1 Infectious Disease the health threatse from or disparate ions around the wass the impact of center in the impac	ter (FIC), te of Child ursing Research se (NIAID) is s posed by ely affected by orld, thereby climate change
114596	Development of Animal Models a Syndrome Research (R21 Clinical	and Related Biological Materials for Down Trials Not Allowed)	National Institutes of Health/DHHS	PAR-23- 067 20-N	/lar-2023	275,000 USD
	Contact Telephone Contact Email Sponsor Website	zous@mail.nih.gov				
	Deadline Dates (ALL)	20-Mar-2023 16-Jun-2023 16-Oct-2023	, 16-Feb-2024 , 16-Jun-2024 , 1	6-Oct-2024 , 16-Fe	b-2025 , 16-Jun-20)25 , 16-Oct-
	Synopsis	The INvestigation of Co-occurring condition Project encourages exploratory and innovation biological materials for Down syndrome (animal models for DS research. The animal or basic science studies in areas highly relencourages, but is not limited to, projects single cell or subcellular level, advanced in (ML), and integration of multiple animal repreclinical DS research.	vative research to develop, chargos) related research and to impeal models and related biological evant to DS. With this funding conformatics technologies including the properties of various and the properties including the properties in t	acterize, or improversove access to informaterials developed opportunity annour arious animal modeing artificial intellige	e animal models a rmation about or f ed must have utilit acement, the INCL ls, genetic resourc nce (AI) or machir	from the use of ty in targeted UDE Project ces, atlases at a ne learning

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
112749	Notice of Special Interest (NOSI): Pathways for Individuals with Hist	HEAL Initiative: Opioid Use Disorder Care cories of Exposure to Violence	National Institutes of Health/DHHS	NOT-DA- 23-007	12-Feb-2023	Not Specified
	Contact Name	Carrie Mulford				
	Contact Telephone	301-827-6473				
	Contact Email	Carrie.Mulford@nih.gov				
	Sponsor Website					
		Link to program URL				
	Deadline Dates (ALL)	12-Feb-2023 , 20-Mar-2023 , 12-Jun-2023 2024 , 12-Feb-2025 , 12-Jun-2025	3 , 12-Oct-2023 , 15-Nov-2023	, 12-Feb-2024	, 20-Mar-2024 , 12-Jun-2	024 , 12-Oct-
		The proposed initiative seeks to test inno outcomes for individuals who have action			substance use and men	al health
L08374	Notice of Special Interest (NOSI): Disruption in Alzheimer's Disease	Sleep Disorders and Circadian Clock and other Dementias of Aging	National Institutes of Health/DHHS	NOT-AG- 21-051	10-Mar-2023	Not Specified
	Contact Name	Miroslaw 'Mack' Mackiewicz, Ph.D.				
	Contact Telephone	301-496-9350				
	Contact Email	mirolsaw.mackiewicz@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	10-Mar-2023 , 10-Jul-2023 , 13-Nov-2023	, 11-Mar-2024 , 09-Jul-2024 ,	12-Nov-2024		
	Synopsis	The aim of this NOSI is to advance basic a circadian clock dysfunction in AD/ADRD, a progression of neurodegeneration.				•
112755	RFA-DA-23-053 HEAL Initiative: Overdose Crisis (R61/R33 Clinical	Translating Research to Practice to End th Trial Optional)	National Institutes of Health/DHHS	RFA-DA- 23-053	18-Feb-2023 [Optional][LOI/Pre-Ap	Not o] Specified
	Contact Name	Carrie Mulford, Ph.D.				
	Contact Telephone	201927 6472				



Contact Email <u>carrie.mulford@nih.gov</u>

			_					
SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount	
	Sponsor Website Program URL	Link to pr		-Mar-2023 , 16-Oct-2023 [Optio	nal][LOI/Pre-App], 1	15-Nov-2023 , 19-F	eb-2024	
	Deadline Dates (ALL)	[Optional)23 [Optional][LOI/Pre-App], 20][LOI/Pre-App], 20-Mar-2024	ion-oriented research that acce	loratos tha translati	ion of rosporab to r	vractica to	
	address the overdose crisis. There remains an urgent need for research that advances the design of stigma-free patient-centered systems of care such that people who experience addiction can recover and sustain their recovery over the long-term. This FOA solicits applications that address understudied areas of opportunity, particularly those that focus on fundamental barriers or facilitators to reducing overdose deaths at the individual, provider, organizational, community, or system levels. Projects should be in alignment with the overall goals of the HEAL Initiative, and should focus on replicable, scalable, equitable approaches for accelerating the movement of evidence-based and promising treatments into routine us. This FOA invites phased applications to support projects for which preliminary or feasibility data is not available at the time of submission. This FOA is a companion to RFA-DA-23-054, which solicits applications for which pilot data is available.							
11//56	RFA-DA-23-054 HEAL Initiative: Overdose Crisis (R33 Clinical Trial		ng Research to Practice to End th	National Institutes of Health/DHHS		eb-2023 ional][LOI/Pre-App	3,750,000] USD	
	Contact Name	Carrie Mu	ılford, Ph.D.					
	Contact Telephone	301827-6	473					
	Contact Email	carrie.mu	llford@nih.gov					
	Sponsor Website							
	Program URL	Link to pr	ogram URL					
	Deadline Dates (ALL)	18-Feb-2023 [Optional][LOI/Pre-App], 20-Mar-2023, 16-Oct-2023 [Optional][LOI/Pre-App], 15-Nov-2023, 19-Feb-2024 [Optional][LOI/Pre-App], 20-Mar-2024						
		The goal of this initiative is to support action-oriented research that accelerates the translation of research to practice to address the overdose crisis. There remains an urgent need for research that advances the design of stigma-free patient-centered systems of care such that people who experience addiction can recover and sustain their recovery over the long-						

Synopsis term. This Funding Opportunity Announcement (FOA) solicits applications that address understudied areas of opportunity,

particularly those that focus on fundamental barriers or facilitators to reducing overdose deaths at the individual, provider, organizational, community, or system levels. Projects should be in alignment with the overall goals of the HEAL Initiative, and should focus on replicable, scalable, equitable approaches for accelerating the movement of moving evidence-based

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
112750	Notice of Special Interest (NOSI): Improve Addiction Care Quality a	and promising treatments into routine us FOA is a companion to RFA-DA-23-053, where the state of	which solicits applications for wh	nich pilot data is una	•	s available. This Not Specified
	Contact Name Contact Telephone	Julia Zur, Ph.D. 301-443-2261 julia.zur@nih.gov				
	Program URL	Link to program URL 20-Mar-2023, 15-Nov-2023, 20-Mar-202 This opportunity addresses a critical barr		crisis: ensuring a ro	bust workforce to	deliver
	Synopsis	interventions and services to people with retaining a robust and highly qualified be opioid misuse and addiction. However, we staff and increases in demand for care has barriers undermine efforts to implement Administration (HRSA) projected that dethis trend has likely worsened in responsito to priorities listed in the Office of Nation workforce undergirds all four elements (for the HHS Overdose Prevention Strategy recruiting, training, and retaining behavior develop and evaluate strategies to address focus on interventions or strategies aimed behavioral health workforce, with the ultidrugs.	e substance use disorders and rechavioral health workforce is essororkforce shortages and high rate ave substantially impacted access innovative approaches to care, mand for addiction counselors we to the COVID-19 pandemic. We nal Drug Control Policy (ONDCP primary prevention, harm reduct.). There are numerous individual coral health professionals. Unforcessing these challenges. Thereford at addressing barriers to recreate	elated comorbidities sential to delivering tes of turnover and set to, cost of, and quality and the Health will exceed supply by orkforce challenge and 2022 Drug Controction, evidence-based al-, organizational-tunately, little research funded uiting, training, and	es. Recruiting, traing effective services ong behavioral heauality of services. In Resources and Services and Services and Services and Services and Services and Services and an electric training a highly aretaining a highly	ing, and that address lith services Further, these ervices 8% in 2030; as one of the effective every support) challenges to ducted to ative must qualified
112904	Notice of Special Interest (NOSI): Bisexual+ People	Research on the Health of Bisexual and	National Institutes of Health/DHHS	NOT-OD- 22-166 07-	Jan-2023	Not Specified
	Contact Name Contact Telephone	Christopher Barnhart, PhD 301-594-8983				

			1					
SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount		
	Contact Email	christopher.barnhart@nih.gov						
	Sponsor Website							
	Program URL	Link to program URL						
	Deadline Dates (ALL) Synopsis	07-Jan-2023, 25-Jan-2023, 05-Feb-2023, 07-Feb-2023, 12-Feb-2023, 15-Feb-2023, 16-Feb-2023, 21-Feb-2023, 25-Feb-2023, 10-Mar-2023, 08-Apr-2023, 07-May-2023, 17-May-2023, 25-May-2023, 05-Jun-2023, 06-Jun-2023, 15-Jun-2023, 16-Jun-2023, 20-Jun-2023, 21-Jun-2023, 25-Jun-2023, 10-Jul-2023, 08-Aug-2023, 15-Aug-2023, 07-Sep-2023, 03-Oct-2023, 05-Oct-2023, 06-Oct-2023, 16-Oct-2023, 17-Oct-2023, 20-Oct-2023, 25-Oct-2023, 13-Nov-2023, 07-Jan-2024, 05-Feb-2024, 06-Feb-2024, 15-Feb-2024, 16-Feb-2024, 20-Feb-2024, 25-Feb-2024, 11-Mar-2024, 07-May-2024, 05-Jun-2024, 12-Jun-2024, 21-Jun-2024, 25-Jun-2024, 09-Jul-2024, 07-Sep-2024, 05-Oct-2024, 16-Oct-2024, 25-Oct-2024, 12-Nov-2024, 07-Jan-2025, 05-Feb-2025, 16-Feb-2025, 07-May-2025 This Notice of Special Interest (NOSI) solicits research, research training, and research career development on the health and well-being of people who identify as bisexual or bisexual+. "Bisexual" or "bi" in this NOSI may describe those with the potential to be attracted, romantically and/or sexually, to people of more than one sex or gender, not necessarily at the same time, not necessarily in the same way, and not necessarily to the same degree. "Bisexual+" or "bi+" in this NOSI is an umbrella term that is intended to encompass non-monosexual identities, including but not limited to bisexual, pansexual, sexually fluid, and queer.						
		sexually fluid, and queer.						
11/3/10	Notice of Special Interest (NOSI): Gender Minority (SGM)	Research on the Health of Sexual and	National Institutes of Health/DHHS	NOT-MD- 22-012	Jan-2023	Not Specified		
	Contact Name	Crystal L. Barksdale, PhD MPH						
	Contact Telephone	301-827-4228						
	Contact Email	crystal.barksdale@nih.gov						
	Sponsor Website							
	Program URL	Link to program URL						
	Deadline Dates (ALL)	07-Jan-2023, 05-Feb-2023, 06-Feb-2023, 2023, 21-Feb-2023, 22-Feb-2023, 23-Feb-2023, 08-Jun-2023, 09-Jun-2023, 08-Aug-2023, 07-Sep-2023, 05-Oct-2023, 20-Oct-2023, 26-Oct-2023, 20-Feb-2024, 22-Feb-2024, 08-Apr-2024	eb-2023 , 13-Mar-2023 , 06-Ap 3 , 12-Jun-2023 , 13-Jun-2023 , 0ct-2023 , 06-Oct-2023 , 10-Oct 08-Dec-2023 , 07-Jan-2024 , 05-	r-2023 , 08-Apr-2023 16-Jun-2023 , 20-Jun -2023 , 12-Oct-2023 -Feb-2024 , 06-Feb-2	3 , 07-May-2023 , 0 n-2023 , 29-Jun-202 s , 13-Oct-2023 , 16- 2024 , 12-Feb-2024	5-Jun-2023 , 3 , 04-Aug- -Oct-2023 , 18- , 16-Feb-2024 ,		



SPIN ID	Program Title	Sponsor Name	Sponsor Number		TDeadline Date	unding mount
	Synopsis	2024, 07-Sep-2024, 05-Oct-2024, 09-Oct Feb-2025, 07-May-2025, 05-Jun-2025, 1 This Notice calls for research on the healt limited to, individuals who identify as less Individuals with same-sex or -gender attraincluded. These populations also encomporientation, gender identity or expression orientation, gender, and/or sex.	2-Jun-2025, 16-Jun-2025 h of sexual and gender minority pian, gay, bisexual, asexual, trans actions or behaviors and those w ass those who do not self-identi	populations. SGM gender, Two-Spirit with a difference in fy with one of thes	populations include, , queer, and/or inte sex development ar e terms but whose s	but are not rsex. e also exual
114589		Research to Address 'Ending the HIV nt to Substance Using Populations At-Risk	National Institutes of Health/DHHS	NOT-DA- 23-013	an-2023	Not Specified
	Contact Name	Vasundhara Varthakavi, PhD				
	Contact Telephone	301-443-2146				
	Contact Email	vasundhara.varthakavi@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	07-Jan-2023, 05-Feb-2023, 16-Feb-2023 2023, 07-Sep-2023, 05-Oct-2023, 16-Oct 07-May-2024, 05-Jun-2024, 16-Jun-2024 2025, 05-Feb-2025, 16-Feb-2025, 21-Ma 16-Oct-2025, 07-Jan-2026, 05-Feb-2026 2026, 16-Oct-2026, 07-Oct-2027	t-2023 , 14-Nov-2023 , 07-Jan-20 , 09-Aug-2024 , 07-Sep-2024 , 0 ar-2025 , 07-May-2025 , 05-Jun-2	024 , 05-Feb-2024 , 5-Oct-2024 , 16-Oc 2025 , 16-Jun-2025	16-Feb-2024 , 21-M t-2024 , 14-Nov-202 , 07-Sep-2025 , 05-0	ar-2024 , 4 , 07-Jan- Oct-2025 ,
	Synopsis	The purpose of this NOSI is to support a k of the four pillars, including Diagnose, Tre initiative. Projects proposed in response t are at high risk for contracting HIV or livin	eat, Prevent, and Respond of the o this NOSI are required to mee	'Ending the HIV Ept the needs of the s	oidemic in the U.S. (Established)	HE)' ulations who
112126	RFA-TR-22-030 Pilot Projects In Associated with Rare Diseases (Re	vestigating Understudied Proteins O3 Clinical Trial Not Allowed)	National Institutes of Health/DHHS		eb-2023 ional][LOI/Pre-App]	100,000 USD
	Contact Name	Karlie Sharma, Ph.D.				



5 11									
SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount		
	Contact Telephone	301-451-	4965						
	Contact Email	Druggabl	eGenome@mail.nih.gov						
	Sponsor Website								
	Program URL	Link to pr	ogram URL						
	Deadline Dates (ALL)][LOI/Pre-App], 17-Oct-2023 , 1	5-Mar-2023 , 17-Jun-2023 [Optio 7-Dec-2023 [Optional][LOI/Pre- <i>i</i>			•		
	The purpose of this funding opportunity announcement (FOA) is to solicit applications for pilot projects to elucidate a role for understudied proteins associated with rare diseases. Awards will support generation of preliminary data and/or tools around eligible understudied protein(s). A list of eligible proteins is provided and are members of druggable protein families that have a known association with a rare disease. This FOA is intended to jumpstart research on understudied proteins that are associated with rare diseases and provide applicants with sufficient funding to perform basic biochemical and/or biological work to further the characterization of understudied proteins associated with rare disease.								
114551	Implementation Research on Nor Low- and Middle-Income Country Environments (R01 Clinical Trial C	and Triba		National Institutes of Health/DHHS	PAR-23- 042 09-N	∕lar-2023	Not Specified		
	Contact Name	Brad New	vsome, Ph.D.						
	Contact Telephone	301-480-	8389						
	Contact Email	FIC-GACE	@mail.nih.gov						
	Sponsor Website								
	Program URL	Link to pr	ogram URL						
	Deadline Dates (ALL)	09-Mar-2	023						
	Synopsis	Chronic E noncomn Indian/Al heat islar health ins	Diseases (GACD), invite applicating nunicable diseases (NCDs) in Waska Native (AI/AN) population ands; lack of safe infrastructure for surance, and cost of medication	articipating Institutes and Center ons for implementation research orld Bank-defined low- and midd is in the United States (US). Air, we or walking, cycling, and active livels; housing condition; and wide a idemic in city environments. In t	h focused on addres dle-income countrie vater, and soil pollu ring; lack of access to availability of tobacc	ssing risk factors for s (LMICs) and Ame tion; lack of greens o healthcare facilit co, alcohol, and un	or common erican space; urban cies, lack of healthy foods		

Announcement (FOA), "cities" include urban centers, informal settlements, slums, and periurban areas. This FOA supports

SPIN ID	Program	Sponsor Name	Sponsor Number	Deadline Date	Funding
31 114 115	Title	Sponsor Hame	Sportsor realities	Deadinic Date	Amount

applications that propose implementation research to reduce the risks of NCDs in the context of cities in LMICs and/or among AI/AN populations in US cities, with the potential to equip policymakers and practitioners with evidence-based strategies for prevention and/or management of NCDs among disadvantaged populations globally. NIH defines implementation research as the scientific study of the use of strategies to adopt and integrate evidence-based health interventions into clinical and community settings to improve individual outcomes and benefit population health. All applications must be within the scope of the mission of one of the Institutes/Centers listed above (see "Components of Participating Organizations," excluding the Fogarty International Center which manages this program but does not support awards). Applications will be accepted from US and World Bank-defined LMIC institutions only.

Implementation Research on Noncommunicable Disease Risk Factors among

114552 Low- and Middle-Income Country and Tribal Populations Living in City
Environments (R61/R33 Clinical Trial Required)

National Institutes of Health/DHHS

PAR-23-043

09-Mar-2023

Not Specified

Contact Name Brad Newsome, Ph.D.

Contact Telephone 301-480-8389

Contact Email FIC-GACD@mail.nih.gov

Sponsor Website

Program URL Link to program URL

Deadline Dates (ALL) 09-Mar-2023

The National Institutes of Health (NIH) participating Institutes and Centers (ICs), in collaboration with the Global Alliance for Chronic Diseases (GACD), invite applications for implementation research focused on addressing risk factors for common noncommunicable diseases (NCDs) in World Bank-defined low- and middle-income countries (LMICs) and American Indian/Alaska Native (Al/AN) populations in the United States (US). Air, water, and soil pollution; lack of greenspace; urban heat islands; lack of safe infrastructure for walking, cycling, and active living; lack of access to healthcare facilities, lack of health insurance, and cost of medications; housing condition; and wide availability of tobacco, alcohol, and unhealthy foods and beverages contribute to the NCD epidemic in city environments. In the context of this Funding Opportunity Announcement (FOA), "cities" include urban centers, informal settlements, slums, and periurban areas. This FOA supports applications that propose implementation research to reduce the risks of NCDs in the context of cities in LMICs and/or among Al/AN populations in US cities, with the potential to equip policymakers and practitioners with evidence-based strategies for prevention and/or management of NCDs among disadvantaged populations globally. NIH defines implementation research as the scientific study of the use of strategies to adopt and integrate evidence-based health interventions into clinical and community settings to improve individual outcomes and benefit population health. This FOA uses the bi-phasic, milestone driven R61/R33 grant mechanism. Awards made under this FOA will initially support a one-year

Synopsis

SPIN ID	Program Title	Sponsor Name S	ponsor Number		Deadline Date	Funding Amount
		milestone-driven initiation (R61) phase, wi years. Only projects that meet the scientifi phase. Applications submitted in response within the scope of the mission of one of the Organizations," excluding the Fogarty Inter Applications will be accepted from US and	c milestones and award requito to this FOA must address bothe Institutes/Centers listed abtractional Center which manage	rements of the R61 h the R61 and R33 p pove (see "Compone ges this program but	phase may transit hases. All applica ents of Participatin	ion to the R33 tions must be g
105957	<u>Time-Sensitive Obesity Policy and Allowed)</u>	d Program Evaluation (R01 Clinical Trial Not	National Institutes of Health/DHHS	PAR-21- 305	an-2023	Not Specified
	Contact Name	Mary Evans, Ph.D.				
	Contact Telephone	301-594-4578				
	Contact Email	evansmary@mail.nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	10-Jan-2023, 09-Feb-2023, 09-Mar-2023, 2023, 09-Oct-2023, 10-Oct-2023, 11-Dec-10-Jun-2024, 09-Aug-2024, 10-Sep-2024	•			•
	Synopsis	This Funding Opportunity Announcement (research to evaluate a new policy or prographysical activity, sedentary behavior, and/of FOA is intended to support research where expedited review and funding. All application related policy or program offers an uncom if the research is initiated with minimum deligible for re-submission. It is intended that application due date; however, administrately beyond that timeline.	am that is likely to influence or sleep) and/or weight outcome opportunities for empirical stons submitted to this FOA mumon and scientifically-compeelay. For these reasons, applications selected	besity related behave mes in an effort to particular tudy are, by their versits demonstrate that lling research opportations submitted to defor funding will be	viors (e.g., dietary prevent or reduce ery nature, only avent the evaluation of tunity that will on this time-sensitive awarded within 4	intake, obesity. This ailable throu f an obesity- ly be availabl re FOA are no 1 months of t
111986	Notice of Special Interest (NOSI): Address Hunger, Food and Nutrit	Stimulating Research to Understand and ion Insecurity	National Institutes of Health/DHHS	NOT-OD- 22-135	an-2023	Not Specified
	Contact Name	Marya Levintova, PhD				
	Contact Telephone	· ·				



SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount	
	Contact Email	marya.lev	vintova@nih.gov					
	Sponsor Website							
	Program URL	Link to pr	ogram URL					
	07-Jan-2023 , 15-Jan-2023 , 05-Feb-2023 , 07-Feb-2023 , 16-Feb-2023 , 07-Mar-2023 , 08-Mar-2023 , 15-Apr 2023 , 07-May-2023 , 05-Jun-2023 , 06-Jun-2023 , 07-Jun-2023 , 16-Jun-2023 , 16-Jun-2023 , 07-Sep-2023 , 03-Oct-2023 , 05-Nov-2023 , 11-Dec-2023 , 07-Jan-2024 , 05-Feb-2024 , 07-Mar-2024 , 07-May-2024 , 05-Jun-2024 , 07-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 08-Oct-2024 , 16-Oct-2024							
The purpose of this NOSI is to encourage research on the efficacy of interventions that address nutrition security and the mechanisms of food insecurity on a variety of health outcomes. It also calls for the development of new measures for synopsis nutrition security and assessment of food insecurity that are broadly applicable It was developed by the Office of Nutrition Research (ONR) Implementation Working Group on Nutrition and Health Disparities in collaboration with NIH Institutes are Centers (ICs) and Offices in support of the goals and objectives of the Strategic Plan for NIH Nutrition Research.							ures for ce of Nutritior Institutes and	
108113	Notice of Special Interest (NOSI):	Health Dis	sparities and Alzheimer's Diseas	National Institutes of Health/DHHS	NOT-AG- 21-033	10-Mar-2023	Not Specified	
	Contact Name	Damali M	lartin, Ph.D.					
	Contact Telephone	301-402-	8310					
	Contact Email	<u>martinda</u>	@mail.nih.gov					
	Sponsor Website							
	Program URL	Link to pr	ogram URL					
	Deadline Dates (ALL)	10-Mar-2	023 , 10-Jul-2023 , 13-Nov-2023	3 , 11-Mar-2024 , 09-Jul-2024 ,	12-Nov-2024			
	Synopsis		ce of Special Interest (NOSI) end o, using diverse cohorts of subje		mine mediators a	nd moderators of disp	arities in	
102050	Research on Current Topics in Alz (R21 Clinical Trial Optional)	heimer's [Disease and Its Related Dement	ias National Institutes of Health/DHHS	PAR-22- 094	10-Mar-2023	275,000 USD	
	Cantast Nama	Sanoi K S	Suneja, Ph.D					



Contact Telephone 301-402-7710

Contact Email sanoj.suneja@nih.gov

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Sponsor Website Program URL Deadline Dates (ALL) Synopsis	Link to program URL 10-Mar-2023 , 10-Jul-2023 , 13-Nov-2023 The purpose of this Funding Opportunity techniques, etc. to advance research on preliminary data with broader disseminate will be announced through a series of No	Announcement (FOA) is to invi Alzheimer's disease (AD) and its tion to establish them for more	te applications prop related dementias general use in this i	(ADRD) that need	nimal models, additional
THXHIL	<u> </u>	heimer's Disease and Its Related Dement		PAR-22-	Лаr-2023	Not Specified
	Contact Telephone	Sanoj K. Suneja, Ph.D 301-402-7710 <u>sanoj.suneja@nih.gov</u>				
	_	Link to program URL 10-Mar-2023 10-Jul-2023 13-Nov-202	3 11-Mar-2024 09-Jul-2024 1	2-Nov-2024		
Deadline Dates (ALL) 10-Mar-2023 , 10-Jul-2023 , 13-Nov-2023 , 11-Mar-2024 , 09-Jul-2024 , 12-Nov-2024 The purpose of this Funding Opportunity Announcement (FOA) is to invite applications proposing research on currer Synopsis in Alzheimer's disease (AD) and its related dementias (ADRD). Further information on the high-priority topics of interpretation be announced through a series of Notices published subsequent to this FOA.						
007787	Summer Internship Program in Bio	omedical Research	National Institutes of Health/DHHS	01-N	/lar-2023	Not Specified
	Contact Telephone Contact Email Sponsor Website	NIH Office of Education 800-445-8283 Summer Postbac Questions@mail.nih.s Link to sponsor website Link to program URL	<u>gov</u>			
	Deadline Dates (ALL)					



SPIN ID Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount			
The sponsor provides support for summer internships in biomedical research. Eligible applicants are U.S. citizens or Synopsis permanent residents who are enrolled at least half-time in an accredited U.S. high school, college, or graduate school. Stipends vary by institution.								
100056 Health Services Research on Mino Clinical Trial Optional)	ority Health and Health Disparities (R01-	National Institutes of Health/DHHS	PAR-20- 310	17-Feb-2023	Not Specified			
Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL)	rada.dagher@nih.gov	he improvement of minority h	_					
RFA-OD-23-003 Short Courses of 114663 Approaches in the Behavioral and Trial Not Allowed)	on Innovative Methodologies and Social Sciences (R25 Independent Clinical	National Institutes of Health/DHHS	RFA-OD- 23-003	17-Mar-2023 [Optional][LOI/Pre-App	800,000] USD			
Contact Telephone Contact Email Sponsor Website Program URL	spottse@od.nih.gov	5) supports research education						



SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
114660		erventions for Firearm and Related evention (CLIF-VP) (UG3/UH3 Clinical Trial	National Institutes of Health/DHHS	PAR-23- 066	15-Feb-2023 [Optional][LOI/Pre-App]	Not Specified
	Contact Telephone Contact Email Sponsor Website Program URL	Dara R. Blachman-Demner, Ph.D. 301-496-8522 dara.blachman-demner@nih.gov Link to program URL 15-Feb-2023 [Optional][LOI/Pre-App], 17	-Mar-2023			
		Violence affects people of all ages and its United States and constitutes a major puracial/ethnic minority, sexual and gender research that identifies innovative prever Within the legislative mandates and limit a network of research projects to develop to prevent firearm and related violence, i UG3/UH3 Phased Innovation Awards Coot to demonstrate sufficient preparation, fe proposed. A UG3 project that meets its mathe UH3 award (phase II). Applicants respunds	impact is far-reaching. It is a lead blic health crisis, especially amore minority (SGM) and disability position approaches to reduce fireations of NIH funding (NOT-OD-20) and test interventions at the conjury and mortality. This FOA so reperative Agreement applications as ibility and capacity to meet for illestones will be administratively	ng young peopulations. NI rm and relate 21-058, NOT-0 mmunity or olicits bi-phasics. Funding for undational my considered	ple, and in particular amount in the second in particular amount in the supposed violence, injury and monopole of the second in	ong rting ortality. e will support level that aim osed in will be used o the work r transition to
114487	Intramural Loan Repayment Prog	ram for AIDS Research (AIDS-LRP)	Office of Loan Repayment/NIH/DHHS	NOT-OD- 23-025	15-Mar-2023	100,000 USD
	Contact Name					

Contact Telephone 866-849-4047

Contact Email Irp@nih.gov

Sponsor Website Link to sponsor website

Program URL Link to program URL

Deadline Dates (ALL) 15-Mar-2023



SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	------------------	--------------	----------------	---------------	-------------------

NIH invites applications for the Intramural Loan Repayment Program for AIDSResearch. The NIH Loan Repayment Programs Synopsis (LRPs) are a set of programs established by Congress and designed to recruit and retain highly qualified health professionals into biomedical or biobehavioral research careers.

Accelerating Innovations in Biomanufacturing Approaches through Collaboration Between NSF and the DOE BETO funded Agile BioFoundry (NSF-DOE/ABF Collaboration) Contact Name Contact Telephone 703-292-7123 Contact Email drockcli@nsf.gov 1	SPIN ID	Program Title		Sponsor Name		Sponsor Number	Deadline Date	Funding Amount
Contact Telephone Contact Email Grockcli@nsf.gov Link to sponsor website Program URL Deadline Dates (ALL) The National Science Foundation (NSF) and the Department of Energy's Bioenergy Technologies Office (DOE BETO) recognize the critical roles that synthetic and engineering biology play in advancing the U.S. Bioeconomy, To translate advances in synthetic and engineering biology into products and processes that will impact the U.S. bioeconomy, there is a need to accelerate innovation and adopt new biomanufacturing approaches. The integrated Design-Build-Test-Learn (DBTL) capabilities of the DOE BETO funded Agile BioFoundry (ABF) offer a unique resource to the academic community to develop and implement innovative biodesign and biomanufacturing technologies and practices. To help advance the U.S. bioeconomy, these agencies invite proposals must leverage the unique DBTL capabilities available at the ABF to translate the latest advances in synthetic biology and engineering biology basic research into testable prototype processes and products that are potentially scalable and manufacturable and can be appropriately validated. Of particular interest are proposals that Synopsis on the leverage the DBTL capabilities of the ABF to translate basic science into bioeconomy-relevant innovation and also lead to the development of generalizable rules or theories of biological systems that enhance our understanding of basic science. In order to facilitate the utilization of the integrated DBTL capabilities available at the ABF and ensure the readiness of basic research projects for their translation to ABF platforms, NSF would support efforts of eligible PIs and their students, postdoctoral fellows, and other lab personnel on projects that can leverage the unique capabilities of the ABF. NSF support would be for all activity at the institution of higher education or non-profit organization that occurs in parallel to, or prior to, the work at ABF that readies the project for translation to practice. In order to increase collab	108216					22-549	15-Mar-2023	Not Specified
Sponsor Website Program URL Deadline Dates (ALL) The National Science Foundation (NSF) and the Department of Energy's Bioenergy Technologies Office (DOE BETO) recognize the critical roles that synthetic and engineering biology play in advancing the U.S. Bioeconomy, To translate advances in synthetic and engineering biology into products and processes that will impact the U.S. bioeconomy, there is a need to accelerate innovation and adopt new biomanufacturing approaches. The integrated Design-Build-Test-Learn (DBTL) capabilities of the DOE BETO Indued Agile Biondorndy (ABF) offer a unique resource to the academic community to develop and implement innovative biodesign and biomanufacturing technologies and practices. To help advance the U.S. bioeconomy, these agencies invite proposals from researchers at institutions of higher education and non-profit organizations (eligible PIs). The proposals must leverage the unique DBTL capabilities available at the ABF to translate the latest advances in synthetic biology and engineering biology basic research into testable prototype processes and products that are potentially scalable and manufacturable and can be appropriately validated. Of particular interest are proposals that Synosis to the development of generalizable rules or theories of biological systems that enhance our understanding of basic science. In order to facilitate the utilization of the integrated DBTL capabilities available at the ABF and ensure the readiness of basic research projects for their translation to ABF platforms, NSF would support efforts of eligible Pls and their students, postdoctoral fellows, and other lab personnel on projects that can leverage the unique capabilities of the ABF. NSF support would be for all activity at the institution of higher education or non-profit organization that occurs in parallel to, or prior to, the work at ABF that readies the project for translation to practice. In order to increase collaboration across sectors and workforce development, NSF, through this prog	'	Contact Name	David Rockcliffe					
Sponsor Website Program URL Deadline Dates (ALL) The National Science Foundation (NSF) and the Department of Energy's Bioenergy Technologies Office (DOE BETO) recognize the critical roles that synthetic and engineering biology play in advancing the U.S. Bioeconomy. To translate advances in synthetic and engineering biology into products and processes that will impact the U.S. bioeconomy, there is a need to accelerate innovation and adopt new biomanufacturing approaches. The integrated Design-Build-Test-Learn (DBTL) capabilities of the DOE BETO funded Agile BioFoundry (ABF) offer a unique resource to the academic community to develop and implement innovative biodesign and biomanufacturing technologies and practices. To help advance the U.S. bioeconomy, these agencies invite proposals from researchers at institutions of higher education and non-profit organizations (eligible PIs). The proposals must leverage the unique DBTL capabilities available at the ABF to translate the latest advances in synthetic biology and engineering biology basic research into testable prototype processes and products that are potentially scalable and manufacturable and can be appropriately validated. Of particular interest are proposals that Synopsis both leverage the DBTL capabilities of the ABF to translate basic science into bioeconomy-relevant innovation and also lead to the development of generalizable rules or theories of biological systems that enhance our understanding of basic science. In order to facilitate the utilization of the integrated DBTL capabilities available at the ABF and ensure the readiness of basic research projects for their translation to ABF platforms, NSF would support efforts of eligible PIs and their students, postdoctoral fellows, and other lab personnel on projects that can leverage the unique capabilities of the ABF. NSF support would be for all activity at the institution of higher education or non-profit organization that occurs in parallel to, or prior to, the work at ABF that readies the project fo		Contact Telephone	703-292-7123					
Program URL Deadline Dates (ALL) 15-Mar-2023 The National Science Foundation (NSF) and the Department of Energy's Bioenergy Technologies Office (DOE BETO) recognize the critical roles that synthetic and engineering biology play in advancing the U.S. Bioeconomy. To translate advances in synthetic and engineering biology into products and processes that will impact the U.S. bioeconomy, there is a need to accelerate innovation and adopt new biomanufacturing approaches. The integrated Design-Build-Test-Learn (DBTL) capabilities of the DOE BETO funded Agile BioFoundry (ABF) offer a unique resource to the academic community to develop and implement innovative biodesign and biomanufacturing technologies and practices. To help advance the U.S. bioeconomy, these agencies invite proposals from researchers at institutions of higher education and non-profit organizations (eligible Pls). The proposals must leverage the unique DBTL capabilities available at the ABF to translate the latest advances in synthetic biology and engineering biology basic research into testable prototype processes and products that are potentially scalable and manufacturable and can be appropriately validated. Of particular interest are proposals that Synopsis both leverage the DBTL capabilities of the ABF to translate basic science into bioeconomy-relevant innovation and also lead to the development of generalizable rules or theories of biological systems that enhance our understanding of basic science. In order to facilitate the utilization of the integrated DBTL capabilities available at the ABF and ensure the readiness of basic research projects for their translation to ABF platforms, NSF would support efforts of eligible Pls and their students, postdoctoral fellows, and other lab personnel on projects that can leverage the unique capabilities of the ABF. NSF support would be for all activity at the institution of higher education or non-profit organization that occurs in parallel to, or prior to, the work at ABF that readies the project for t		Contact Email	drockcli@nsf.gov					
Deadline Dates (ALL) 15-Mar-2023 The National Science Foundation (NSF) and the Department of Energy's Bioenergy Technologies Office (DOE BETO) recognize the critical roles that synthetic and engineering biology play in advancing the U.S. Bioeconomy. To translate advances in synthetic and engineering biology into products and processes that will impact the U.S. bioeconomy, there is a need to accelerate innovation and adopt new biomanufacturing approaches. The integrated Design-Build-Test-Learn (DBTL) capabilities of the DOE BETO funded Agile BioFoundry (ABF) offer a unique resource to the academic community to develop and implement innovative biodesign and biomanufacturing technologies and practices. To help advance the U.S. bioeconomy, these agencies invite proposals from researchers at institutions of higher education and non-profit organizations (eligible Pls). The proposals must leverage the unique DBTL capabilities available at the ABF to translate the latest advances in synthetic biology and engineering biology basic research into testable prototype processes and products that are potentially scalable and manufacturable and can be appropriately validated. Of particular interest are proposals that Synopsis Synopsis Synopsis both leverage the DBTL capabilities of the ABF to translate basic science into bioeconomy-relevant innovation and also lead to the development of generalizable rules or theories of biological systems that enhance our understanding of basic science. In order to facilitate the utilization of the integrated DBTL capabilities available at the ABF and ensure the readiness of basic research projects for their translation to ABF platforms, NSF would support efforts of eligible Pls and their students, postdoctoral fellows, and other lab personnel on projects that can leverage the unique capabilities of the ABF. NSF support would be for all activity at the institution of higher education or non-profit organization that occurs in parallel to, or prior to, the work at ABF that readies the proj		Sponsor Website	Link to sponsor website					
The National Science Foundation (NSF) and the Department of Energy's Bioenergy Technologies Office (DOE BETO) recognize the critical roles that synthetic and engineering biology play in advancing the U.S. Bioeconomy. To translate advances in synthetic and engineering biology into products and processes that will impact the U.S. bioeconomy, there is a need to accelerate innovation and adopt new biomanufacturing approaches. The integrated Design-Build-Test-Learn (DBTL) capabilities of the DOE BETO funded Agile BioFoundry (ABF) offer a unique resource to the academic community to develop and implement innovative biodesign and biomanufacturing technologies and practices. To help advance the U.S. bioeconomy, these agencies invite proposals from researchers at institutions of higher education and non-profit organizations (eligible PIs). The proposals must leverage the unique DBTL capabilities available at the ABF to translate the latest advances in synthetic biology and engineering biology basic research into testable prototype processes and products that are potentially scalable and manufacturable and can be appropriately validated. Of particular interest are proposals that Synopsis both leverage the DBTL capabilities of the ABF to translate basic science into bioeconomy-relevant innovation and also lead to the development of generalizable rules or theories of biological systems that enhance our understanding of basic science. In order to facilitate the utilization of the integrated DBTL capabilities available at the ABF and ensure the readiness of basic research projects for their translation to ABF platforms, NSF would support efforts of eligible PIs and their students, postdoctoral fellows, and other lab personnel on projects that can leverage the unique capabilities of the ABF. NSF support would be for all activity at the institution of higher education or non-profit organization that occurs in parallel to, or prior to, the work at ABF that readies the project for translation to practice. In order to increase co		Program URL	Link to program URL					
the critical roles that synthetic and engineering biology play in advancing the U.S. Bioeconomy. To translate advances in synthetic and engineering biology into products and processes that will impact the U.S. bioeconomy, there is a need to accelerate innovation and adopt new biomanufacturing approaches. The integrated Design-Build-Test-Learn (DBTL) capabilities of the DOE BETO funded Agile BioFoundry (ABF) offer a unique resource to the academic community to develop and implement innovative biodesign and biomanufacturing technologies and practices. To help advance the U.S. bioeconomy, these agencies invite proposals from researchers at institutions of higher education and non-profit organizations (eligible PIs). The proposals must leverage the unique DBTL capabilities available at the ABF to translate the latest advances in synthetic biology and engineering biology basic research into testable prototype processes and products that are potentially scalable and manufacturable and can be appropriately validated. Of particular interest are proposals that Synopsis both leverage the DBTL capabilities of the ABF to translate basic science into bioeconomy-relevant innovation and also lead to the development of generalizable rules or theories of biological systems that enhance our understanding of basic science. In order to facilitate the utilization of the integrated DBTL capabilities available at the ABF and ensure the readiness of basic research projects for their translation to ABF platforms, NSF would support efforts of eligible PIs and their students, postdoctoral fellows, and other lab personnel on projects that can leverage the unique capabilities of the ABF. NSF support would be for all activity at the institution of higher education or non-profit organization that occurs in parallel to, or prior to, the work at ABF that readies the project for translation to practice. In order to increase collaboration across sectors and workforce development, NSF, through this program, can also support short term faculty fel		Deadline Dates (ALL)	15-Mar-2023					
facilitate eventual scale up and regulatory approval.	111503		synthetic and engineering biology in accelerate innovation and adopt new capabilities of the DOE BETO funded and implement innovative biodesign bioeconomy, these agencies invite porganizations (eligible PIs). The proplatest advances in synthetic biology that are potentially scalable and may both leverage the DBTL capabilities to the development of generalizable In order to facilitate the utilization or research projects for their translation postdoctoral fellows, and other lab pwould be for all activity at the instituthe work at ABF that readies the proworkforce development, NSF, through graduate students or undergraduate costs for implementation of approve facilitate eventual scale up and regular	to products and process by biomanufacturing ap I Agile BioFoundry (ABF) and biomanufacturing proposals from research cosals must leverage the and engineering biolog nufacturable and can be of the ABF to translate a rules or theories of bid of the integrated DBTL of the projects the projects of the projects the project of translation to project for translation translation to project for translation to project for translation translation translation translation to project for translation translat	isses that will impact proaches. The integ offer a unique resolution of technologies and papers at institutions of the unique DBTL capally basic research into the appropriately valid basic science into biological systems that capabilities available of the proof of	the U.S. bioed rated Design-lource to the auractices. To he find higher educabilities available testable produced. Of particle conomy-rest enhance our at the ABF arorts of eligible unique capal anization that increase colla m faculty felloal laboratories y is encourage	conomy, there is Build-Test-Learn cademic communelp advance the leation and non-proble at the ABF to totype processes icular interest and ensure the read PIs and their stubilities of the ABF occurs in paralle boration across sows, post-doctoration defor technological and for technological content of the ABF.	a need to (DBTL) nity to develop J.S. ofit translate the and products e proposals that a and also lead of basic science. diness of basic udents, E. NSF support I to, or prior to, sectors and al fellows, TO will cover the

SPIN ID Program Title			Sponsor Name		ponsor Iumber	Deadline Date	Funding Amount
			Foundat	tion			
	Contact Name	Steven Breckler					
	Contact Telephone	703-292-7369					
	·	sbreckle@nsf.gov					
	Sponsor Website	<u>Link to sponsor website</u>					
	Program URL	Link to program URL					
De	eadline Dates (ALL)	15-Mar-2023					
	Synopsis	Strengthening American Infrastructure potentially transformative research air strong foundation for socioeconomic vinfrastructure spurs private-sector innefficient, strengthens communities, presecurity and fuels American leadership science and engineering disciplines. Somaking, governance, and social and culimproves lives and society and builds convergence of expertise in one or mosupport substantial and potentially painfrastructure.	med at strengthening America's vitality and broad improvement ovation, grows the economy, cromotes equal opportunity, process. Achieving these objectives real focuses on how fundamental ultural processes enables the but on advances in technology and ore social, behavioral or economics.	s infrastructors in quality of reates jobs, tects the nare quires the irrest knowledge wilding and mengineering nic sciences,	ure. Effective f life. Strong makes publicated environtegration of about human aintenance . Successfuldeeply inte	ye infrastructure g, reliable and effices ector service inment, enhance of expertise from an reasoning and e of effective infreprojects will repertated with other	provides a fective provision more s national across all decision- astructure that resent a er disciplines to
113761 Expanding Al I	Innovation through	Capacity Building and Partnerships	Nationa Foundat	l Science tion	23-506	13-Mar-2023	Not Specified
	Contact Name						
	Contact Tolonhono	702 202 5111					

Contact Telephone 703-292-5111

Contact Email <u>ExpandAIProgram@nsf.gov</u>

Sponsor Website Link to sponsor website

Program URL Link to program URL

Deadline Dates (ALL) 13-Mar-2023, 26-Jun-2023, 20-Oct-2023, 11-Mar-2024, 24-Jun-2024, 18-Oct-2024, 10-Mar-2025, 23-Jun-2025

Synopsis The National Science Foundation and its partners support the continued growth of a broad and diverse interdisciplinary



SPIN ID Program Title		Sponsor Name		Sponsor Number	Deadline Date	Funding Amount
	research community for the adpromote the NSF vision and consultation and Partnerships (Expension workforce development through Institutes ecosystem.	re values, especially inclusio andAI) program aims to sign	n and collaboration. ificantly broaden par	The Expanding ticipation in A	g AI Innovation tall research, educ	hrough Capacity ation, and
114634 Designing Materials to F	Revolutionize and Engineer our Future (D	DMREF)	National Science Foundation	23-530	13-Mar-2023	2,000,000 USD
Conta	ct Name John A. Schlueter					
Contact Te	elephone 703-292-7766					
Conta	act Email <u>jschluet@nsf.gov</u>					
Sponsor	Website Link to sponsor website					
Prog	ram URL Link to program URL					
Deadline Da	tes (ALL) 13-Mar-2023					
	DMREF seeks to foster the desinate harnessing the power of data a integration of experiments, concontinuum; and strengthening experimentalists as well as the training of a next-generation method well-equipped for successful can development continuum and in the principal NSF program responderiven a transformational para the 2021 MGI Strategic Plan and power of materials data; and experiments of the seeks to foster the data and experiments.	and computational tools in computation, and theory; the connections among theorist use from academia, industry, naterials research and develorancers as educators and innovation infrastructures the consive to the National Scientials on the Materials (adigm shift in the philosophy and its three primary goals, i.e.	oncert with experiments of accessible digits, computational scients, computational scients, computational scients (R&D) workforwators; and able to the at NSF is creating with the and Technology (Genome Initiative (More of how materials research).	ent and theory tal data across entists (includ MREF is commorce that is divake full advanth partners in Council's (NSTCGI). Over its integrated is perforalls innovation	y. DMREF emphasis the materials ding data scientis itted to the educerse, equitable, tage of the material agrammed. DMREF is infrastructure;	esizes a deep evelopment ts), and cation and and inclusive; erials encies. DMREF is ence and , the MGI has supportive of
114501 NSF/CASIS Collaboration Space Station (ISS) to Be	n on Tissue Engineering and Mechanobic enefit Life on Earth	ology on the International	National Science Foundation	23-522 (06-Mar-2023	400,000 USE



SPIN ID	Program Title		Sponsor Name		Sponsor Number	Deadline Date	Funding Amount
	Contact Telephone	703-292-4465					
	·	lkuxhaus@nsf.gov					
		Link to sponsor website					
	•	Link to program URL					
	Deadline Dates (ALL)						
	Synopsis	The Divisions of Chemical, Bioengineer Infrastructure (CMMI) in the Engineeri for the Advancement of Science in Spa and mechanobiology that can utilize the life on Earth. For utilization of the ISS Nu.S. Code §6010: "'United States persunited States, and any corporation, page 1.0."	ng Directorate of the loce, Inc. (CASIS) to solo loce International Space National Lab through on' means any United	National Science Foicit research projecte Station (ISS) Nation this solicitation, enter States citizen or al	oundation (NS is in the gener nal Lab to cor ities must qualien admitted	F) are partnering ral fields of tissue duct research thalify as "U.S. Persfor permanent re	g with the Center e engineering nat will benefit sons" under 22 esidence in the
114475	NSF/CASIS Collaboration on Tran Station (ISS) to Benefit Life on Ea	sport Phenomena Research on the Inte	ernational Space	National Science Foundation	23-523	06-Mar-2023	350,000 USD
	Contact Name	Ronald Joslin					
	Contact Telephone	703-292-7030					
	Contact Email	rjoslin@nsf.gov					
	Sponsor Website	Link to sponsor website					
	Program URL	Link to program URL					
	Deadline Dates (ALL)	06-Mar-2023					
	Synopsis	The Division of Chemical, Bioengineering, Environmental, and Transport Systems (CBET) in the Engineering Directorate of the National Science Foundation (NSF) is partnering with The Center for the Advancement of Science in Space, Inc. (CASIS) to solicit research projects in the general field of fluid dynamics, particulate and multiphase processes, combustion and fire systems, thermal transport processes, and nanoscale interactions that can utilize the International Space Station (ISS) National Lab to conduct research that will benefit life on Earth. Only entities that qualify as "U.S. Persons" under 22 U.S. Code §6010, including academic investigators, non-profit independent research laboratories and academic-commercial teams are eligible to apply.					
108144	Long-Term Ecological Research (LTER) - Renewal		National Science Foundation	22-543	02-Mar-2023	Not Specified



SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount

Contact Name Roberto Delgado

Contact Telephone 703-292-2397

Contact Email robdelga@nsf.gov

Sponsor Website Link to sponsor website

Program URL Link to program URL

Deadline Dates (ALL) 02-Mar-2023

To address ecological questions that cannot be resolved with short-term observations or experiments, NSF established the Long-Term Ecological Research Program (LTER) in 1980. Two components differentiate LTER research from projects supported by other NSF programs: the research is located at specific sites chosen to represent major ecosystem types or natural biomes, and it emphasizes the study of ecological phenomena over long periods of time based on data collected in five core areas. Long-term studies are critical to achieve an integrated understanding of how components of ecosystems interact as well as to test ecological theory. Ongoing research at LTER sites is expected to contribute to the development and Synopsis testing of fundamental ecological theories and significantly advance understanding of the long-term dynamics of populations, communities and ecosystems. It often integrates multiple disciplines and, through cross-site interactions may examine patterns or processes over broad spatial scales. Recognizing that the value of long-term data extends beyond use at any individual site, NSF requires that data collected by all LTER sites be made publicly accessible. NSF currently supports 28 LTER sites. The program is on-going and proposals are periodically invited when a need is identified to balance the LTER portfolio

or when funding opportunities arise to support new LTERs. These opportunities are announced through separate

solicitations. This solicitation governs submission of renewal proposals for active LTER site awards.

113769 Experiential Learning for Emerging and Novel Technologies

National Science Foundation

23-507 02-Mar-2023

Not Specified

Contact Name Rebecca Shearman

Contact Telephone 703-292-7403

Contact Email rshearma@nsf.gov

Sponsor Website Link to sponsor website

Program URL Link to program URL

Deadline Dates (ALL) 02-Mar-2023, 14-Sep-2023

Through this new initiative, the Directorate for Education and Human Resources (EHR) and the newly established Directorate for Technology, Innovation and Partnerships (TIP) seek to support experiential learning opportunities for individuals from

SPIN ID Program Title Sponsor Name Sponsor Number Date Fundame	
--	--

diverse professional and educational backgrounds that will increase access to, and interest in, career pathways in emerging technology fields (e.g., advanced manufacturing, advanced wireless, artificial intelligence, biotechnology, quantum information science, semiconductors, and microelectronics). As NSF seeks to support the development of technologies in such fields, similar support will be needed to foster and grow a diverse science, technology, engineering, and mathematics (STEM) workforce to contribute to such innovation. Large scale societal challenges like climate change and clean energy also require a STEM workforce that brings varied perspectives and expertise to further accelerate the translation of science and engineering discoveries into large-scale solutions. Moreover, as current and new emerging technologies continue to evolve, unforeseen issues around security, safety and privacy will impact the preparation of the workforce. Emerging technologies are also dynamic and rapidly changing, with career entry and advancement often requiring "learning-by-doing" experience, even for those with some STEM education. Therefore, NSF recognizes that a competitive emerging technology workforce must include individuals from traditional and nontraditional education pathways as well as those individuals who may have "stopped" out of traditional educational pathways.

Dear Colleague Letter: Mid-Scale Research Infrastructure Incubators and Conferences for 111072 STEM Education Research with a Focus on Education Equity

National Science Foundation

NSF 22-01-Mar-2023 085

Not Specified

Contact Name Xiufeng Liu

Contact Telephone 703-292-5111

Contact Email edumidsc@nsf.gov

Sponsor Website

Program URL Link to program URL

Deadline Dates (ALL) 01-Mar-2023

With this Dear Colleague Letter (DCL), the National Science Foundation's (NSF) Directorate for Education and Human Resources (EHR) notifies the community of a collaboration with the Bill & Melinda Gates Foundation, Schmidt Futures, and the Walton Family Foundation to offer Incubator and Conference proposal opportunities that support the development of Mid-Scale Research Infrastructure (RI) efforts, especially those that enable research on the assets and needs of those traditionally left out of STEM and that lead to greater education equity. Mid-Scale RI is a relatively new concept for the science, technology, engineering, and mathematics (STEM) education community because STEM education research has traditionally been distributed, individual, and less reliant on instrumentation. Improving the speed and scale at which STEM education research advances, however, requires national research infrastructures. Through this DCL, NSF aims to conceptualize and consolidate viable infrastructure ideas to support STEM education research that will transform teaching

and learning. This DCL establishes an opportunity for the field to incubate Mid-Scale RI ideas in STEM education, allowing for

SPIN ID	Program Title	Sponsor Name		Sponsor Number	Deadline Date	Funding Amount
		idea progression through conception and planning, an proposals. As one of NSF's Big Ideas, the NSF-wide Micresearch capabilities with total project costs between	l-Scale RI initiative is des	•	•	
111866	Mid-Career Advancement (MCA)		National Science Foundation	22-603	01-Mar-2023	Not Specified
	Contact Name	Leslie J. Rissler				
	Contact Telephone	703-292-4628				
	Contact Email	<u>Irissler@nsf.gov</u>				
	Sponsor Website	<u>Link to sponsor website</u>				
	Program URL	Link to program URL				
	Deadline Dates (ALL)	01-Mar-2023				
	Synopsis	The MCA program offers an opportunity for scientists advance their research program and career trajectory they need to advance their research programs to ensuservice, teaching, or other activities that limit the amount these constraints to reduce workload inequities and edisabilities, and individuals from groups that have been	Mid-career scientists ar re long-term productivit unt of time devoted to r nable a more diverse sci	e at a critical c y and creativit esearch. MCA entific workfor	areer transition y but are often c support is expec ce (more womer	stage where onstrained by ted to help lift
114307	NSF Small Business Innovation Ro (STTR) Programs Phase II (SBIR/S	esearch Phase II (SBIR)/ Small Business Technology Trai TTR Phase II)	National Science Foundation	NSF 23- 516	01-Mar-2023	1,000,000 USD
	Contact Name					
	Contact Telephone	703-292-8050				
		sbir@nsf.gov				
		Link to sponsor website				
	·	Link to program URL				
	Deadline Dates (ALL)	01-Mar-2023 , 05-Jul-2023 , 01-Nov-2023				
	Synopsis	The NSF SBIR/STTR programs support moving scientifi By investing federal research and development funds economy and stimulate the creation of novel products	nto startups and small b	ousinesses, NSF	hopes to build a	strong national



SPIN ID	Program Title		Sponsor Name		Sponsor Number	Deadline Date	Funding Amount
		small business in meeting federal reseasupported research results; and developy socially and economically disadvant proposals based on groundbreaking scients with NSF's mission to promound to secure the national defense.	pp and increase the Uaged and women-ow ientific discoveries o	JS workforce, especi vned small businesse r significant enginee	ally by foster es. The SBIR/ ring breakth	ring and encourag STTR programs at roughs from the s	ing participation NSF solicit mall businesses
114288	NSF Small Business Innovation Re Programs Phase I (SBIR/STTR Pha	esearch (SBIR)/ Small Business Technolo ase I)	gy Transfer (STTR)	National Science Foundation	NSF 23- 515	01-Mar-2023	275,000 USD
	Sponsor Website Program URL Deadline Dates (ALL)	,	moving scientific excelopment funds into some products, serverch and development and increase the Laged and women-ow on groundbreaking	startups and small bu vices, and solutions in t needs; increase th JS workforce, especi vned small businesse scientific discoveries	usinesses, NS n the private e commerci ally by foster es. The NSF S or significar	F hopes to build a e sector; strengthe al application of for ring and encourag BIR/STTR program at engineering bre	a strong national en the role of ederally ing participation as solicit akthroughs
107089	Internet Measurement Research	: Methodologies, Tools, and Infrastructu	ure (IMR)	National Science Foundation	22-519	15-Feb-2023	Not Specified
	Contact Name Contact Telephone	Deepankar (Deep) Medhi 703-292-2935					



Contact Email dmedhi@nsf.gov

	SPIN ID	Program Title	Sponsor Name		Deadline Date	Funding Amount
--	---------	---------------	--------------	--	------------------	-------------------

Sponsor Website Link to sponsor website

Program URL Link to program URL

Deadline Dates (ALL) 15-Feb-2023, 08-Mar-2023

With this solicitation, the National Science Foundation's (NSF) Directorate for Computer and Information Science and Engineering (CISE), in partnership with the Directorate of Mathematical and Physical Sciences (MPS), is launching a new, focused program to support methodologies, tools, and research infrastructure for Internet measurement spanning access (both wireless and fixed broadband) and core Internet. Currently, Internet measurement is conducted in a piecemeal and uncoordinated manner, and the infrastructure to collect, share, and process the data does not include data on all aspects of the network covering both wireless and wired Internet. The scope, complexity, and means of accessing the Internet have changed dramatically throughout its existence. Internet measurement work has mostly focused on the wired core networks for which existing Internet measurement repositories/infrastructure provides yeomen service. Methods, data collection, and data sharing have not kept up with the importance and proliferation of wireless and fixed broadband access networks. This leaves important aspects of the access network (both wireless and fixed broadband) in many geographic regions unmeasured or under-measured. With citizens now using cellular phones for accessing the Internet, more accurate and/or additional ways to measure and assess performance, connectivity, network topology, and service gap have also become necessary. The goal of the IMR program is to encourage, coordinate, and connect research in Internet measurement in a comprehensive manner. Such research is essential and timely to assess the health of the Internet more comprehensively, improve network technologies and systems, and develop new methods of networking, especially with the development of new methodologies

Synopsis

108663 Expanding Capacity in Quantum Information Science and Engineering

National Science Foundation

22-561

03-Feb-2023 [LOI/Pre-App]

Not Specified

Contact Name Tomasz Durakiewicz

and tools.

Contact Telephone 703-292-4892

Contact Email tdurakie@nsf.gov

Sponsor Website Link to sponsor website

Program URL Link to program URL

Deadline Dates (ALL) 03-Feb-2023 [LOI/Pre-App], 03-Mar-2023, 07-Apr-2023

The NSF Expanding Capacity in Quantum Information Science and Engineering (ExpandQISE) program aims to increase research capacity and broaden participation in Quantum Information Science and Engineering (QISE) and related disciplines

SPIN ID	Program Title	Sponsor Name	Sponsor	Deadline	Funding
SPIN ID	Program riue		Number	Date	Amount

through the creation of a diversified investment portfolio in research and education that will lead to scientific and engineering breakthroughs, while securing a talent pipeline in a field where workforce needs of industry, government and academia continue to outgrow the available talent. The ExpandQISE program helps build and maintain a close connection between new efforts and existing impactful work done at the existing QISE Centers or leading QISE research Institutions, while creating and nurturing necessary critical mass at Institutions not yet fully involved in QISE. In keeping with the NSF goal of increasing the participation of all members of society in the scientific enterprise, institutions at which more than 50% of enrolled students come from groups that are currently under-represented in the sciences, e.g. minority-serving institutions (MSIs), are especially encouraged to apply.

SPIN ID	Program Title	Sponsor Nam	e	Sponsor N	umber	Deadline	Date Fu	nding Amount
114808	Alzheimer's Disease Programs Ini Community Grant Program (Wint		Administration for C	Community	HHS-2023-ACL ADPI-0045	-AOA-	21-Feb-2023	1,000,000 USD
	Contact Name	Erin Long						
	Contact Telephone	202-401-4634						
	Contact Email	Erin.Long@acl.hhs.gov						
	Sponsor Website	<u>Link to sponsor website</u>						
	Program URL							
	Deadline Dates (ALL)	21-Feb-2023						
	Synopsis	Cooperative agreements under the development and expansion Communities. There are two approximately Communities (Option B). No ermore than one ADPI grant at a option are expected to provide their caregiver remain independent	on of dementia-capable ho pplication options contain ntity is eligible to apply for ny one time. The dementi e quality, person-centered	ome and comed in this single both State a-capable systems.	munity-based segle FOA: Grants and Community of stems resulting f	ervice (HCl to States (options an from progr	BS) systems in Option A) and id no entity is ram activities u	States and Grants to eligible to hold under either
114013	Empowering Communities to Del Chronic Disease Self-Managemen		d Administration on A	ging/DHHS	HHS-2023-ACL CSSG-0003	-AOA-	11-Jan-2023	600,000 USD
	Contact Name	Donna Bethge						
	Contact Telephone							
	Contact Email	Donna.Bethge@acl.hhs.gov						
	Sponsor Website	Link to sponsor website						
	Program URL	Link to program URL						
	Deadline Dates (ALL)	11-Jan-2023						
	Synopsis	The mission of the Administrat older adults, people with disab designed for applicants to prop self-management education ar with the greatest social determ	oilities across the lifespan, pose how they will develo and support programs for o	and their far p capacity fo lder adults a	nilies and caregi r, deliver, and su nd adults with d	vers. This Istain evid Isabilities.	funding oppor ence-based ch Applicants mu	tunity is ronic disease ust target those



SPIN ID	Program Title	Sponsor Name	Sponsor Nu	ımber	Deadline Date	Funding Amount			
		areas and populations as defined b Communities Through the Federal	•	ng Racial Equity	and Support for Und	erserved			
109186	Notice of Special Interest (NOSI): Health System and Healthcare Pr COVID-19		Agency for Healthcare Research and Quality/DHHS	NOT-HS-22-01	0 25-Jan-20	Not Specified			
	Contact Name	Leeann Comfort, PhD, MPP							
	Contact Telephone								
	Contact Email	Leeann.Comfort@ahrq.hhs.gov							
	Sponsor Website								
	Program URL	Link to program URL							
	Deadline Dates (ALL)								
	Synopsis	his Special Emphasis Notice (SEN) informs the research community that the Agency for Healthcare Research and Qual AHRQ) is interested in receiving health services research grant applications to develop models of care that improve ac uality, and outcomes of care related to COVID-19 and post-acute sequalae from COVID-19 (PASC).							
114270	Special Emphasis Notice (SEN): Infections and Combating Antibio		Agency for Healthcare Research and Quality/DHHS	NOT-HS-23-00	3 25-Jan-20	Not Specified			
	Contact Name	Leyi Lin, MD							
	Contact Telephone	301-427-1333							
	Contact Email	leyi.lin@ahrq.hhs.gov							
	Sponsor Website								
	Program URL	Link to program URL							
	Deadline Dates (ALL)	25-Jan-2023, 05-Feb-2023, 25-May-2023, 05-Jun-2023, 25-Sep-2023, 05-Oct-2023, 25-Jan-2024, 05-Feb-2024, 25-May-2024, 05-Jun-2024, 25-Sep-2024, 25-Jan-2025, 05-Feb-2025, 25-May-2025, 05-Jun-2025, 25-Sep-2025, 25-Jan-2026, 05-Feb-2026, 25-May-2026, 05-Oct-2026							
	Synopsis	The purpose of this Special Emphas Research and Quality (AHRQ) conti							



CDINIID	Duoguam Title	Sucrear Name	Spansor N	······································	Doodling Data Fur	ding Amount			
SPIN ID	Program Title	Sponsor Name	Sponsor N	umber	Deadline Date Fur	ding Amount			
		reduce the burden of healthcare-as resistant organisms. HAIs continue consequences for healthcare facilit observed increases of several types developing and studying resilient a	to cause significant patient harm ies and for patients. Unfortunatel s of HAIs as well as increases in an	and are also ass y, the COVID-19	ociated with considerable pandemic has been asso	e financial ciated with			
107017	Large Health Services Research Derojects for Combating Antibiotic	Demonstration and Dissemination c-Resistant Bacteria (CARB)(R18)	Agency for Healthcare Research and Quality/DHHS	PA-22-048	25-Jan-2023	2,500,000 USD			
	Contact Name	James Cleeman, MD							
	Contact Telephone	301-427-1330							
	Contact Email	james.cleeman@ahrq.hhs.gov							
	Sponsor Website	Link to sponsor website							
	Program URL	Link to program URL							
	Deadline Dates (ALL)	25-Jan-2023 , 25-May-2023 , 25-Se 2025 , 25-Jan-2026 , 25-May-2026 ,		24 , 25-Sep-2024	4 , 25-Jan-2025 , 25-May-	2025 , 25-Sep-			
	Synopsis	Agency for Healthcare Research and Quality (AHRQ) invites applications to conduct Large Health Services Research Demonstration and Dissemination Projects (R18) focused on Combating Antibiotic-Resistant Bacteria (CARB). This FOA will use the R18 Research Demonstration and Dissemination Projects award mechanism.							
107009	Large Research Projects for Com (CARB) (R01)	bating Antibiotic-Resistant Bacteria	Agency for Healthcare Research and Quality/DHHS	PA-22-047	05-Feb-2023	2,500,000 USD			
	Contact Name	James Cleeman, MD							
	Contact Telephone	301-427-1330							
	Contact Email	james.cleeman@ahrq.hhs.gov							
	Sponsor Website	Link to sponsor website							
	Program URL	Link to program URL							
	Deadline Dates (ALL)	05-Feb-2023 , 05-Jun-2023 , 05-Oct-2023 , 05-Feb-2024 , 05-Jun-2024 , 05-Oct-2024 , 05-Feb-2025 , 05-Jun-2025 , 05-Oct-2025 , 05-Feb-2026 , 05-Jun-2026 , 05-Oct-2026							
	Synopsis	Agency for Healthcare Research and Quality (AHRQ) invites applications to conduct Large Health Services Research Demonstration and Dissemination Projects (R18) focused on Combating Antibiotic-Resistant Bacteria (CARB). This FOA will							



SPIN ID	Program Title	Sponsor Name	Sponsor N	lumber	Deadline Date Fo	unding Amount
		use the R01 Research Project Grant	t award mechanism.			
113493	Identify and Evaluate Potential R Sclerosis (ALS)	tisk Factors for Amyotrophic Lateral	Agency for Toxic Substances and Disease Registry/DHHS	RFA-TS-23-00:	1 05-Jan-202	Not Specified
	Contact Name	Susana Panero, MD				
	Contact Telephone	HWT0@cdc.gov				
	Contact Email	lxv8@cdc.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	05-Jan-2023				
	Synopsis	developing guidance, and building research program is to fund research data to determine whether or not puthis Notice of Funding Opportunity factors contributing to ALS, with procontact sports, traumatic brain injuice funded under one of two funding	ch that promotes healthy commupeople are at risk because of their, CDC/ATSDR is seeking investigate ferred focus on research proposity, neuroinflammation, and infectives.	nity environmen exposures to ha or-initiated resea als that will exan tious agents. Res	ts by assessing the avai irmful chemicals in the arch that will identify an nine factors related to i	lable scientific environment. In nd evaluate risk military service,
114178	FCOStrengthening Resilient Em Through Engineering Neuroplast		Defense Advanced Research Projects Agency	HR001123S00	16 23-Jan-202	Not Specified
	Contact Name					
	Contact Telephone					
	Contact Email	STRENGTHEN@darpa.mil				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	23-Jan-2023				
	Synopsis	The Defense Sciences Office (DSO) research proposals in the area of n				



SPIN ID	Program Title	Sponsor Name	Sponsor Nu	umber	Deadline Date	Funding Amount
		traumatic stress leading to suicidal innovative approaches that enable evolutionary improvements to the	revolutionary advances in science,	, devices, or syst	•	
093351	FCO AMENDMENT Biomedica Development Authority (BARDA) (BAA)		Department of Health & Human Services	BARDABAA	17-Mar-2	023 Not Specified
	Sponsor Website	BARDA-BAA@hhs.gov				
	Deadline Dates (ALL)	17-Mar-2023				
	Synopsis	Manufacturing Technologies All co language for rolling review of COVICOVID-19 response related white paper submit 31, 2020 or as specified in the invit Id Obba3967c3404799aba43a1a	those that are in support of COVID sume normal review of submissions ated in the Broad Agency Announce as that will occur. The latest BARDA COVID-19 response related Areas of EDA-cleared platforms AOI 7.7.2 Potential of COVID-19 disease (a.9 Therapeutics AOI 9.3 Immunomore prophylaxis AOI 10 Respiratory prophylaxis AOI 10 Respiratory prophylaxis AOI 10 Respiratory prophylaxis and full proposals appers and full proposals. Offeror session deadline is October 31, 2020. Seation letter. Additional beta.sam.graphylobba3967c3404799aba43a1a9b	n-19, will be put it is for other reseatement. Thank you had been a second of Interest including the second of Interest including SARS-CoV-2 infective devices a sent to BARDA will concluded also compared to the second of the s	into a queue. Once the rich areas of interest. In for understanding the Announcement (BAA) des: AOI 7.7.1 Diagno mostic assay for detection), Including Sero rapeutics targeting luces AOI 11 Ventilators A-BAA@hhs.gov. BAR ontinuously review a polete the Submission deposal submission decreases.	ne response to BARDA will not be this is amendment stic assay for thion of SARS-CoV-plogy Tests AOI 8.3 ng repair AOI AOI 17 Advanced DA clarified the end expedite Data Integration eadline is October



SPIN ID	Program Title	Sponsor Name		Sponsor Number	Deadline Date	Funding Amount	1
114023	Deployed War Fighter Protection	n (DWFP) Research Program	Department of the A	rmy W911SR-22-S	-DWFP 08-Mar	-2023 900,000 US	SD
	Contact Name	Richard Totten					
	Contact Telephone	301-619-2446					
	Contact Email	richard.w.totten2.civ@army.mil					
	Sponsor Website						
	Program URL	Link to program URL					
	Deadline Dates (ALL)	08-Mar-2023					
	Synopsis	The U. S. Army Contracting Comma applications for funding opportunit renewable for up to 3 years, admin primarily applicable to the military, oriented, consisting of advanced refor military uses, or research direct commercialization. Research should include testing and evaluation of coproducts described in the proposed Agency, as appropriate.	ies for the Fiscal Year istered by the Armed and products should search related to a paed towards the develous include the semi-field ammercial products un	2023 Deployed War Fighter Forces Pest Management Be be transferable to civilian us inticular technology or new copment of an existing protoid or field evaluation of protonless they are used in company to the proton of the prot	Protection (DWFP) oard (AFPMB). The ses. Research should capability, field evalutype product for cotype products. Resartson with prototy	Research Program, research must be d be product-luation of products search should not pe products. End us	
114165	FCOAMENDMENTFY23 FDA B	road Agency Announcement (BAA) Plopment of Regulatory Science	Food and Drug Administration/DHH	S FDABAA-23-0	0123 23-Jan-	2023 Not Specified	
	Contact Name	lan Weiss					
	Contact Telephone	301-796-5728					
	Contact Email	lan.Weiss@fda.hhs.gov					
	Sponsor Website						
	Program URL	Link to program URL					
	Deadline Dates (ALL)	23-Jan-2023					
	Synopsis	In accordance with FAR 6.102(d)(2) basic and applied research and dev Agency Announcement (BAA). Research	elopment proposals to	o support regulatory science	e and innovation the	rough this Broad	



SPIN ID	Program Title	Sponsor Name	Sı	ponsor Number	Deadline Date Fun	ding Amount
		scientific knowledge in specific reso accomplishing its mission to protect are not limited solely to the PSC co agency-wide Broad Agency Annour innovation. Join us to learn more a	ct and promote the health de "AJ11" specified in thi ncement (BAA) for resear	n of our nation. Proposals s announcement. FDA fo ch and development to su	submitted under this an unds extramural research	nouncement n through an
114156	National Center for Newborn Scr Excel)	eening System Excellence (NBS	Maternal and Child Hea Bureau/HRSA/DHHS	lth HRSA-23-077	13-Feb-2023	11,500,000 USD
	Contact Name	Kim Morrison				
	Contact Telephone	301-443-6672				
	Contact Email	KMorrison@hrsa.gov				
	Sponsor Website	Link to sponsor website				
	Program URL					
	Deadline Dates (ALL)	13-Feb-2023				
	Synopsis	The Health Resources and Services Program, which consists of two pro HRSA-23-065: State Newborn Scree Screening System Excellence (NBS provide screening, counseling, and help them achieve the best possible	ojects to be funded in fisc ening Priorities Program (Excel). The overall purpos health care services to no	al year (FY) 2023 through NBS Propel) and HRSA-23 se of the NBS Program is t	this Notice of Funding O -077: National Center fo o strengthen the NBS sys	pportunity: Newborn Item to
114621	FCOAMENDMENTOutreach (In Summer Camps for Science, Tech (STEM) - related career fields at N		National Aeronautics & Administration	Space GSFC-23-WFF-	AFP1 04-Feb-2023	Not Specified
	Contact Name	Victor Mask				
	Contact Telephone	757-990-2017				
	Contact Email	victor.mask@nasa.gov				
	Sponsor Website	Link to sponsor website				
	Program URL					



SPIN ID Program Title Sponsor Name Sponsor Number Deadline Date Funding Amount

Deadline Dates (ALL) 04-Feb-2023

Description: NASA Goddard Space Flight Center's (GSFC) Wallops Flight Facility (WFF) is seeking to partner with one organization on a nonreimbursable (no exchange of funds) basis over the next five years to afford opportunities for youth to enhance their interest in science, technology, engineering, math, and related careers. NASA WFF has facilities and STEM opportunities that third parties could utilize to formulate informal education STEM outreach programs and camps for youth. To facilitate an orderly use of these opportunities, NASA is seeking to partner with one organization that will develop, manage and offer these informal education outreach opportunities to the public. Only proposals from U.S. entities will be considered. NASA seeks proposals from organizations with a commitment to and experience in high-quality student engagement. This AFP outlines the process for submitting a proposal to become a partner ("Partner") with NASA for this coordinated effort and the expected partner responsibilities. NASA is interested in receiving responses from organizations with creative proposals for this opportunity to formulate informal education STEM-related outreach programs and camps at NASA WFF for youth. Those entities that can expand participation among youth STEM program community members with disabilities and/or from underrepresented or historically minoritized groups are encouraged to apply. This AFP is anticipated to result in the establishment of a nonreimbursable Space Act Agreement for the selected Partner that will define the full roles and responsibilities of NASA and the proposing organization(s) in a form similar to the model agreement shown in Exhibit A attached hereto (the "Model Agreement") (for more information on Space Act Agreements, please see https://www.nasa.gov/partnerships.html). Background Over the past two decades, NASA WFF has been involved with supporting youth camp participants showcasing STEM-related careers by providing facility tours of WFF missions areas — Sounding Rockets, Scientific Balloons, Airborne Science, Range Control Center and Wallops Island Launch Pad tours – along with subject matter experts to engage with campers. NASA values this opportunity which advances inspiring the next generation of explorers and innovators, exposure to WFF, and recruitment efforts. NASA has found that partnering with other organizations with similar interests and complementary goals in supporting STEM exposure has been a successful way to respond and adapt to the needs of this diverse and growing community. Scope This request will be open for at least 45 days following the date of release of this announcement. All proposals must be received by 11:59 pm Eastern time, on January 31, 2023, to be considered. The successful Proposer will agree to coordinate any involvement for outreach (informal education) programs and summer camps with NASA consistent with the resulting Space Act Agreement. Partner responsibilities include at a minimum: Between the first week of June and the last week of August each year during the term of the Agreement, provide weeklong camp sessions primarily intended for students in middle and junior high school (ages 11 to 16 years) allowing for other age groups as program interest diversifies. Coordinate all activities on NASA WFF property with the Wallops Office of Communications (the Office of Communications will, in turn, coordinate activities with relevant organizations on Wallops and ensure outreach activities do not impact mission activities). Provide scheduling

requests 30 days in advance of all WFF tours and lecture sessions, which are subject to approval by the Office of

Communications prior to conduct of any activities. Meet annually with NASA WFF Office of Communication in advance of

Synopsis

SPIN ID	Program Title	Sponsor Name	Spor	nsor Number	Deadline Date	Funding Amount
		scheduling programs. While not an scheduled missions, underscoring NASA support. Provide one adult stechnical and scientific expertise in space mission simulations, robotic Transport participants to and from safety at all times. Arrange accom representative sufficiently in adva Provide adequate staff to support applicable to any person while at a participants and staff while at WF	the need to have a plan for e taff for each 10 youth partici n topics such as astronomy, we activities, problem solving e www. WFF and provide for oversign modation for any student that here to enable WFF's assessmall academy activities with lin WFF and all instructions prov	executing outreach property of the property of	ograms from time to to le on GSFC WFF premotics, computer, mod s, and weather ballood le at WFF to ensure to commodations and not list with such special as F personnel. Ensure the	ime with minimal ises. Offer el rocket launches, n launches. heir health and tify the GSFC WFF accommodations. hat all rules
113222	Notice of Special Interest (NOSI): of Understudied, Underrepresen Populations (Admin Supp Clinical	-	Office of Research on Won Health/NIH/DHHS	nen's NOT-OD-22-20	08 31-Jan-20	2,000,000 USD
	Contact Name	Damiya (Miya) Whitaker, Psy.D., N	1.A.			
	Contact Telephone	301-451-8206				
	Contact Email	damiya.whitaker@nih.gov				
	Sponsor Website					
	_	Link to program URL				
	Deadline Dates (ALL)					
	Synopsis	The Office of Research on Women research highlighting health inequ underreported (U3) in biomedical health are needed to reduce inequor 3 of the "2019-2023 Trans-NIH Women."	ities among women in the Ui research. Robust studies exp iities. The proposed research	nited States who are u Noring sex and gender In must address at least	inderstudied, underre influences and social one objective from s	presented and determinants of trategic goals 1, 2,
114774	Delta States Rural Development	Network Program	Office of Rural Health Policy/HRSA/DHHS	HRSA-23-031	22-Mar-2	023 169,812 USD
	Contact Name	Diana Alatorre				



SPIN ID	Program Title	Sponsor Name	s	ponsor Number	Deadline	Date Fund	ling Amount
0	1.108.4	oponior rumo					
	Contact Telephone	301-287-2618					
	Contact Email	DeltaStatesGrantPrgm@hrsa.gov					
	Sponsor Website	Link to sponsor website					
	Program URL						
	Deadline Dates (ALL)	22-Mar-2023					
	Synopsis	The Health Resources and Services Rural Development Network progrimplementation of integrated heal and improve the quality of basic hosystem as a whole.	ram. The purpose of this plant that col	program is to support laborate to achieve e	the planning, officiencies; exp	development, a pand access to, o	nd coordinate,
114484	Climate Resilience Centers		Office of Science/Depar Energy	tment of DE-FOA-0	002915	19-Jan-2023 [LOI/Pre-App]	5,000,000 USD
	Contact Name	Dr. Jeff Stehr					
	Contact Telephone	630-252-4329					
	Contact Email	Jeff.Stehr@science.doe.gov					
	Sponsor Website	<u>Link to sponsor website</u>					
	Program URL	Link to program URL					
	Deadline Dates (ALL)	19-Jan-2023 [LOI/Pre-App], 30-Ma	r-2023				
	Synopsis	The DOE SC program in Biological a scientific community for Climate R models, and capabilities to addres mission is to support transformative biological, Earth, and environment	esilience Centers (CRCs) t s climate resiliency, partion ve science and scientific u	hat will improve the cularly by underrepre ser facilities to achie	availability and sented or vulno ve a predictive	utility of BER re erable commun understanding	esearch, data, ities. BER's of complex
102196	Diversifying Partnerships in WAS	H Program (DiP-WASH)	U.S. Agency for Interna Development	tional 7200AA2:	1APS00004	11-Feb-2023	Not Specified
	Contact Name	Jason Hoppe					
	Contact Telephone	2029162748					
	Contact Email	jhoppe@usaid.gov					



Other Federal Funding Opportunities										
SPIN ID	Program Title	Sponsor Name	Sponso	or Number	Deadline Date	Funding Amount				
	Sponsor Website									
	Program URL	Link to program URL								
	Deadline Dates (ALL)	11-Feb-2023								
	The United States Agency for International Development is announcing the Diversifying Partnerships in WASH Program (Di WASH). Through this Annual Program Statement (APS), USAID announces its desire to engage a diverse range of partners, including new, underutilized and/or locally-established partners, on innovative and evidence-based approaches that addressed to the safe drinking water, sanitation and hygiene (WASH) and water resources management (WRM) sectors that are not adequately addressed by other USAID investments, and that result in increasing the equitable availability and sustainable management of safe water and sanitation for the underserved and most vulnerable.									
109492	FCOAMENDMENT2022 ERDC	Broad Agency Announcement (BAA) Engine Defens	•	W912HZ-22-B	AA-01 28-Feb-2	Not Specified				
	Contact Name	Gayle Rouse								
	Contact Telephone	601-634-3462								
	Contact Email	Gayle.E.Rouse@usace.army.mil								
	Sponsor Website	ž								
	Program URL	Link to program URL								
	Deadline Dates (ALL)	28-Feb-2023								
	Synopsis	The U.S. Army Engineer Research and Deve various research and development topic ar and Structures Lab (GSL), the Reachback Op Technology Lab (ITL) in Vicksburg, Mississip Hampshire, the Construction Engineering R Laboratory (GRL) in Alexandria, Virginia. Th dredging, coastal engineering, instrumenta	eas. The ERDC consists perations Center (URO ppi, the Cold Regions Research Lab (CERL) in e ERDC is responsible	s of the Coastal and C), the Environment esearch and Engine Champaign, Illinois, for conducting resea	Hydraulics Lab (CHL cal Lab (EL) and the I ering Lab (CRREL) in and the Geospatial arch in the broad fie), the Geotechnical Information Hanover, New Research Ids of hydraulics,				



engineering, soil effects, vehicle mobility, self-contained munitions, military engineering, geophysics, pavements, protective structures, aquatic plants, water quality, dredged material, treatment of hazardous waste, wetlands, physical/mechanical/chemical properties of snow and other frozen precipitation, infrastructure and environmental issues for installations, computer science, telecommunications management, energy, facilities maintenance, materials and structures, engineering processes, environmental processes, land and heritage conservation, and ecological processes. The BAA is available as an

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	----------------------	----------------

attachment to this posting and is also available at http://erdc.usace.army.mil. The BAA is open until superseded by another announcement. Proposals may be accepted at any time. ERDC prefers to receive pre-proposals and proposals electronically. Pre-proposals and proposals for EL, GRL, GSL, ITL and UROC regarding this BAA should be submitted via email to ERDC-BAA@usace.army.mil. For inquiries, please contact the ERDC at ERDC-BAA@usace.army.mil. You may also contact either or both of the following: Ms. Andrea Knowles at 703-428-6519 or Andrea.D.Knowles@usace.army.mil or Ms. Gayle Rouse at Gayle.E.Rouse@usace.army.mil. Pre-proposals and proposals for CERL shall be submitted via email to CERL-CT-Quotes@usace.army.mil. For inquiries, please contact Ms. Andrea Thomas via email at CERL-CT-Quotes@usace.army.mil or phone at 217-373-6746. Pre-proposals and full proposals for CHL shall be submitted via email to CHL-BAA@usace.army.mil. For inquiries, please contact Ms. Christine Wilson via email at CHL-BAA@usace.army.mil or phone at 217-552-5258. Preproposals and proposals for CRREL shall be submitted via email to CRREL-BAA@usace.army.mil. For inquiries, please contact Ms. Melodie Fisher via email at CRREL-BAA@usace.army.mil or phone at 601-634-4687. Contact the technical personnel listed at the end of each topic area for questions concerning the topic areas themselves. The following information must be included in the body of the e-mail when submitting the proposal electronically: Laboratory Name and Topic number (Spell out the complete name of the laboratory. Do not use the acronym.) Vendor name and Address Proposal Title Total Dollar Amount Please note: Proposals should not be submitted to the technical personnel listed at the end of each topic area. Proposals shall be submitted as stated at Section 2, Paragraph C of the announcement.

The Development Office offers assistance with many non profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team for assistance or questions. DevCorpFound@mountsinai.org below.

SPIN ID Program Title		Sponsor Name	Sponsor Number	Deadline Date	Fundir	ng Amount				
114142 Post-Doctoral Career Developm	nent Fellowship	Action for A-T		09-Jan-2023 [LOI, App]		300,000 USD				
Contact Name										
Contact Telephone	01428 853313									
Contact Email	tania.wheeler@	PactionforAT.org								
Sponsor Website	Link to sponsor	website								
Program URL	Link to program	o program URL								
Deadline Dates (ALL)	09-Jan-2023 [L0	an-2023 [LOI/Pre-App], 06-Mar-2023								
Synopsis	The Action for A-T and MRC Nucleic Acid Therapy Accelerator (NATA) Career Development Fellowship is a 2-year programme with associated funding of up to info@actionforat.orgwhich will support post-doctoral scientists to become independent group leaders and drive high quality research in Ataxia Telangiectasia (A-T). Funds will cover Fellow's salary, support staff costs and project running costs.									
Applicant Types										
Funding Limit	250,000.00 max	ximum								
Limited Submission	No									
093527 Innovation Grant		Alex's Lemonade St	and	15-Mar-2023		125,000 USD				
Contact Name										
Contact Telephone	610-649-3034									
Contact Email	Grants@AlexsL	emonade.org								
	•									



Non Federal Funding Opportunities: March 2023

SPIN ID	Program Title		Sponsor Name		Sponsor Number	Deadline Date	Funding Amount				
	Sponsor Website	Link to sponsor	<u>website</u>								
	Program URL	Link to program	<u>URL</u>								
	Deadline Dates (ALL)	15-Mar-2023									
	Synopsis		_	•	d significant seed funding ures for childhood cancers	·	•				
	Applicant Types										
	Funding Limit	125,000.00 max	25,000.00 maximum								
	Limited Submission	No									
071372	Treat FTD Fund – Funding for Ir	nnovative Clinica	l Trials for	Alzheimer's Drug D	iscovery	27-Jan-2023 [LOI/	/Pre- 2,000,000				
0/13/2	Frontotemporal Degeneration			Foundation		App]	USD				
	Contact Name	Meriel Owen, P	hD, Assistant Direc	tor, ADDF							
	Contact Telephone	212-901-8000									
	Contact Email	lfriedman@alzd	liscovery.org								
	Sponsor Website	Link to sponsor	<u>website</u>								
	Program URL	Link to program	URL								
	Deadline Dates (ALL)	27-Jan-2023 [LC	OI/Pre-App], 17-Ma	ar-2023							
Leveraging scientific advances in FTD research to develop effective medications has proven challenging. Synopsis FTD Fund, a major new funding opportunity initiated by AFTD in partnership with ADDF, seeks to accele development by focusing exclusively on clinical trials of FTD therapeutics. Over the next 10 years, The T											



The Development Office offers assistance with many non profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team for assistance or questions. DevCorpFound@mountsinai.org below.

SPIN ID Program Title	Sponsor Nam	e Sponsor Num	ber Deadline Date	Funding Amount
	will award \$10 million to suppomechanisms.	ort clinical trials of novel or repurposed	d drugs to treat FTD symptom	s or target disease
Applicant Types				
Funding Limit	2,000,000.00 maximum			
Limited Submission	No			
003686 Strategic Research Grant	'	American Academy of Sleep Medicine Foundation	13-Mar-2023	250,000 USD
Contact Name				
Contact Telephone	630-737-9724			
Contact Email	foundation@aasm.org			
Sponsor Website	Link to sponsor website			
Program URL	Link to program URL			
Deadline Dates (ALL)	13-Mar-2023			
Synopsis	disorders. To ensure that there disorders, the AASM Foundation investigator-initiated and support the ability to provide optimal, disorders. This is a focused recademy of Sleep Medicine (A Technology Innovation and Westers	mitted to improving patient-centered de is a continued advancement in effect on provides research funding through to ports high-impact research projects aim patient-centered, cost-effective diagnoquest for applications (RFA) open to topo (ASM) Strategic Plan Goals: Advocacy to orkforce Development. Topic areas that dicine and population sleep health.	ive diagnosis and care of pati the Strategic Research Grant. ned at addressing gaps in kno osis and care for patients with pic areas related to the follow o Improve Patient Care, Publi	ents with sleep This grant is wledge that impact a sleep ring American c Awareness,



Non Federal Funding Opportunities: March 2023

SPIN ID	Program Title	Sp	onsor Name	Sponsor Numb	er Deadline Date	Funding Amount
	Applicant Types					
	Funding Limit	250,000.00 see det	ail			
	Limited Submission	No				
064841 <u>A</u>	Anatomy Training Program		American Anatomy	Association for	01-Mar-2023	Not Specified
	Contact Name					
	Contact Telephone	301-634-7910				
	Contact Email	info@anatomy.org				
	Sponsor Website	Link to sponsor we	<u>bsite</u>			
	Program URL	Link to program UF	<u>RL</u>			
	Deadline Dates (ALL)	01-Mar-2023				
	Synopsis	The Anatomy Train who have not had	ing Program is intended to much exposure to either h	o provide vocational train numan anatomy or clinica	ing to those involved in teac I experience.	hing anatomy but
	Applicant Types					
	Funding Limit	0.00 see detail				
	Limited Submission	No				
030860	Discovery Grants		American Associatio	Brain Tumor on	29-Mar-2023	50,000 USD
	Contact Name					
	Contact Telephone	773-577-8742				



SPIN ID	Program Title		Sponsor Name	Sponso	or Number	Deadline Date	Funding Amount
	Contact Email	grants@abta.o	rg				
	Sponsor Website	Link to sponsor	website				
	Program URL	Link to program	<u>ı URL</u>				
	Deadline Dates (ALL)	29-Mar-2023					
	Synopsis	with the potent	Brain Tumor Association so tial to change current diag or Grants provide up to \$50	nostic or treatment p	paradigms for adu	lt and pediatric bra	
	Applicant Types						
	Funding Limit	50,000.00 maxi	mum				
	Limited Submission	No					
001811	Basic Research Fellowships		Ameri Assoc	can Brain Tumor iation		29-Mar-2023	100,000 USD
	Contact Name						
	Contact Telephone	773-577-8750					
	Contact Email	grants@abta.o	rg				
	Sponsor Website	Link to sponsor	website				
	Program URL	Link to program	ı URL				
	Deadline Dates (ALL)	29-Mar-2023					
	Synopsis	Basic Research conducting labor	Fellowships are two-year, oratory or field-based rese	\$100,000 mentored earch projects that fo	grants supporting cus on brain tumo	postdoctoral fellowers. Fellows must ha	vs who are ave a lead mentor



SPIN ID	Program Title	Sponsor Name		Sponsor Number	Deadline Date	Funding Amount
	Applicant Types Funding Limit	who currently conducts brain tun management and other research 50,000.00 per year				elp with scientific
	Limited Submission	No				
057160 <u>F</u>	Research Collaboration Grants		American Brain Tur Association	mor	29-Mar-2023	200,000 USD
	Contact Name	ABTA Research Programs Departi	ment			_
	Contact Telephone	773-577-8742				
	Contact Email	grants@abta.org				
	Sponsor Website	Link to sponsor website				
	Program URL	Link to program URL				
	Deadline Dates (ALL)	29-Mar-2023				
The ABTA Research Collaboration Grants are intended to promote team science in a way that will st accelerate progress and effect the desired change in clinical outcome for brain tumors. The research supported under this mechanism must be conducted by a team of two co-principal investigators (Co institutions.						
	Applicant Types					
	Funding Limit	200,000.00 maximum				
	Limited Submission	No				



SPIN ID	Program Title	Sponsor Name		Sponsor Number	Deadline Date	Funding Amount			
021735 /	AGRO New Investigator Award		American Chemica	l Society	29-Mar-2023	1,275 USD			
	Contact Name	Aaron Gross							
	Contact Telephone								
	Contact Email	adgross@vt.edu							
	Sponsor Website	Link to sponsor website							
	Program URL	Link to program URL							
	Deadline Dates (ALL) 29-Mar-2023								
The AGRO Division seeks nominations for the New Investigator Award (NIA) to be awarded at the ACS meeti Synopsis Chicago, Illinois, in August 2022. The purpose of the New Investigator Award is to recognize scientists who hobtained a doctoral degree and are actively conducting academic, industrial, consulting, or regulatory studies.									
	Applicant Types								
	Funding Limit	1,275.00 see detail							
	Limited Submission	No							
043444 <u>F</u>	Research Grants		American College of Laboratory Animal Foundation		09-Mar-2023	Not Specified			
	Contact Name	Jennifer Pullium, MVB, DACLAN	л						
	Contact Telephone	212-263-6532							
	Contact Email	jennifer.pullium@nyumc.org							
	Sponsor Website	Link to sponsor website							
		•							



SPIN ID	Program Title		Sponsor Name		Sponsor Number	Deadline Date	Funding Amount		
	Program URL	Link to program	<u>ı URL</u>						
	Deadline Dates (ALL)	09-Mar-2023							
	Synopsis		The Mission of the ACLAM Foundation is to expand the body of knowledge in the fields of laboratory Animal Science and Medicine through funding research grants.						
	Applicant Types								
	Funding Limit	0.00 not provid	ed						
	Limited Submission	No							
057836	Medical Toxicology Foundation Practice Grants	Innovative Rese	earch, Teaching, &	American College of Toxicology	of Medical	01-Mar-2023	20,000 USD		
	Contact Name	Alison Meyn							
	Contact Telephone	844-226-8333							
	Contact Email	alison.meyn@a	cmt.net)						
	Sponsor Website	Link to sponsor	<u>website</u>						
	Program URL	Link to program	<u>uRL</u>						
	Deadline Dates (ALL)	01-Mar-2023							
	Synopsis				projects that support the F ent of patients adversely in				
	Applicant Types								
	Funding Limit	20,000.00 maxi	mum						



The Development Office offers assistance with many non profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team for assistance or questions. DevCorpFound@mountsinai.org below.

SPIN ID	Program Title	Sponsor Name		Sponsor Number	Deadline Date	Funding Amount
	Limited Submission	No				
062103 <u>C</u>	Collaborative Sciences Award		American Heart Ass	sociation	09-Mar-2023	750,000 USD
	Contact Name					
	Contact Telephone					
	Contact Email	apply@heart.org				
	Sponsor Website	Link to sponsor website				
	Program URL	Link to program URL				
	Deadline Dates (ALL)	09-Mar-2023				
	Synopsis	This award fosters innovative, ne investigators from at least two be the scientific objectives could no respective disciplines. The combinand/or translational research. The	road disciplines. The put to be achieved without nation and integration	proposal must focus on the the efforts of at least two n of studies may be inclus	e collaborative rela co-principal inves	ationship, such that stigators and their
	Applicant Types					
	Funding Limit	750,000.00 maximum				
	Limited Submission	No				
096452 <u>B</u>	SCVS Cardiovascular Outreach	<u>Awards</u>	American Heart Ass	sociation	15-Mar-2023	500 USD
	Contact Name	Donna Tu				
	Contact Telephone	1-800-242-8721				



Non Federal Funding Opportunities: March 2023

SPIN ID	Program Title	Sponsor Nan	ne	Sponsor Number	Deadline Date	Funding Amount				
	Contact Email	donna.tu@heart.org								
	Sponsor Website	Link to sponsor website								
	Program URL	Link to program URL								
	Deadline Dates (ALL)	15-Mar-2023								
The BCVS Cardiovascular Outreach Awards are aimed at encouraging US minority early career investigators and students to participate in the Basic Cardiovascular Sciences Scientific Sessions. Although preference will be given investigators and trainees with a successful research abstract, no research abstract is required for consideration to ten competitive awards of \$500 each will be presented to qualified applicants, based on the curriculum vitae strength of endorsement letters.										
	Applicant Types									
	Funding Limit	500.00 maximum								
	Limited Submission	No								
U90453	Basic Cardiovascular Sciences O Investigator Award	utstanding Early Career	American Heart As	sociation	15-Mar-2023	1,500 USD				
	Contact Name	Donna Tu								
	Contact Telephone									
	Contact Email	Donna.Tu@heart.org								
	Sponsor Website	Link to sponsor website								
	Program URL	Link to program URL								
	Deadline Dates (ALL)	15-Mar-2023								



SPIN ID	Program Title	Sponsor N	lame	Sponsor Number	Deadline Date	Funding Amount
	Synopsis	selected for oral presentat	tion at the Basic Cardiova inality, quality, and impa	ly Career Investigator Award ascular Sciences 2023 Scientifact of the work presented in t	fic Sessions. The aw	ardees will be
	Applicant Types					
	Funding Limit	1,500.00 maximum				
	Limited Submission	No				
108595 <u>E</u>	BCVS New Investigator Travel G	<u>Grant</u>	American Heart	Association	15-Mar-2023	500 USD
	Contact Name	Donna Tu				
	Contact Telephone					
	Contact Email	Donna.Tu@heart.org				
	Sponsor Website	<u>Link to sponsor website</u>				
	Program URL	Link to program URL				
	Deadline Dates (ALL)	15-Mar-2023				
	Synopsis	Cardiovascular Sciences Co	onference 2022 Scientific	ncourage new investigators to c Sessions. Up to twenty com se who are accepted to prese	petitive awards of \$	
	Applicant Types					
	Funding Limit	500.00 maximum				
	Limited Submission	No				
		•				



SPIN ID	Program Title	Sponsor	Name	Sponsor Number	Deadline Date	Funding Amount
043879 [043879 Mathre Education Endowment Award		American Phytopa Society	American Phytopathological Society		1,000 USD
	Contact Name					
	Contact Telephone	651-454-7250				
	Contact Email					
	Sponsor Website	<u>Link to sponsor website</u>				
	Program URL	Link to program URL				
	Deadline Dates (ALL)	15-Mar-2023				
	Synopsis	content on the APS Educa	for Education will fund gene ation Center, assistance in re llogy teacher or university p and teachers.	e-formatting educationa	al material for electroi	nic use, supporting a
	Applicant Types					
	Funding Limit	1,000.00 maximum				
	Limited Submission	No				
059739 [Basic Science Grants		American Society of the Hand	for Surgery	06-Jan-2023 [Optional][LOI/F	20,000 Pre-App] USD
	Contact Name					
	Contact Telephone	312-880-1900				
	Contact Email	afsh@assh.org				
	'					



SPIN ID	Program Title	Sponsor	r Name	Sponsor Number	Deadline Date	Funding Amount			
	Sponsor Website	Link to sponsor website							
	Program URL Link to program URL								
	Deadline Dates (ALL) 06-Jan-2023 [Optional][LOI/Pre-App], 06-Feb-2023 [LOI/Pre-App], 31-Mar-2023								
	The American Society for Surgery of the Hand (ASSH) and the American Foundation for Surgery of the Hand (AFSH) have established grant funding to encourage investigators to perform basic science research studies. The goal is to enable investigators to initiate pilot projects that will lead to subsequent funding from other sources such as the National Institutes of Health (NIH). The AFSH is committed to excellence in basic science research while maintaining the highest academic integrity and fiscal responsibility.								
	Applicant Types								
	Funding Limit	20,000.00 maximum							
	Limited Submission	No							
059738 <u>C</u>	Clinical Grants		American Society for the Hand	or Surgery	06-Jan-2023 [Optional][LOI/P	40,000 re-App] USD			
	Contact Name								
	Contact Telephone	312-880-1900							
	Contact Email	afsh@assh.org							
	Sponsor Website	Link to sponsor website							
	Program URL	Link to program URL							
	Deadline Dates (ALL)	06-Jan-2023 [Optional][L	LOI/Pre-App], 06-Feb-2023 [L0	OI/Pre-App], 31-Mar-2023					
	Synopsis	The American Society fo have established grant for	r Surgery of the Hand (ASSH) a unding to encourage investiga	and the American Foundat stors to perform clinical res	tion for Surgery of search studies. The	the Hand (AFSH) goal is to enable			



SPIN ID	Program Title	Sponsor Na	me S	ponsor Number	Deadline Date	Funding Amount
		investigators to initiate pilot Institutes of Health (NIH). Ti academic integrity and fiscal	he AFSH is committed to exc			
	Applicant Types					
	Funding Limit	40,000.00 maximum				
	Limited Submission	No				
032663 <u>(</u>	Clinical Research Training Instit	ute (CRTI) Program	American Society of Hematology		06-Jan-2023	Not Specified
	Contact Name					
	Contact Telephone	202-776-0544				
	Contact Email	training@hematology.org				
	Sponsor Website	Link to sponsor website				
	Program URL	Link to program URL				
	Deadline Dates (ALL)	06-Jan-2023 , 31-Mar-2023				
	Synopsis	The ASH Clinical Research Tr hematology fellows and juni	raining Institute (CRTI) is a ur ior faculty at academic medi	nique, year-long educ cal centers.	cation and mentoring	program for
	Applicant Types					
	Funding Limit	0.00 see detail				
	Limited Submission	NI-				



The Development Office offers assistance with many non profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team for assistance or questions. DevCorpFound@mountsinai.org below.

SPIN ID	Program Title	Sponsor Name	Sponsor Nu	mber Deadline Date	Funding Amount
002579	ACSUS-Enders Graduate Fellow	ship in Canada-US Relations	Association for Canadian Studies in the U.S.	31-Mar-2023	5,000 USD
	Contact Name				
	Contact Telephone				
	Contact Email	info@acsus.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	31-Mar-2023			
	Synopsis	ACSUS-Enders Graduate Fellowsh content in comparative research/social, economic, political, securit 6 weeks at a Canadian university, thesis, dissertation or graduate w	projects that have policy relevancy, and quality of life issues. The fe research site or business other th	ce for Canada-U.S. relations as vellowship enables successful catantheir own conducting resea	well as Canadian ndidates to spend 4-
	Applicant Types				
	Funding Limit	5,000.00 see detail			
	Limited Submission	No			
057952	Seed Grant Program		Brain Research Foundation	28-Mar-2023	80,000 USD
	Contact Name				
	Contact Telephone	312-759-5150			
	Contact Email	info@thebrf.org			



Non Federal Funding Opportunities: March 2023

The Development Office offers assistance with many non profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team for assistance or questions. <u>DevCorpFound@mountsinai.org</u> below.

SPIN ID	Program Title		Sponsor Name		Sponsor Number	Deadline Date	Funding Amount
	Sponsor Website	Link to sponsor v	<u>vebsite</u>				
	Program URL	Link to program	<u>URL</u>				
	Deadline Dates (ALL)	28-Mar-2023					
	Synopsis		oscience that will		rogram provides start-up nural funding from the Na		
	Applicant Types						
	Funding Limit	80,000.00 see de	etail				
	Limited Submission	Yes					
001439 <u>C</u>	linic and Laboratory Integratio	on Program (CLIP)		Cancer Research In Inc.	stitute,	01-Mar-2023	200,000 USD
	Contact Name						
	Contact Telephone	800-992-2623					
	Contact Email	grants@cancerre	esearch.org				
	Sponsor Website	Link to sponsor v	<u>vebsite</u>				
	Program URL	Link to program	<u>URL</u>				
	Deadline Dates (ALL)	01-Mar-2023					
	Synopsis	studying critical		section of laborator	aboratory Integration Pro y and clinical research in i		•
	Applicant Types						



Non Federal Funding Opportunities: March 2023

SPIN ID	Program Title	Sponsor Name		Sponsor Number	Deadline Date	Funding Amount
	Funding Limit	200,000.00 maximum				
	Limited Submission	No				
000087 (CRI Irvington Postdoctoral Fello	owships .	Cancer Research In Inc.	stitute,	01-Mar-2023	Not Specified
	Contact Name					
	Contact Telephone	212-688-7515				
	Contact Email	grants@cancerresearch.org				
	Sponsor Website	Link to sponsor website				
	Program URL	Link to program URL				
	Deadline Dates (ALL)	01-Mar-2023 , 01-Sep-2023				
	Synopsis	The CRI Irvington Postdoctoral Fresearch centers around the wor	ellowship Program su rld who wish to receiv	pports qualified young scie e training in fundamental	entists at leading u immunology or ca	niversities and ncer immunology.
	Applicant Types					
	Funding Limit	0.00 see detail				
	Limited Submission	Yes				
058489 <u>1</u>	Technology Impact Award		Cancer Research In Inc.	stitute,	15-Mar-2023	200,000 USD
	Contact Name					
	Contact Telephone	212-688-7515				
	Contact Email	grants@cancerresearch.org				



SPIN ID	Program Title		Sponsor Name		Sponsor Number	Deadline Date	Fundir	ng Amount
	Sponsor Website	Link to sponsor	website					
	Program URL	Link to program	<u> URL</u>					
	Deadline Dates (ALL)	15-Mar-2023						
	Synopsis		address the gap betw	• •	ord provides seed funding development and clinical	· · · · · · · · · · · · · · · · · · ·		ed over 12
	Applicant Types							
	Funding Limit	200,000.00 max	kimum					
	Limited Submission	No						
086052	Young Investigator Award		Chi	dren's Tumor Fo	oundation	02-Jan-2023 [LOI, App]	/Pre-	Not Specified
	Contact Name	Vidya Browder						
	Contact Telephone	646-738-8586						
	Contact Email	vbrowder@ctf.	org					
	Sponsor Website	Link to sponsor	<u>website</u>					
	Program URL	Link to program	<u>URL</u>					
	Deadline Dates (ALL)	02-Jan-2023 [L0	OI/Pre-App], 03-Mar-20	23				
	Synopsis	helping them to established indo	get established as ind ependent investigators	ependent invest in NF-related fi	for two years to early-care igators. The goal is to ena elds. The YIA program pro larger grants, such as fror	ble these trainees t vides seed funding t	o becor to attra	ne ct



SPIN ID	Program Title		Sponsor Name		Sponsor Number	Deadline Date	Funding Amount
	Applicant Types						
	Funding Limit	0.00 see detail					
	Limited Submission	No					
054015 <u>C</u>	CURE Epilepsy Award			Citizens United for in Epilepsy (CURE E		10-Jan-2023 [LOI/F App]	Pre- 250,000 USD
	Contact Name						
	Contact Telephone	312-255-1801					
	Contact Email	Research@CUR	Eepilepsy.org				
	Sponsor Website	Link to sponsor	<u>website</u>				
	Program URL	Link to program	URL				
	Deadline Dates (ALL)	10-Jan-2023 [LC	I/Pre-App], 28-Ma	r-2023			
	Synopsis	The CURE Epiler modifying break	sy Award will prov throughs for peop	vide grants of up to solle living with epileps	\$250,000 paid over 2 years	for research leading	to disease-
	Applicant Types						
	Funding Limit	250,000.00 max	imum				
	Limited Submission	No					
024600 <u>1</u>	Faking Flight Awards			Citizens United for in Epilepsy (CURE E		10-Jan-2023 [LOI/F App]	Pre- 100,000 USD
	Contact Name						
	Contact Telephone	312-255-1801					



SPIN ID	Program Title	Sponsor Name		Sponsor Number	Deadline Date	Funding Amount					
	Contact Email	Research@CUREepilepsy.org									
	Sponsor Website	<u>Link to sponsor website</u>									
	Program URL	nk to program URL									
	Deadline Dates (ALL)	0-Jan-2023 [LOI/Pre-App], 28-Mar-2023									
	Synopsis	The Taking Flight Award (1 year / them to develop a research focus	\$100,000) seeks to p independent of thei	promote the careers of your remoter in the careers of your mentor(s).	ung epilepsy invest	tigators to allow					
	Applicant Types										
	Funding Limit	100,000.00 maximum									
	Limited Submission	No									
098533	Frist Family Endowed Young Inv	vestigator Award (YIA) in Mantle	Conquer Cancer Fo	undation	13-Mar-2023	50,000					
	Cell Lymphoma (MCL)		of ASCO		13-IVId1-2023	USD					
	Contact Name										
	Contact Telephone	571-483-1700									
	Contact Email	grants@conquer.org									
	Sponsor Website	Link to sponsor website									
	Program URL	Link to program URL									
	Deadline Dates (ALL)	13-Mar-2023									
	Synopsis	The Conquer Cancer – Frist Famil- funding to promising investigator mantle cell lymphoma. The purpo	rs to encourage and p	promote quality research	in clinical oncology	with a focus on					



SPIN ID	Program Title	Sponsor Nan	ne	Sponsor Number	Deadline Date	Funding Amount
	Applicant Types	program to a faculty appoints are committed to conducting	•	* *	•	estigators who
	Funding Limit Limited Submission	50,000.00 maximum No				
059521	Grants Program		Conservation, Food Health Foundation	l and	02-Jan-2023 [LOI/ App]	/Pre- 20,000 USD
	Sponsor Website Program URL Deadline Dates (ALL)		Health Foundation seeks mote public health in Asia ganizations and coalition to complex problems. The essional development in	to protect natural resource a, Africa, Latin America, and s with grants that support e foundation supports pro the conservation, agricultu	es, improve the prod d the Middle East. T research or improve jects that demonstra Iral, and health sciel	The foundation the learning and ate local nces; develop the
	Applicant Types	projects that address under-f	unaea issues ana geogra	pnic areas.		



SPIN ID	Program Title	Sponsor Name		Sponsor Number	Deadline Date	Funding Amount
	Funding Limit Limited Submission	20,000.00 on average Yes				
007739	Grants Program		Cummings (James I Foundation	Н.)	10-Jan-2023	5,000 USD
	Contact Name					
	Contact Telephone	716-874-0040				
	Contact Email	info@jameshcummings.com				
	Sponsor Website	<u>Link to sponsor website</u>				
	Program URL	Link to program URL				
	Deadline Dates (ALL)	10-Jan-2023 , 22-Mar-2023 [LOI/	'Pre-App]			
	Synopsis	The James H. Cummings Foundar Hendersonville, North Carolina to provide services for vulnerable c with services that help them mai	o advance medical res hildren and children v	search, science, and post-s with disabilities; and to ass	econdary medical ed ist older adults and v	lucation; to
	Applicant Types					
	Funding Limit	5,000.00 see detail				
	Limited Submission	No				
114830 Repurposing Research to Improve Patient Outcomes in Meniere's Disease and Related Diagnoses: Clinical and Preclinical Projects Cures Within Reach O1-Mar-2023 [LOI/Pre-App]						Pre- Not Specified
	Contact Name	Clare Thibodeaux, PhD, Director	of Scientific Affairs			



SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount				
	Contact Telephone	847-745-1246							
	Contact Email	clare@cureswithinreach.org							
	Sponsor Website	<u>Link to sponsor website</u>							
	Program URL	Program URL Link to program URL							
	Deadline Dates (ALL) 01-Mar-2023 [LOI/Pre-App]								
	The sponsor provides support for clinical repurposing trials (up to \$100,000) and preclinical repurposing research (up Synopsis to \$50,000) in Meniere's disease as well as other vertigo and hearing loss-related diagnoses, such as benign paroxysmal positional vertigo (BPPV), tinnitus, labyrinthitis and vestibular neuritis.								
	Applicant Types								
		0.00 see detail							
033065 (Funding Limit	No	sis Foundation	02-Feb-2023	Not Specified				
033065 (Funding Limit Limited Submission Clinical Pilot and Feasibility Awa	No	sis Foundation	02-Feb-2023					
033065 <u>(</u>	Funding Limit Limited Submission Clinical Pilot and Feasibility Awa	No Cystic Fibro Dara Riva, Program Officer	sis Foundation	02-Feb-2023					
033065 (Funding Limit Limited Submission Clinical Pilot and Feasibility Awa Contact Name	No Cystic Fibro Dara Riva, Program Officer 301-841-2614	sis Foundation	02-Feb-2023					
033065 (Funding Limit Limited Submission Clinical Pilot and Feasibility Awa Contact Name Contact Telephone Contact Email	No Cystic Fibro Dara Riva, Program Officer 301-841-2614	sis Foundation	02-Feb-2023					
033065 <u>(</u>	Funding Limit Limited Submission Clinical Pilot and Feasibility Awa Contact Name Contact Telephone Contact Email Sponsor Website	No Cystic Fibro Dara Riva, Program Officer 301-841-2614 driva@cff.org	sis Foundation	02-Feb-2023					



SPIN ID Program Title	Sponsor Nam	e	Sponsor Number	Deadline Date	Funding Amount	
Synopsi Applicant Type Funding Limi Limited Submissio	develop and test new hypothes t 0.00 see detail	ty Award is intended to seeses and/or new method	support a project involving ds in research areas releva	g human subjects or nt to cystic fibrosis.	samples that will	
005450 Clinical Research Award		Cystic Fibrosis Four	ndation	02-Feb-2023	Not Specified	
Contact Nam	Dara Riva, Program Officer					
Contact Telephon	e 301-841-2637					
Contact Ema	grants@cff.org					
Sponsor Websit	Link to sponsor website					
Program UR	L Link to program URL					
Deadline Dates (ALL) 02-Feb-2023 , 23-Mar-2023 [L	OI/Pre-App], 08-Aug-202	23			
Synopsi	The Foundation's Investigator-initiated Clinical Research Programs aim to provide support for academic clinical research projects that have the potential to make an important contribution to the CF Foundation's mission. Academic clinical research projects may address diagnosis, treatment, management of disease or symptoms, or the pathophysiology of CF using clinical (observational or interventional), translational or epidemiologic study approaches.					
Applicant Type	s					
Funding Limi	t 0.00 see detail					
Limited Submissio	n No					



SPIN ID	Program Title	Sponsor Nam	e	Sponsor Number	Deadline Date	Funding Amount
089449 <u>F</u>	Research Grants		Daisy Foundation		05-Feb-2023 [LOI/I App]	Pre- 7,500 USD
	Contact Name	Bonnie Barnes				
	Contact Telephone	707-996-7936				
	Contact Email	ErinAscher@DAISYFoundation	.org			
	Sponsor Website	<u>Link to sponsor website</u>				
	Program URL	Link to program URL				
	Deadline Dates (ALL)	05-Feb-2023 [LOI/Pre-App], 19	9-Mar-2023			
	Synopsis	The DAISY Foundation is eager populations by funding nursing determinants of health aimed	g research and evidence	e-based practice (EBP) proj		•
	Applicant Types					
	Funding Limit	7,500.00 maximum				
	Limited Submission	No				
001443 <u>E</u>	Evidence-based Practice (EBP) (<u>Grants</u>	Daisy Foundation		05-Feb-2023 [LOI/I App]	Pre- 2,500 USD
	Contact Name	Bonnie Barnes				
	Contact Telephone	707-996-7936				
	Contact Email	bonniebarnes@daisyfoundation	on.org			
	Sponsor Website	Link to sponsor website				



SPIN ID	Program Title	Sponsor Name	Spo	onsor Number	Deadline Date	Funding Amount			
	Program URL Linl	k to program URL							
	Deadline Dates (ALL) 05-	Feb-2023 [LOI/Pre-App], 19-Mar-202	23						
	Evidence-based Practice (EBP) grants will be awarded to stimulate the use of patient-focused data and/or previously Synopsis generated research findings to develop, implement and evaluate changes in nursing practice in treatment of patients with cancer and auto-immune diseases.								
	Applicant Types								
	Funding Limit 2,50	00.00 maximum							
	Limited Submission No								
020270 [Damon Runyon Fellowship Award		on Runyon Cancer arch Foundation	r	15-Mar-2023	52,000 USD			
	Contact Name								
	Contact Telephone								
	Contact Email <u>awa</u>	ards@damonrunyon.org							
	Sponsor Website <u>Linl</u>	k to sponsor website							
	Program URL <u>Linl</u>	k to program URL							
	Deadline Dates (ALL) 15-	Mar-2023							
	for Synopsis guid the	Foundation encourages all theoreticancer causes, mechanisms, therapidance of a Sponsor—a scientist (tenerallow. In addition to aiding in the person to foster the development of the	es and prevention. ured, tenure-track llanning, execution	. Candidates must appl or equivalent position) n and supervision of the	y for the fellowship capable of providi proposed researc	o under the ng mentorship to h, the sponsor's			



SPIN ID	Program Title		Sponsor Name		Sponsor Number	Deadline Date	Funding Amount	
		to work in foreig	gn-based or United nusual opportunit	d States governmen	st the Fellow in attaining to t laboratories may be awa raining. Foreign candidate	arded a fellowship if	the program	
	Applicant Types							
	Funding Limit	52,000.00 for th	e first year					
	Limited Submission	No						
038247 <u>C</u>	038247 Clinical Scientist Development Award			Duke (Doris) Charitable Foundation		14-Mar-2023	150,000 USD	
	Contact Name	Joanne Sullivan						
	Contact Telephone	212-974-7000						
	Contact Email	ddcf@aibs.org						
	Sponsor Website	Link to sponsor	<u>website</u>					
	Program URL	Link to program	URL					
	Deadline Dates (ALL)	14-Mar-2023						
	Synopsis	The 2023 Clinical Scientist Development Award consists of \$150,000 annual direct costs plus \$15,000 (10%) annual sindirect costs for three years. The award project period is July 1, 2023 to June 30, 2026. nDDCF expects to fund approximately 16 applications in 2023.						
	Applicant Types							
	Funding Limit	150,000.00 see	detail					
	Limited Submission	No						



SPIN ID	Program Title	Sponsor Name		Sponsor Number	Deadline Date	Funding Amount				
037090	Fellows Research Grant		Endocrine Fellows Foundation		10-Mar-2023	10,000 USD				
	Contact Name									
	Contact Telephone									
	Contact Email	info@endocrinefellows.org								
	Sponsor Website	Link to sponsor website								
	Program URL	Link to program URL								
	Deadline Dates (ALL)	10-Mar-2023								
	Synopsis	The Endocrine Fellows Foundat Obtaining new grants is often of initiate new research projects. grant process gives a very thore whose projects pass this rigoro creating our leaders of tomorro	lependent on prior gran This is critical for furthe ough high-level evaluat us review can utilize th	nt recipient history and the r long-term career devel ion and feedback to all fe ese projects as springboa	ne ability of fellows opment. A rigorous Illows who participa	to successfully MD peer-reviewed ite. Grant awardees				
	Applicant Types									
	Funding Limit	10,000.00 maximum								
	Limited Submission	No								
U/3/3/	Research Experiences for Gradu (REGMS)	nate and Medical Students	Endocrine Society		06-Jan-2023	Not Specified				
	Contact Name Contact Telephone	202-971-3636								



SPIN ID	Program Title	Sponsor Name		Sponsor Number	Deadline Date	Funding Amount			
	Contact Email	awards@endocrine.org							
	Sponsor Website	Link to sponsor website							
	Program URL	Link to program URL							
	Deadline Dates (ALL)	06-Jan-2023 , 01-Mar-2023							
	Synopsis The Endocrine Society offers Summer Research Fellowships to encourage promising undergraduate students, medical students and first year graduate school students to pursue careers in endocrinology.								
	Applicant Types								
	Funding Limit	0.00 see detail							
	Limited Submission	No							
114785 g	nnovative Health Initiative Join Strengthening the European Tra for Advanced Therapy Medicina Diseases	anslational Research Ecosystem	European Commiss	ion HORIZON-JU- IHI-2022-03-04	1 ^{13-Mar-2023}	Not Specified			
	Contact Name								
	Contact Telephone	+32 (0)2 221 81 81							
	Contact Email	infodesk@ihi.europa.eu							
	Sponsor Website	Link to sponsor website							
	Program URL	Link to program URL							
	Deadline Dates (ALL)	13-Mar-2023							
	Synopsis	Proposals are being accepted aga Ecosystem for Advanced Therapy	inst the following top Medicinal Products (oic: Strengthening the Euro ATMPs) for Rare Diseases	ppean Translational The Innovative Hea	Research Ith Initiative Joint			



The Development Office offers assistance with many non profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team for assistance or questions. <u>DevCorpFound@mountsinai.org</u> below.

SPIN ID	Program Title		Sponsor Name		Sponsor Number	Deadline Date	Funding Amount
	Applicant Types Funding Limit Limited Submission	involved in heal EFPIA, including and MedTech E health research JU).	Ithcare, namely COCIR (i g Vaccines Europe (phari urope (medical technolo	medical imaging maceutical indu ogy industry). IH	pean Union and industry g, radiotherapy, health ICT stry and vaccine industry) II JU aims to pioneer a new om the Innovative Medici	and electromedical; EuropaBio (bioted w, more integrated	al industries); chnology industry); approach to
114782	nnovative Health Initiative Joir Platform and Biomarkers for Pr Diseases of Unmet Public Healt	ediction and Pre		pean Commissi	on HORIZON-JU- IHI-2022-03-02	13-Mar-2023	Not Specified
	Sponsor Website	+32 (0)2 221 81 infodesk@ihi.eu Link to sponsor Link to program 13-Mar-2023	uropa.eu website n URL	ne following top	ic: Screening Platform and	d Biomarkers for Pr	rediction and
	Synopsis	Prevention of D partnership bet	iseases of Unmet Public ween the European Uni	: Health Need Th on and industry	ne innovative Health Initial associations representing CT and electromedical inc	ative Joint Undertal g the sectors involv	king (IHI JU) is a red in healthcare,



The Development Office offers assistance with many non profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team for assistance or questions. <u>DevCorpFound@mountsinai.org</u> below.

SPIN ID	Program Title	Sponsor	r Name	Sponsor I	Number	Deadline Date	Funding Amount
	Applicant Types Funding Limit Limited Submission	0.00 see detail	ustry). IHI JU aims t	o pioneer a new, mor	re integrated ap	proach to health re	•
114780	Innovative Health Initiative Joir Health Technologies for the Pre Management of Mental Disord Consequences	nt Undertaking (IHI JU) I evention and Personalised	<u>d</u> Furonea	n Commission	HORIZON-JU- IHI-2022-03-05	13-Mar-2023	Not Specified
	Contact Name Contact Telephone	+32 (0)2 221 81 81					
		infodesk@ihi.europa.eu Link to sponsor website					
	Program URL	Link to program URL					
	Deadline Dates (ALL) Synopsis	Proposals are being acce Personalised Manageme Initiative Joint Undertaki representing the sectors electromedical industrie EuropaBio (biotechnolog	ent of Mental Disording (IHI JU) is a part involved in healthdes); EFPIA, including	ders and Their Long-tonership between the care, namely COCIR (r Vaccines Europe (pha	erm Health Cons European Unior medical imaging, armaceutical ind	sequences The Inno n and industry asso , radiotherapy, hea lustry and vaccine i	ovative Health ciations lth ICT and ndustry);



SPIN ID Program Title	Sponsor Name	Sponso	r Number	Deadline Date	Funding Amount
		والانتجار المرم والمرموم والمارم والمارم		and the second the second	an avetive NA adiaira
	new, more integrated approach to Initiative 2 Joint Undertaking (IMI2		on the experience	gained from the ii	inovative iviedicine
Applicant Types					
Funding Limit	0.00 see detail				
Limited Submission	No				
Innovative Health Initiative Joi 114784 Combining Hospital Intervention Patient Outcomes and Increase	onal Approaches to Improve	European Commission	HORIZON-JU- IHI-2022-03-0	3 13-Mar-2023	Not Specified
Contact Name					
Contact Telephone	+32 (0)2 221 81 81				
Contact Emai	infodesk@ihi.europa.eu				
Sponsor Website	<u>Link to sponsor website</u>				
_	Link to program URL				
Deadline Dates (ALL)	13-Mar-2023				
Synopsis	Proposals are being accepted again Patient Outcomes and Increase Hospartnership between the European namely COCIR (medical imaging, rac Europe (pharmaceutical industry ar (medical technology industry). IHI J on the experience gained from the	spital Efficiency The Innovat Union and industry associa diotherapy, health ICT and ond vaccine industry); Europa U aims to pioneer a new, m	cive Health Initiati ations representin electromedical ind aBio (biotechnolo nore integrated ap	ve Joint Undertaking the sectors involved the sectors involved the sectors involved the sectors in the sectors	ng (IHI JU) is a ved in healthcare, cluding Vaccines ledTech Europe



SPIN ID	Program Title		Sponsor Name		Sponsor Number	Deadline Date	Funding Amount		
	Applicant Types Funding Limit Limited Submission	0.00 see detail							
114783	nnovative Health Initiative Join Generated Evidence to Improve Making, and Accelerate Innovat	Outcomes, Sup		European Commiss	ion HORIZON-JU- IHI-2022-03-02	13-Mar-2023	Not Specified		
	Sponsor Website	infodesk@ihi.eu Link to sponsor Link to program	iropa.eu website						
	Synopsis	Proposals are being accepted against the following topic: Patient-Generated Evidence to Improve Outcomes, Support Decision Making, and Accelerate Innovation The Innovative Health Initiative Joint Undertaking (IHI JU) is a partnership between the European Union and industry associations representing the sectors involved in healthcare, namely COCIR (medical imaging, radiotherapy, health ICT and electromedical industries); EFPIA, including Vaccines Europe (pharmaceutical industry and vaccine industry); EuropaBio (biotechnology industry); and MedTech Europe (medical technology industry). IHI JU aims to pioneer a new, more integrated approach to health research and builds on the experience gained from the Innovative Medicine Initiative 2 Joint Undertaking (IMI2 JU).							
	Applicant Types Funding Limit	0.00 see detail							



The Development Office offers assistance with many non profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team for assistance or questions. <u>DevCorpFound@mountsinai.org</u> below.

SPIN ID	Program Title	Sponsor Name		Sponsor Number	Deadline Date	Funding Amount		
	Limited Submission	No						
	Elimited Subimission	140						
006588	Pilot Research Grant		Eye Bank Association America	on of	20-Mar-2023	7,500 USD		
	Contact Name	Stacey Gardner, Director of Educ	ation					
	Contact Telephone	202-775-4999						
	Contact Email	stacey@restoresight.org						
	Sponsor Website	Link to sponsor website						
	Program URL	Link to program URL						
	Deadline Dates (ALL)	20-Mar-2023						
	Synopsis	The Eye Bank Association of America awards the EBAA Pilot Research Grant annually. These awards are intended to provide support for proposals specifically concerned with issues directly related to eye banking and/or corneal transplantation. Each proposal may be funded up to \$7,500.						
	Applicant Types							
	Funding Limit	7,500.00 maximum						
	Limited Submission	Yes						
006584	Crystal Cornea Award		Eye Bank Association America	on of	10-Mar-2023	Not Specified		
	Contact Name							
	Contact Telephone	202-775-4999						
	Contact Email							



i								
Sponsor Website Link to sponsor website								
Program URL Link to program URL								
Deadline Dates (ALL) 10-Mar-2023								
Synopsis The Crystal Cornea Awa	d is presented to individuals or	r organizations from outs	de healthcare and	eye banking.				
Applicant Types								
Funding Limit 0.00 see detail								
Limited Submission No								
030560 Therapeutic Pipeline Program	Fox (Michael J.) Four for Parkinson's Rese		12-Jan-2023	500,000 USD				
Contact Name								
Contact Telephone 800-708-7644								
Contact Email grants@michaeljfox.org								
Sponsor Website Link to sponsor website								
Program URL Link to program URL								
Deadline Dates (ALL) 12-Jan-2023, 23-Mar-20	23 , 25-May-2023 , 27-Jul-2023	3						
Synopsis clinical results through t	The Pre-clinical Therapeutics Pipeline Program seeks to accelerate the path of the therapeutic pipeline towards clinical results through the support of ambitious and scientifically robust pre-clinical studies aiming at developing and testing treatments and interventions that can address the unmet needs of people with PD.							
Applicant Types								
Funding Limit 500,000.00 maximum								



SPIN ID	Program Title	Sponsor Name		Sponsor Number	Deadline Date	Funding Amount
	Limited Submission	No				
036254	Keith Michael Andrus Cardiac A	ward	Friedreich's Ataxia F Alliance	Research	15-Jan-2023	300,000 USD
	Contact Name					
	Contact Telephone	484-879-6160				
	Contact Email	grants@curefa.org				
	Sponsor Website	Link to sponsor website				
	Program URL	Link to program URL				
	Deadline Dates (ALL)	15-Jan-2023 , 01-Mar-2023				
	Synopsis	The Keith Michael Andrus Cardiac and to help advanced our underst award should focus on advancing may request a budget of up to \$15	anding and treatmer understanding and/c	nt of the cardiomyopathy a or treatment of the cardia	associated with FA.	Proposals for this
	Applicant Types					
	Funding Limit	150,000.00 per year				
	Limited Submission	No				
036255]	Kyle Bryant Translational Resea	rch Award	Friedreich's Ataxia F Alliance	Research	15-Jan-2023 [LOI/ App]	Pre- 500,000 USD
	Contact Name					
	Contact Telephone	484-879-6160				
	·					



SPIN ID	Program Title	Sponsor Name		Sponsor Number	Deadline Date	Funding Amount
	Contact Email	grants@curefa.org				
	Sponsor Website	Link to sponsor website				
	Program URL	Link to program URL				
		15-Jan-2023 [LOI/Pre-App], 15-N				
	Synopsis	The Kyle Bryant Translational Re that will advance treatments for	search Award is given Friedreich's Ataxia.	to proposals focused on p	re-clinical and clinic	al investigations
	Applicant Types					
	Funding Limit	250,000.00 per year				
	Limited Submission	No				
006873 <u>E</u>	Bronya J. Keats Research Collab	poration Award	Friedreich's Ataxia Alliance	Research	15-Jan-2023 [LOI/ App]	Pre- 400,000 USD
	Contact Name					
	Contact Telephone	484-879-6160				
	Contact Email	grants@curefa.org				
	Sponsor Website	Link to sponsor website				
	Program URL	Link to program URL				
	Deadline Dates (ALL)	15-Jan-2023 [LOI/Pre-App], 15-N	1ar-2023			
	Synopsis	The Bronya J. Keats Research Co GAA triplet repeat mutation in F. on FA research that relies on coll consideration will be given to pro	A, and her continued aboration among inve	role in managing FARA's gr estigators from at least two	ant program. Propo o different Institutio	osals should focus ons. Special



SPIN ID	Program Title	Sponsor Name		Sponsor Number	Deadline Date	Funding	g Amount
		community. The rationale for the			•		
		research goals could not be achie essential for the success of the pr		e participating groups and	d that the synergy a	among the	e groups is
	Applicant Types	·	•				
	Funding Limit	200,000.00 per year					
	Limited Submission	No					
UILLI //In	Bioethics Grants Program - Mal Bioethics Dilemmas	king a Difference in Real-World	Greenwall Foundat	ion	03-Jan-2023 [LO App]	-	Not Specified
		III I D			Abbl		Specified
		Kyle Ruempler					
	Contact Telephone						
		kruempler@greenwall.org					
	Sponsor Website	<u>Link to sponsor website</u>					
	Program URL	Link to program URL					
	Deadline Dates (ALL)	03-Jan-2023 [LOI/Pre-App], 13-M	ar-2023				
		The Greenwall Foundation is requ Difference in Real-World Bioethic important emerging or unanswer or practice. The Foundation's visi mission is to expand bioethics known and practice. Projects funded und mission through innovative bioet	es Dilemmas. The Mal red bioethics problem on is to make bioethi owledge to improve of der the Making a Diffo	king a Difference program in clinical, biomedical, o cs integral to decisions in clinical, biomedical, and p erence program should p	n supports research r public health decis health care, policy, ublic health decisio romote the Founda	to help r sion-mak , and rese on-making	resolve an ing, policy, earch. Its



SPIN ID	Program Title	Sponsor Name		Sponsor Number	Deadline Date	Funding Amount
	Applicant Types Funding Limit Limited Submission	0.00 see detail				
081163	SWOG/Hope Impact Award		Hope Foundation for Research	or Cancer	15-Jan-2023 [LOI App]	/Pre- 250,000 USD
	Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL) Synopsis	io@thehopefoundation.org Link to sponsor website Link to program URL 15-Jan-2023 [LOI/Pre-App], 15-W The SWOG/Hope Foundation Impresearch by supporting early and completed SWOG trials or be dire	pact Award is a funding conceptual stages of ectly translatable to follow the future. These stud cular area, or to the d	ng program that encourage these projects. The work uture clinical trials in SWO dies may involve considera levelopment of novel tech	es novel and innova proposed should us G and the National ble scientific risk bu	se resources from Clinical Trials ut may potentially
	Applicant Types					
	Funding Limit Limited Submission	250,000.00 maximum No				



The Development Office offers assistance with many non profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team for assistance or questions. <u>DevCorpFound@mountsinai.org</u> below.

SPIN ID	Program Title	Sponso	or Name	Sponsor Number	Deadline Date	Funding Amount					
081191	SWOG Coltman Fellowship Prog	gram	Hope Fou Research	undation for Cancer	01-Mar-2023	100,000 USD					
	Contact Name	Johanna Horn									
	Contact Telephone	734-998-7150									
	Contact Email	jo@thehopefoundation	n.org								
	Sponsor Website	Link to sponsor website	<u>e</u>								
	Program URL	Link to program URL									
	Deadline Dates (ALL)	01-Mar-2023	1-Mar-2023								
		The SWOG Cancer Research Network Dr. Charles A. Coltman, Jr. Fellowship Program protects time for clinical or translational research on SWOG-associated projects. The funding encourages investigators from SWOG member institutions to engage either in learning clinical trial methodology or in expanding current research interests within a cooperative group environment. Each award provides \$100,000 over two years to successful candidates, as well as key travel support.									
	Applicant Types										
	Funding Limit	100,000.00 maximum									
	Limited Submission	No									
040263	Donald A. King Summer Researd	ch Fellowships	Huntingt of Ameri	on's Disease Society ca, Inc.	03-Mar-2023	4,500 USD					
	Contact Name	Leora Fox, PhD, Manag	ger of Mission and Res	search Programs							
	Contact Telephone	212-242-1968									
	Contact Email	lfox@hdsa.org									



SPIN ID	Program Title		Sponsor Name		Sponsor Number	Deadline Date	Funding Amount
	Sponsor Website	Link to sponsor	<u>website</u>				
	Program URL	Link to program	<u>URL</u>				
	Deadline Dates (ALL)	03-Mar-2023					
	Synopsis	be conducted o supervision of s	ver a 10-week peri	od, between May ar , will undertake a pr	nsors college students to p and September. Fellowship roject that is focused and a	recipients, working	under the
	Applicant Types						
	Funding Limit	4,500.00 see de	etail				
	Limited Submission	No					
042376 <u>k</u>	Kevin Nurse Memorial Scholars	hip		Institute of Culinary Education	У	01-Mar-2023	10,000 USD
	Contact Name	Stephanie Bour	geois				
	Contact Telephone	(212) 847-0775					
	Contact Email	kevinnurse-mei	morial@ice.edu				
	Sponsor Website	Link to sponsor	website				
	Program URL	Link to program	<u>URL</u>				
	Deadline Dates (ALL)	01-Mar-2023					
	Synopsis				a student who has overco I hardship. The scholarship		
	Applicant Types						



The Development Office offers assistance with many non profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team for assistance or questions. <u>DevCorpFound@mountsinai.org</u> below.

SPIN ID	Program Title	Sponsor Name		Sponsor Number	Deadline Date	Funding Amount
	Funding Limit	10,000.00 see detail				
	Limited Submission	No				
000405	Christianson Fellowship		InterExchange Four	ndation	15-Mar-2023	10,000 USD
	Contact Name					
	Contact Telephone	212-924-0446				
	Contact Email	foundation@interexchange.org				
	Sponsor Website	Link to sponsor website				
	Program URL	Link to program URL				
	Deadline Dates (ALL)	15-Mar-2023				
	Synopsis	The InterExchange Foundation Ch who create and carry out their ov	nristianson Grant pro vn meaningful service	vides awards of up to \$10, e projects abroad.	,000 to motivated y	oung Americans
	Applicant Types					
	Funding Limit	10,000.00 see detail				
	Limited Submission	No				
072198 <u>C</u>	072198 Colgate Oral Health Research Award			iation for	15-Mar-2023	2,000 USD
	Contact Name	Sylvia L. Santos, RDH, MS, CCRP				
	Contact Telephone	703-548-0066				
	Contact Email	sersantos@verizon.net				



SPIN ID	Program Title		Sponsor Name		Sponsor Number	Deadline Date	Funding Amount		
	Sponsor Website	Link to sponsor v	<u>vebsite</u>						
	Program URL	Link to program	<u>URL</u>						
	Deadline Dates (ALL)	15-Mar-2023							
	Synopsis	research. The pu	rpose of the awar	_	g nominations for a group- oody of meritorious resear ntal Hygienist.	•			
	Applicant Types								
Funding Limit 2,000.00 see detail									
	Limited Submission	No							
070603	Aubrey Sheiham Award for Dist Public Health Sciences	inguished Resear	ch in Dental	International Associ Dental Research	ciation for	31-Mar-2023	350 USD		
	Contact Name	Dr. Kimon Divari	5						
	Contact Telephone	703-548-0066							
	Contact Email	Kimon_Divaris@	<u>unc.edu</u>						
	Sponsor Website	Link to sponsor v	<u>vebsite</u>						
	Program URL	Link to program	<u>URL</u>						
	Deadline Dates (ALL)	31-Mar-2023							
	Synopsis	The Executive Committee of the Behavioral, Epidemiologic and Health Services Research Group (BEHSR) of IADR announces the Aubrey Sheiham Award for Distinguished Research in Dental Public Health Sciences. This award recognizes a single peer-reviewed paper in the field of dental public health published between January 1, 2022 and December 31, 2022.							



The Development Office offers assistance with many non profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team for assistance or questions. <u>DevCorpFound@mountsinai.org</u> below.

SPIN ID	Program Title	Spo	nsor Name		Sponsor Number	Deadline Date	Funding Amount		
	Applicant Types								
	Funding Limit	350.00 see detail							
	Limited Submission No								
11//199	Giddon Award for Distinguished	d Research in the Bel	naviora <u>l</u>	International Associ Dental Research	iation for	31-Mar-2023	350 USD		
	Contact Name	Dr. George Tsakos, E	BEHSR Preside	nt					
	Contact Telephone								
	Contact Email	g.tsakos@ucl.ac.uk							
	Sponsor Website	Link to sponsor web	<u>site</u>						
	Program URL	Link to program URI	<u>L</u>						
	Deadline Dates (ALL)	31-Mar-2023							
	The Behavioral, Epidemiologic and Health Services Research group announces the Giddon Award for Distinguished Research in the Behavioral Sciences. The Giddon Award for Distinguished Research in the Behavioral Sciences recognizes a single research investigation published, or accepted for publication, between January 1, 2020 and December 31, 2020 in the fields of social or cultural anthropology, education, psychology, psychiatry, sociology, and social work applied to dentistry. Both applied and basic research group announces the Giddon Award for Distinguished Research in the Behavioral Sciences recognizes a single research investigation published, or accepted for publication, between January 1, 2020 and December 31, 2020 in the fields of social or cultural anthropology, education, psychology, psychiatry, sociology, and social work applied to dentistry. Both applied and basic research manuscripts are eligible.								
	Applicant Types								
	Funding Limit	350.00 see detail							
	Limited Submission	No							
006210 <u>/</u>	Annual Balzan Prizes			International Balzar Foundation	n Prize	15-Mar-2023	Not Specified		



SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount		
	Contact Name							
	Contact Telephone	39-02-7600-221	12					
	Contact Email	balzan@balzan	<u>.it</u>					
	Sponsor Website	Link to sponsor	<u>website</u>					
	Program URL	Link to program	<u>ı URL</u>					
	Deadline Dates (ALL)	15-Mar-2023						
	Synopsis	The Balzan Prizes are chosen by the General Prize Committee in two general subject areas: Literature, Moral Sciences and the Arts; and the Physical, Mathematical and Natural Sciences and Medicine. The four Balzan Prizes, two per category, are awarded to scholars, artists and scientists who have distinguished themselves in their fields on an international level.						
	Applicant Types							
	Funding Limit	0.00 not provid	ed					
	Limited Submission	No						
009241	nternational Pigment Cell Conf Suspended)	erence Travel A	ward (Temporarily International Pigment Cell S	Federation of ocieties (IFPCS)	01-Mar-2023	Not Specified		
	Contact Name							
	Contact Telephone	33-556-42-44-0	5					
	Contact Email	travel@ipcc201	.1.org					
	Sponsor Website	Link to sponsor	website					
	Program URL	Link to program	<u>ı URL</u>					



SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount						
	Deadline Dates (ALL)	01-Mar-2023									
	Synopsis	Pigment Cell Conference which is held ever registration and gala dinner fees. Selection applicants at an early stage of their training	e International Federation of Pigment Cell Societies (IFPCS) offers travel grants for attendance at the International ment Cell Conference which is held every three years. The award will assist travel to Singapore and will include gistration and gala dinner fees. Selection criteria will be based on scientific merits, and priority will be given to plicants at an early stage of their training/career (age 35 or below), including students, junior post-docs and young D's. One must submit an abstract to be eligible for this award.								
	Applicant Types										
	Funding Limit	0.00 not provided	00 not provided								
	Limited Submission	No									
015167.5		Interna	tional Retinal		Not						
U15167 <u>F</u>	Postdoctoral Scholar Awards		h Foundation, Inc.	15-Mar-2023	Specified						
015167 <u>F</u>			h Foundation, Inc.	15-Mar-2023							
015167 <u>F</u>		Researd Sandra Blackwood, MPA, Executive Direct	h Foundation, Inc.	15-Mar-2023							
<u> </u>	Contact Name Contact Telephone	Researd Sandra Blackwood, MPA, Executive Direct	h Foundation, Inc.	15-Mar-2023							
012167	Contact Name Contact Telephone Contact Email	Researd Sandra Blackwood, MPA, Executive Director 205-325-8103	h Foundation, Inc.	15-Mar-2023							
015167	Contact Name Contact Telephone Contact Email Sponsor Website	Researd Sandra Blackwood, MPA, Executive Director 205-325-8103 sblackwood@irrfonline.org	h Foundation, Inc.	15-Mar-2023							
012167	Contact Name Contact Telephone Contact Email Sponsor Website	Researd Sandra Blackwood, MPA, Executive Director 205-325-8103 sblackwood@irrfonline.org Link to sponsor website Link to program URL	h Foundation, Inc.	15-Mar-2023							



The Development Office offers assistance with many non profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team for assistance or questions. <u>DevCorpFound@mountsinai.org</u> below.

SPIN ID	Program Title	Sponsor Name		Sponsor Number	Deadline Date	Funding Amount	
		David Rich Scholar Award. The IR	RF Postdoctoral Scho	lar Awards were establish	ed to provide salar	y and research	
		support in the amount of \$35,00	0 per year for a postd	loctoral scholar nearing th	e end of his/her tra	aining.	
	Applicant Types						
	Funding Limit	35,000.00 per year					
	Limited Submission	No					
000412	Graduate Scholarship Award fo	r Study in Marine Sciences	International Wom Fishing Association		01-Mar-2023	3,000 USD	
	Contact Name						
	Contact Telephone						
	Contact Email	scholarshiptrust@iwfa.org					
	Sponsor Website	Link to sponsor website					
	Program URL	Link to program URL					
	Deadline Dates (ALL)	01-Mar-2023					
	Synopsis	The IWFA Scholarship Trust has been established to provide financial aid to qualified graduate students of Marine Science, which is defined as "the study of the ocean, its ecosystems, and its life forms, as well as the study of coastal environments, oceanic currents, and the sea floor." The Board of Trustees will award scholarships each year to assist in funding research and related expenses in such amounts and to such students as will be determined at its discretion. Awards are competitive and typically range between \$1000 and \$3000.					
	Applicant Types						
	Funding Limit	3,000.00 maximum					
	Limited Submission	No					



The Development Office offers assistance with many non profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team for assistance or questions. <u>DevCorpFound@mountsinai.org</u> below.

SPIN ID	Program Title	Sponsor Name	e	Sponsor Number	Deadline Date	Funding Amount
081/24	Therapeutic Area Contributions Program	- Infectious Disease & Vaccines	S Janssen Pharmaceu	iticals, Inc.	31-Jan-2023	Not Specified
•	Contact Name					_
	Contact Telephone	908-218-6095				
	Contact Email					
	Sponsor Website	Link to sponsor website				
	Program URL	Link to program URL				
	Deadline Dates (ALL)	31-Jan-2023 , 31-Mar-2023 , 31	1-May-2023 , 31-Jul-202	23		
	Synopsis	Janssen Pharmaceuticals, Inc. r evaluated competitively with e disparities or unmet needs. The areas: HIV/AIDS Vaccines	emphasis given to innov	ative programs with meas	urable outcomes tl	hat address
	Applicant Types					
	Funding Limit	0.00 see detail				
	Limited Submission	No				
010366 <u>H</u>	Health Economics & Outcomes	Research Fellowships	Jefferson (Thomas)	University	31-Mar-2023	Not Specified
	Contact Name	Vittorio Maio, PharmD, MS, MS	SPH, Outcomes Researc	h Fellowship Director		
	Contact Telephone			•		
	'					



The Development Office offers assistance with many non profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team for assistance or questions. <u>DevCorpFound@mountsinai.org</u> below.

SPIN ID	Program Title	Spor	nsor Name	Sponsor Number	Deadline Date	Funding Amount			
	Contact Email	JCPHFellowship@jeff	ferson.edu						
	Sponsor Website	Link to sponsor webs	site_						
	Program URL	Link to program URL							
	Deadline Dates (ALL)	Deadline Dates (ALL) 31-Mar-2023							
	The goal of the fellowship program is to prepare pharmacists and other health professionals for careers in health economics and outcomes research. One of the oldest and most established programs of its kind in the country, the JCPH fellowship program has more than 50 alumni to date. Current industry sponsors include Ethicon, Janssen, Novartis Pharmaceuticals, Inc., Otsuka, Teva Pharmaceuticals and United Therapeutics Corporation.								
	Applicant Types								
	Funding Limit	0.00 see detail							
	Limited Submission	No							
051093	Specialized Center of Research	(SCOR) Program	Leukemia and Lym Society	phoma	27-Mar-2023	5,000,000 USD			
	Contact Name								
	Contact Telephone	914-949-5213							
	Contact Email	researchprograms@l	lls.org						
	Sponsor Website	Link to sponsor webs	site_						
	Program URL	Link to program URL							
	Deadline Dates (ALL)	27-Mar-2023							
	Synopsis		ter of Research (SCOR) grant propositions to develop a focused						



SPIN ID	Program Title	S	ponsor Name	Sponsor Number	Deadline Date	Funding Amount		
		development of i	ciplinary research among the part nnovative strategies for the treati ategies that move discoveries from ects.	ment, diagnosis or prevent	ion of hematological			
	Applicant Types							
	Funding Limit	1,000,000.00 per	year					
	Limited Submission	No						
067718 <u>P</u>	Pisart Award in Vision Science		Lighthouse Guil	d	01-Mar-2023	25,000 USD		
	Contact Name	Fernanda Garcia-	Peña, Director of Research Opera	tions				
	Contact Telephone	212-769-7833						
	Contact Email							
	Sponsor Website	Link to sponsor w	<u>rebsite</u>					
	Program URL	Link to program L	<u>JRL</u>					
	Deadline Dates (ALL)	01-Mar-2023						
		The Pisart Award was established in 1981 to recognize an individual, group of individuals or organization that have developed technology that improves the lives of people with vision loss. Their efforts will have directly contributed to the mission of Lighthouse Guild to inspire people who are visually impaired to attain their goals.						
	Applicant Types							
	Funding Limit	25,000.00 maxim	um					
	Limited Submission	No						



SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date F	unding Amount			
089679	Global Team Science Awards	Lupus Rese	Lupus Research Alliance					
	Contact Name	Diomaris Gonzalez, Director, Grant Programs						
	Contact Telephone	646-884-6056						
Contact Email dgonzalez@lupusresearch.org								
Sponsor Website Link to sponsor website								
	Program URL	Link to program URL						
	Deadline Dates (ALL)	01-Mar-2023						
	Synopsis	The Global Team Science Award supports into boundaries of innovation and bridge research unraveling human lupus heterogeneity by app bring about breakthroughs in lupus care, rese	and clinical efforts in lupus. The plying cutting-edge technologies	e successful Teams will fo	ocus on			
	Applicant Types							
	Funding Limit	0.00 see detail						
	Limited Submission	No						
061158	Everest Award	Marfan Fo	undation	31-Jan-2023 [LOI/Pi App]	re- 800,000 USD			
	Contact Name	Lauren May, MPH						
	Contact Telephone							
	Contact Email	Imay@marfan.org						



SPIN ID	Program Title	Sponsor I	Name	Sponsor Number	Deadline Date	Funding Amount			
	Sponsor Website	Link to sponsor website							
	Program URL	Link to program URL							
	Deadline Dates (ALL)	31-Jan-2023 [LOI/Pre-App], 27-Mar-2023						
	The Marfan Foundation and its divisions are requesting Letters of Intent to the Everest Grant Award Program to support four-year grants in the amount of \$200,000 per year for a total of \$800,000 to researchers studying Marfan Synopsis syndrome, Vascular Ehlers-Danlos syndrome, Ehlers-Danlos syndrome, Loeys-Dietz syndrome, and other aortic and vascular related conditions. Grant awards and yearly renewals will be based on full proposal evaluation and annual milestone reviews by The Marfan Foundation Scientific Advisory Board with the approval of the Board of Directors.								
	Applicant Types								
	Funding Limit	200,000.00 per year							
	Limited Submission	No							
011835	Epilepsy Fellowship (Minnesota	<u>a)</u>	Mayo Clinic College Medicine and Scier		01-Mar-2023	Not Specified			
	Contact Name	Lily Wong-Kisiel, M.D., Epi	lepsy Fellowship Director						
	Contact Telephone	507-266-0774							
	Contact Email	wongkisiel.lily@mayo.edu	!						
	Sponsor Website	Link to sponsor website							
	Program URL	Link to program URL							
	Deadline Dates (ALL)	01-Mar-2023							



SPIN ID	Program Title	Sponsor Nam	ne Sponsor	Number	Deadline Date	Funding Amount
	Synopsis		ayo Clinic's campus in Rochester, I). This one-year fellowship is desi	• •		•
	Зупорыз		mprehensive management of peo			
	Applicant Types					
	Funding Limit	0.00 see detail				
	Limited Submission	No				
013071 Neurology - Neurocritical Care Fellowship (Minnesota)			Mayo Clinic College of Medicine and Science		15-Mar-2023	Not Specified
	Contact Name	Chelsea Becker, Education Co	ordinator			
	Contact Telephone	507-266-1787				
	Contact Email	becker.chelsea@mayo.edu				
	Sponsor Website	Link to sponsor website				
	Program URL	Link to program URL				
	Deadline Dates (ALL)	15-Mar-2023				
		multidisciplinary approach to Clinic in Rochester, Minnesota Intensive Care Unit (ICU). The the team, in agreement with a procedures, but all procedure	e newest and fastest-growing spetreating life-threatening neurologa, is responsible for two services: model of care in our ICU is closed neurosurgery when pertinent. And as are expected to be performed by rological consultations in all other	gical diseases. To a primary care so d: All orders in popers esthesia suppor by the neurocriti	he Neurocritical Car service in their 20-be patients under their t is available for sup ical care fellow; and	e Division at Mayo ed Neuroscience care are written by pervision of invasive a consulting



SPIN ID	Program Title	Spo	nsor Name	Sponsor Number	Deadline Date	Funding Amount
	Applicant Types					
	Funding Limit	0.00 see detail				
	Limited Submission	No				
114510 JMCDF/MSRG Partnership Research Grant			McGovern (. Disease Fou	lack) Coats ndation (JMCDF)	31-Mar-2023	35,000 USD
	Contact Name					
Contact Telephone 888-314-8853						
Contact Email maculasociety@maculasociety.org						
	Sponsor Website	Link to sponsor web	<u>site</u>			
	Program URL	Link to program URL				
	Deadline Dates (ALL)	31-Mar-2023				
	Synopsis	program and suppor	artnership Research Grant ts medical research specifints and understanding of the	c to Coats' Disease and oth	ner retinal diseases which	may lead to a cure
	Applicant Types					
	Funding Limit	35,000.00 maximum				
	Limited Submission	No				
037592 (Call for Proposals		Medicines fo Venture (MI		31-Mar-2023	Not Specified



SPIN ID	Program Title		Sponsor Name		Sponsor Number	Deadline Date	Funding Amount		
	Contact Name								
	Contact Telephone	+41 22 555 03 0	00						
	Contact Email	proposals@mm	iv.org						
Sponsor Website Link to sponsor website									
	Program URL Link to program URL								
	Deadline Dates (ALL) 31-Mar-2023								
	Synopsis	The Medicines for Malaria Venture (MMV) seeks to reduce the burden of malaria in disease-endemic countries by discovering, developing and facilitating delivery of new, effective and affordable antimalarial drugs.							
	Applicant Types								
	Funding Limit	0.00 not provid	ed						
	Limited Submission	No							
114353 <u>N</u>	NTSAD Research Initiative Prog	<u>ram</u>		National Tay-Sachs Diseases Associatio		08-Jan-2023	140,000 USD		
	Contact Name								
	Contact Telephone	617-277-4463							
	Contact Email	info@ntsad.org							
	Sponsor Website	Link to sponsor	website						
	Program URL	Link to program	<u>URL</u>						
	Deadline Dates (ALL)	08-Jan-2023 , 1	2-Mar-2023						



SPIN ID	Program Title	Sponso	or Name	Sponsor Number	Deadline Date	Funding Amount		
	Applicant Types	140,000.00 maximum	llied Diseases Association's Re ring the following diseases: Tay	search Initiative Program is v- Sachs, Canavan, GM1, an	s soliciting proposa Id Sandhoff disease	ls for innovative es.		
010847	Kaplan Graduate Awards Progra	am (KAP)	Panthera		15-Mar-2023	20,000 USD		
	Contact Name							
	Contact Telephone	+1(646) 786 0400						
	Contact Email	grants@panthera.org						
	Sponsor Website	Link to sponsor website	2					
	Program URL	Link to program URL						
	Deadline Dates (ALL)	15-Mar-2023						
	Synopsis	The Kaplan Graduate Awards Program (KAP) was created to help develop the next generation of wild cat biologists. The program supports the conservation efforts of outstanding young biology graduate students working on wild felids in situ. Panthera welcomes applications for projects on all wild cat species in all regions. All Kaplan Awards are granted for one year up to a maximum of \$25,000 and may be renewable under certain circumstances.						
	Applicant Types							
	Funding Limit	20,000.00 maximum						
	Limited Submission	No						
		•						



SPIN ID	Program Title	Sponsor Name		Sponsor Number	Deadline Date	Funding Amount
089497	Translational Research Grant		Pediatric Cancer Re Foundation	esearch	01-Mar-2023	150,000 USD
	Contact Name					
	Contact Telephone	949-859-6312				
	Contact Email	info@pcrf-kids.org				
	Sponsor Website	Link to sponsor website				
	Program URL	Link to program URL				
Deadline Dates (ALL) 01-Mar-2023 , 01-Jun-2023						
	Synopsis	Translational Research Grants fun and accelerate cures from the lab up to \$75,00 per year, for up to 2	ooratory bench to the	· ·	•	•
	Applicant Types					
	Funding Limit	75,000.00 per year				
	Limited Submission	No				
113811	Competitive Grant Program: 20	22/2023 Global COVID-19 ASPIRE	Pfizer Pharmaceuti	cals	31-Mar-2023	200,000 USD
	Contact Name	Derek Warnick, Grant Officer				
	Contact Telephone					
	Contact Email	derek.warnick@pfizer.com				
	Sponsor Website	<u>Link to sponsor website</u>				
	·					



SPIN ID Program Title	Sponsor Name		Sponsor Number	Deadline Date	Funding Amount	
Program UR	L Link to program URL					
Deadline Dates (ALL	.) 31-Mar-2023					
Synopsi	Pfizer is issuing this Request for projects requesting up to \$200,0	Proposals (RFP) for th 200 USD will be consid	ne 2022/2023 Global COVII dered.	D-19 ASPIRE progra	m. Individual	
Applicant Type	s					
Funding Limi	t 200,000.00 maximum					
Limited Submission	n No					
015566 Princess of Asturias Award for	Technical and Scientific Research	Princess of Asturia Foundation	S	02-Mar-2023	53,000 USD	
Contact Name	е					
Contact Telephone	e + 34 985 258 755					
Contact Emai	il					
Sponsor Website	<u>Link to sponsor website</u>					
Program UR	L Link to program URL					
Deadline Dates (ALL) 02-Mar-2023					
Synopsi	The Princess of Asturias Award for Technical and Scientific Research is aimed at recognizing the work of fostering and advancing research, discovery and/or invention in the field of mathematics, astronomy and astrophysics, physics, chemistry, life sciences, medical sciences, earth and space sciences or technological sciences, including those disciplines corresponding to each of these fields as well as their related technologies.					
Applicant Type	s					
Funding Limi	t 50,000.00 see detail					



SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Limited Submission	No			
086556 <u>F</u>	PFF Scholars Program	Pulmonary F Foundation	ibrosis	31-Mar-2023	100,000 USD
	Contact Name	Zoe Bubany, VP of Board and External Relations	3		
	Contact Telephone	888-733-6741			
	Contact Email	zbubany@pulmonaryfibrosis.org			
	Sponsor Website	<u>Link to sponsor website</u>			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	31-Mar-2023			
	Synopsis	The PFF Scholars Program is designed to suppo opportunities to future leaders in the field of post 5100,000 USD to be given over a two-year period doctoral trainees, instructors, or Assistant professional trainees.	ulmonary fibrosis. Awards wil od to encourage early stage ir	I be offered from betw nvestigators (individua	ween \$75,000 and als must be post-
	Applicant Types				
	Funding Limit	100,000.00 maximum			
	Limited Submission	No			
099444	New Investigator Operating Gra	nts Research Ma	anitoba	01-Mar-2023	Not Specified
	Contact Name	Jennifer Cleary			
	Contact Telephone	204-924-7070			



The Development Office offers assistance with many non profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team for assistance or questions. DevCorpFound@mountsinai.org below.

SPIN ID	Program Title	Sponsor Name	2	Sponsor Number	Deadline Date	Funding Amount		
	Contact Email	jennifer.cleary@researchmb.ca	<u>a</u>					
	Sponsor Website	Link to sponsor website						
	Program URL	Link to program URL						
	Deadline Dates (ALL) 01-Mar-2023 , 15-Mar-2023							
	Research Manitoba is a provincial funding agency, which provides funds for research and innovation in health, natural sciences and engineering, and social sciences and humanities in Manitoba. New Investigator Operating Grants are designed to defray the direct costs of research such as personnel costs, supplies and expendable materials, experimental animals, small equipment and computers, and knowledge mobilization/knowledge translation costs.							
	Applicant Types							
	Funding Limit	0.00 see detail						
	Limited Submission	No						
020077 <u>Y</u>	Yearly Competitions		Royal Academy for Sciences	Overseas	01-Mar-2023	2,650 USD		
	Contact Name							
	Contact Telephone	+32 (0)2 790 39 02						
	Contact Email	contact_raos@kaowarsom.be						
	Sponsor Website	Link to sponsor website						
	Program URL	Link to program URL						
	Deadline Dates (ALL)	01-Mar-2023						
	Synopsis	Every year each Section of the yearly competition is granted a	Academy puts question prize of 2,500 EUR.	s forward on specific subj	ects. Each award-w	vinning work in the		



Non Federal Funding Opportunities: March 2023

SPIN ID	Program Title	Sponsor	Name	Sponsor Number	Deadline Date	Funding Amount
	Applicant Types					
	Funding Limit	2,500.00 maximum				
	Limited Submission	No				
057960 <u>C</u>	areer Development Awards		Sarcoma Alliance fo Research Through Collaboration (SAR		01-Mar-2023	100,000 USD
	Contact Name					
	Contact Telephone	734-930-7600				
	Contact Email	sarc@sarctrials.org				
	Sponsor Website	Link to sponsor website				
	Program URL	Link to program URL				
	Deadline Dates (ALL)	01-Mar-2023				
	Synopsis	SARC is seeking career de research in the United Sta	evelopment applications from ates or Canada.	n early-stage physicians or	scientists conducting	g sarcoma
	Applicant Types					
	Funding Limit	100,000.00 maximum				
	Limited Submission	No				
114167 <u>N</u>	euroscience Collaborations Vis	sion Statements Call for P	roposals Simons Foundation	ı	08-Mar-2023 [LOI/ App]	Pre- Not Specified
	Contact Name					



SPIN ID	Program Title	Sponsor Name		Sponsor Number	Deadline Date	Funding Amount		
	Contact Telephone							
	Contact Email	neurogrants@simonsfoundation	n.org					
	Sponsor Website	Link to sponsor website						
	Program URL	Link to program URL						
	Deadline Dates (ALL)	ates (ALL) 08-Mar-2023 [LOI/Pre-App]						
	Synopsis	The Simons Foundation seeks proposals for new neuroscience collaborations. Vision statements are sought that identify new, emerging breakthrough areas of neuroscience that are poised for high-impact funding by the Simons Foundation. They are interested in bold and cutting edge, idea-generating research that focuses on basic principles of brain function and may be overlooked or too risky for other funding organizations.						
	Applicant Types							
	Funding Limit	0.00 see detail						
	Limited Submission	No						
020497 <u>I</u>	Distinguished Career Award		Society for the Stud Ingestive Behavior	dy of	31-Mar-2023	1,500 USD		
	Contact Name							
	Contact Telephone	847-807-4924						
	Contact Email	info@ssib.org						
Sponsor Website Link to sponsor website								
	Program URL	Link to program URL						
	Deadline Dates (ALL)	31-Mar-2023						



SPIN ID	Program Title	Sponsor Name	Spon	nsor Number	Deadline Date	Funding Amount	
		1					
	Synopsis	The award honors an individual for behavior.	or his or her accomplishme	ents in and contributi	ions to the underst	anding of ingestive	
	Applicant Types						
	Funding Limit	1,500.00 see detail					
	Limited Submission	No					
036955 <u>F</u>	Hoebel Prize for Creativity		Society for the Study of Ingestive Behavior		31-Mar-2023	750 USD	
	Contact Name						
	Contact Telephone	847-807-4924					
	Contact Email	info@ssib.org					
	Sponsor Website	Link to sponsor website					
	Program URL	Link to program URL					
	Deadline Dates (ALL)	31-Mar-2023					
	Synopsis	The Hoebel Prize for Creativity is intended to honor a SSIB member, at any stage of their career, for an exceptional level of creativity and excellence in his or her research on ingestive behavior. The Prize consists of a plaque, a check for 750 USD, and an invitation for the awardee to speak at the Annual SSIB Meeting.					
	Applicant Types						
	Funding Limit	750.00 see detail					
	Limited Submission	No					



SPIN ID	Program Title	Sponsor Name		Sponsor Number	Deadline Date	Funding Amount	
UhhX49	Mentored Clinical Scientist Reso (K08)	earch Career Development Award	Society for Vascular	Surgery	12-Feb-2023	Not Specified	
	Contact Name	Jane D. Scott					
	Contact Telephone	301-435-0535					
	Contact Email	scottj2@nhlbi.nih.gov					
Program URL Link to program URL Deadline Dates (ALL) 12-Feb-2023, 12-Mar-2023, 12-Jun-2023, 12-Jul-2023, 12-Oct-2023, 12-Nov-2023							
	Applicant Types						
	Funding Limit	0.00 see detail					
	Limited Submission	No					
019649	Clinical Research Seed Grants		Society for Vascular	Surgery	01-Mar-2023	25,000 USD	
	Contact Name						
	Contact Telephone	800-258-7188					
	Contact Email	svsfoundation@vascularsociety.o	rg				
	Sponsor Website	Link to sponsor website					



SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount		
	Program URL	Link to program	<u>ı URL</u>					
	Deadline Dates (ALL)	01-Mar-2023						
	Synopsis		Vascular Surgery provides Clinical I vascular disease.	Research Seed Grants in reco	gnition of the impo	rtance of clinical		
	Applicant Types							
	Funding Limit	25,000.00 maxi	000.00 maximum					
	Limited Submission	No						
073189 <u>[</u>	Distinguished Scientist Award		Sontag Founda	tion	15-Mar-2023	750,000 USD		
	Contact Name	Shandra Koler,	Senior Program Officer					
	Contact Telephone	904-273-8755						
	Contact Email	skoler@sontagt	foundation.org					
	Sponsor Website	Link to sponsor	<u>website</u>					
	Program URL	Link to program	<u>ı URL</u>					
	Deadline Dates (ALL)	15-Mar-2023						
	Synopsis	The Distinguished Scientist Award (DSA) seeks to provide career and research support to early career scientists who demonstrate outstanding promise for making scientific and medical breakthroughs in the field of brain cancer research.						
	Applicant Types							
	Funding Limit	750,000.00 see	detail					



SPIN ID	Program Title	Sponsor Name		Sponsor Number	Deadline Date	Funding Amount
	Limited Submission	No				
067272 9	Grants Program		Sorenson Legacy Fo	oundation	01-Mar-2023	Not Specified
	Contact Name	Lisa Meiling				
	Contact Telephone	801-461-9700				
	Contact Email	lisa@sorensonlegacyfoundation	n.org			
Sponsor Website Link to sponsor website						
Program URL Link to program URL						
	Deadline Dates (ALL)	01-Mar-2023, 01-Jun-2023, 01	-Sep-2023			
	Synopsis	The Sorenson Legacy Foundation by the late biotechnology pione Beverley Taylor Sorenson, the followed by the sorenson of the s	eer and entrepreneur Ja oundation provides su	ames LeVoy Sorenson and oport for a wide range of ϵ	his wife, educatio	n philanthropist
	Applicant Types					
	Funding Limit	0.00 not provided				
	Limited Submission	No				
0/50/5	Research for Pediatric Osteosa Together Super Grant	coma Fight Osteosarcoma	St. Baldrick's Found	lation	03-Mar-2023	1,500,000 USD
	Contact Name					
	Contact Telephone	626-792-8247				



SPIN ID	Program Title	Sp	ponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Contact Email	Grants@StBaldricl	ks.org			
	Sponsor Website	Link to sponsor we	<u>ebsite</u>			
	Program URL	Link to program U	<u>RL</u>			
	Deadline Dates (ALL) 03-Mar-2023					
	The St. Baldrick's Foundation has issued a request for applications (RFA) for high-impact research for pediatric Osteosarcoma. The focus of applications should be on creating new therapeutic options for patients as quickly as possible, aiming for a clinical trial in the next 1 to 3 years. Applications may focus on first line treatment or relapsed/metastatic disease.					
	Applicant Types					
	Funding Limit	500,000.00 per ye	ar			
	Limited Submission	No				
036310 <u>F</u>	Research Career Development	<u>Awards</u>	Triological Society		15-Mar-2023	40,000 USD
	Contact Name	Beth Slovinski				
	Contact Telephone	402-346-5500				
	Contact Email	beth@triological.c	org			
	Sponsor Website	Link to sponsor we	<u>ebsite</u>			
	Program URL	Link to program U	<u>RL</u>			
	Deadline Dates (ALL)	15-Mar-2023				



SPIN ID	Program Title	Sponsor Na	me	Sponsor Number	Deadline Date	Funding Amount
		The Triological Society offers development of otolaryngolo otolaryngology-head and ne	ogists-head and neck surg	eons whose projects have	specific applicatio	
	Applicant Types					
	Funding Limit	40,000.00 maximum				
	Limited Submission	No				
014822 <u>P</u>	Post Baccalaureate Internship (Tufts PREP)	Tufts Graduate Sch Biomedical Science		01-Mar-2023	Not Specified
	Contact Name	Maya Zakharia				
	Contact Telephone	617-636-6836				
	Contact Email	maya.zakharia@tufts.edu				
	Sponsor Website	Link to sponsor website				
	Program URL	Link to program URL				
	Deadline Dates (ALL)	01-Mar-2023				
The Post-Baccalaureate Research Program (PREP) at the Graduate School of Biomedical Sciences (GSBS) offers research training for recent graduates of undergraduate colleges and universities who are interested in pursuing Synopsis research careers in the biomedical sciences. Tufts PREP trainees perform one year of fully supported research wor on a hypothesis-driven problem in a field of their choosing. During this research apprenticeship they are mentored members of the GSBS Graduate Faculty.						ed in pursuing ed research work
	Applicant Types					
	Funding Limit	0.00 see detail				



SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Limited Submission No				

